{"PMC7505073": [["SARS-CoV-2 pathogenesis ::: IntroductionSARS-CoV-2, which belongs to the Coronavirus family, is an enveloped positive single-stranded RNA virus, and is derived from a novel strain of Beta coronavirus[16].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["IntroductionSARS-CoV-2", "ORGANISM", 28, 50], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 73, 84], ["Beta coronavirus", "ORGANISM", 183, 199], ["Coronavirus family", "DNA", 73, 91], ["Beta coronavirus", "SPECIES", 183, 199], ["Beta coronavirus", "SPECIES", 183, 199], ["SARS", "PROBLEM", 0, 4], ["an enveloped positive single-stranded RNA virus", "PROBLEM", 96, 143], ["Beta coronavirus", "PROBLEM", 183, 199]]], ["Historically, human coronavirus infections, from strains such as hCOV-OC43, HKU, and 229E, caused mild common cold like symptoms [17].", [["coronavirus infections", "DISEASE", 20, 42], ["human", "ORGANISM", 14, 19], ["coronavirus", "ORGANISM", 20, 31], ["hCOV-OC43", "GENE_OR_GENE_PRODUCT", 65, 74], ["HKU", "GENE_OR_GENE_PRODUCT", 76, 79], ["human", "SPECIES", 14, 19], ["coronavirus", "SPECIES", 20, 31], ["human coronavirus", "SPECIES", 14, 31], ["hCOV-OC43", "SPECIES", 65, 74], ["human coronavirus infections", "PROBLEM", 14, 42], ["strains", "PROBLEM", 49, 56], ["hCOV", "TEST", 65, 69], ["HKU", "TEST", 76, 79], ["mild common cold like symptoms", "PROBLEM", 98, 128], ["coronavirus infections", "OBSERVATION", 20, 42], ["mild", "OBSERVATION_MODIFIER", 98, 102]]], ["However, since 2000, at least two highly pathogenic and deleterious coronavirus strains have emerged, including SARS-CoV in 2002\u20132003 and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012.", [["SARS-CoV", "DISEASE", 112, 120], ["Respiratory Syndrome Coronavirus", "DISEASE", 154, 186], ["coronavirus", "ORGANISM", 68, 79], ["SARS-CoV", "ORGANISM", 112, 120], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 142, 186], ["MERS-CoV", "ORGANISM", 188, 196], ["SARS-CoV", "SPECIES", 112, 120], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 142, 196], ["deleterious coronavirus strains", "PROBLEM", 56, 87], ["SARS-CoV", "TEST", 112, 120], ["the Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 138, 186], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["pathogenic", "OBSERVATION", 41, 51], ["deleterious", "OBSERVATION_MODIFIER", 56, 67], ["coronavirus strains", "OBSERVATION", 68, 87], ["Middle", "ANATOMY_MODIFIER", 142, 148], ["Respiratory Syndrome", "OBSERVATION", 154, 174]]], ["SARS-CoV originated in China and rapidly spread to five of the seven continents, mainly through air travel; it resulted in 8098 cases with death rate of 10%.", [["SARS", "DISEASE", 0, 4], ["death", "DISEASE", 139, 144], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["death rate", "TEST", 139, 149], ["CoV", "OBSERVATION", 5, 8]]], ["MERS, on the other hand, originated in the Arabian Peninsula, and resulted in 2494 confirmed cased, but with devastating fatality rate of 35% [18].SARS-CoV-2 pathogenesis ::: IntroductionViral entry into host cells is a key determinant of infectivity and disease pathogenesis.", [["cells", "ANATOMY", 209, 214], ["SARS", "DISEASE", 147, 151], ["host cells", "CELL", 204, 214], ["host cells", "CELL_TYPE", 204, 214], ["fatality rate", "TEST", 121, 134], ["disease pathogenesis", "PROBLEM", 255, 275], ["Arabian Peninsula", "ANATOMY", 43, 60], ["host cells", "OBSERVATION", 204, 214]]], ["While the virus entry is dictated by efficient binding of the virus to host receptor, severity of infectivity and disease pathogenesis are determined by the host immune system.", [["immune system", "ANATOMICAL_SYSTEM", 162, 175], ["the virus entry", "PROBLEM", 6, 21], ["infectivity", "PROBLEM", 98, 109], ["disease pathogenesis", "PROBLEM", 114, 134], ["virus", "OBSERVATION", 10, 15], ["infectivity", "OBSERVATION", 98, 109], ["disease", "OBSERVATION", 114, 121]]], ["Generation of viral specific neutralizing antibodies by the host can definitively dampen the viral load and infectivity.SARS-CoV-2 pathogenesis ::: IntroductionSARS-CoV-2 shares significant structural and genetic similarity with the original SARS-CoV.", [["SARS", "DISEASE", 120, 124], ["SARS", "DISEASE", 242, 246], ["SARS-CoV-2", "ORGANISM", 120, 130], ["IntroductionSARS-CoV-2", "ORGANISM", 148, 170], ["SARS-CoV", "ORGANISM", 242, 250], ["viral specific neutralizing antibodies", "PROTEIN", 14, 52], ["SARS-CoV", "SPECIES", 242, 250], ["viral specific neutralizing antibodies", "PROBLEM", 14, 52], ["the viral load", "PROBLEM", 89, 103], ["infectivity", "PROBLEM", 108, 119], ["SARS", "PROBLEM", 120, 124], ["IntroductionSARS", "TEST", 148, 164], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["viral load", "OBSERVATION", 93, 103]]], ["Both viruses are spherical in shape and have multiple transmembrane spike (S) glycoproteins embedded in the virion envelope that form homotrimers [19].", [["transmembrane", "ANATOMY", 54, 67], ["transmembrane spike (S) glycoproteins", "PROTEIN", 54, 91], ["spherical in shape", "PROBLEM", 17, 35], ["multiple transmembrane spike", "PROBLEM", 45, 73], ["glycoproteins", "TREATMENT", 78, 91], ["viruses", "OBSERVATION", 5, 12], ["spherical", "OBSERVATION_MODIFIER", 17, 26], ["shape", "OBSERVATION_MODIFIER", 30, 35], ["multiple", "OBSERVATION_MODIFIER", 45, 53], ["transmembrane spike", "OBSERVATION", 54, 73]]], ["In both cases, infection in humans is mediated mainly by binding of the viral surface spike protein (S) to the human angiotensin-converting enzyme 2 (ACE2) receptor following its cleavage and activation by transmembrane protease serine 2 (TMPRSS2) or cathepsins secreted by the host.", [["surface", "ANATOMY", 78, 85], ["infection", "DISEASE", 15, 24], ["angiotensin", "CHEMICAL", 117, 128], ["serine", "CHEMICAL", 229, 235], ["humans", "ORGANISM", 28, 34], ["human", "ORGANISM", 111, 116], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 117, 148], ["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 206, 237], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 239, 246], ["cathepsins", "GENE_OR_GENE_PRODUCT", 251, 261], ["viral surface spike protein", "PROTEIN", 72, 99], ["S", "PROTEIN", 101, 102], ["human angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 111, 164], ["transmembrane protease serine 2", "PROTEIN", 206, 237], ["TMPRSS2", "PROTEIN", 239, 246], ["cathepsins", "PROTEIN", 251, 261], ["humans", "SPECIES", 28, 34], ["human", "SPECIES", 111, 116], ["humans", "SPECIES", 28, 34], ["human", "SPECIES", 111, 116], ["infection", "PROBLEM", 15, 24], ["the human angiotensin", "TREATMENT", 107, 128], ["enzyme 2 (ACE2) receptor", "TREATMENT", 140, 164], ["its cleavage", "TREATMENT", 175, 187], ["transmembrane protease serine", "TREATMENT", 206, 235], ["cathepsins", "TREATMENT", 251, 261], ["infection", "OBSERVATION", 15, 24]]], ["[[20], [21], [22], [23], [24]].", [["[[20], [21], [22], [23], [24]]", "SIMPLE_CHEMICAL", 0, 30]]], ["The S1 harboring receptor binding domain binds to the cellular receptor ACE2, while the transmembrane unit S2 facilitates fusion of the viral membrane with host cellular membrane.", [["cellular", "ANATOMY", 54, 62], ["membrane", "ANATOMY", 142, 150], ["cellular membrane", "ANATOMY", 161, 178], ["cellular", "CELL", 54, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["transmembrane", "CELLULAR_COMPONENT", 88, 101], ["unit S2", "GENE_OR_GENE_PRODUCT", 102, 109], ["viral membrane", "CELLULAR_COMPONENT", 136, 150], ["cellular membrane", "CELLULAR_COMPONENT", 161, 178], ["S1", "PROTEIN", 4, 6], ["receptor binding domain", "PROTEIN", 17, 40], ["cellular receptor", "PROTEIN", 54, 71], ["ACE2", "PROTEIN", 72, 76], ["transmembrane unit S2", "PROTEIN", 88, 109], ["the transmembrane unit S2", "TREATMENT", 84, 109], ["fusion", "OBSERVATION", 122, 128], ["viral membrane", "OBSERVATION", 136, 150], ["host cellular membrane", "OBSERVATION", 156, 178]]], ["Membrane fusion is facilitated by cleavage of S protein by host cell proteases such as TMPPRSS2 or cathepsin at the S1/S2 and the S2\u2032 site, which results in S protein activation [21,25,26].", [["Membrane", "ANATOMY", 0, 8], ["cell", "ANATOMY", 64, 68], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["S protein", "GENE_OR_GENE_PRODUCT", 46, 55], ["host cell proteases", "GENE_OR_GENE_PRODUCT", 59, 78], ["TMPPRSS2", "GENE_OR_GENE_PRODUCT", 87, 95], ["cathepsin", "GENE_OR_GENE_PRODUCT", 99, 108], ["S2", "GENE_OR_GENE_PRODUCT", 119, 121], ["S2", "GENE_OR_GENE_PRODUCT", 130, 132], ["S protein", "GENE_OR_GENE_PRODUCT", 157, 166], ["S protein", "PROTEIN", 46, 55], ["host cell proteases", "PROTEIN", 59, 78], ["TMPPRSS2", "PROTEIN", 87, 95], ["cathepsin", "PROTEIN", 99, 108], ["S1", "PROTEIN", 116, 118], ["S2", "PROTEIN", 119, 121], ["S2", "PROTEIN", 130, 132], ["S protein", "PROTEIN", 157, 166], ["Membrane fusion", "TREATMENT", 0, 15], ["host cell proteases", "TREATMENT", 59, 78], ["TMPPRSS2", "TREATMENT", 87, 95], ["cathepsin", "TREATMENT", 99, 108], ["S protein activation", "TEST", 157, 177], ["fusion", "OBSERVATION", 9, 15], ["S2", "ANATOMY", 119, 121], ["S2", "ANATOMY", 130, 132]]], ["This cleavage of the S protein in the constitutive endocytic pathway of infected cells or during viral entry into target cells is a key determinant of viral infectivity and pathogenesis[[27], [28], [29]].SARS-CoV-2 pathogenesis ::: IntroductionIn addition, the SARS-CoV-2 spike protein also contains a polybasic cleavage site, allowing it to also be processed by furin-like proteases, a feature also shared by other highly pathogenic avian flu viruses [30,31].", [["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 121, 126], ["SARS", "DISEASE", 204, 208], ["SARS", "DISEASE", 261, 265], ["flu viruses", "DISEASE", 440, 451], ["cells", "CELL", 81, 86], ["cells", "CELL", 121, 126], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 261, 271], ["furin", "GENE_OR_GENE_PRODUCT", 363, 368], ["avian flu viruses", "ORGANISM", 434, 451], ["S protein", "PROTEIN", 21, 30], ["infected cells", "CELL_TYPE", 72, 86], ["target cells", "CELL_TYPE", 114, 126], ["SARS-CoV-2 spike protein", "PROTEIN", 261, 285], ["polybasic cleavage site", "PROTEIN", 302, 325], ["furin-like proteases", "PROTEIN", 363, 383], ["avian flu viruses", "SPECIES", 434, 451], ["SARS-CoV", "SPECIES", 261, 269], ["the S protein", "TEST", 17, 30], ["infected cells", "PROBLEM", 72, 86], ["viral infectivity", "PROBLEM", 151, 168], ["the SARS", "TEST", 257, 265], ["CoV", "TEST", 266, 269], ["2 spike protein", "PROBLEM", 270, 285], ["a polybasic cleavage site", "PROBLEM", 300, 325], ["furin-like proteases", "PROBLEM", 363, 383], ["highly pathogenic avian flu viruses", "PROBLEM", 416, 451], ["infected cells", "OBSERVATION", 72, 86], ["viral infectivity", "OBSERVATION", 151, 168], ["polybasic cleavage", "OBSERVATION", 302, 320]]], ["Recent reports demonstrate that furin cleaves the S protein precursor of SARS-Cov2 virus to generate a polybasic ArgArg-Ala-Arg (RRAR) C-terminal amino acid sequence on S1 protein, which increases the association of the virus to neuropilin-1 (NPR-1), a cell receptor widely expressed in respiratory and olfactory epithelium.", [["cell", "ANATOMY", 253, 257], ["respiratory", "ANATOMY", 287, 298], ["olfactory epithelium", "ANATOMY", 303, 323], ["ArgArg-Ala-Arg", "CHEMICAL", 113, 127], ["amino acid", "CHEMICAL", 146, 156], ["ArgArg-Ala-Arg", "CHEMICAL", 113, 127], ["C-", "CHEMICAL", 135, 137], ["amino acid", "CHEMICAL", 146, 156], ["furin", "GENE_OR_GENE_PRODUCT", 32, 37], ["SARS-Cov2 virus", "ORGANISM", 73, 88], ["amino acid", "AMINO_ACID", 146, 156], ["neuropilin-1", "GENE_OR_GENE_PRODUCT", 229, 241], ["NPR-1", "GENE_OR_GENE_PRODUCT", 243, 248], ["cell", "CELL", 253, 257], ["olfactory epithelium", "TISSUE", 303, 323], ["furin", "PROTEIN", 32, 37], ["S protein precursor", "PROTEIN", 50, 69], ["polybasic ArgArg-Ala-Arg (RRAR) C-terminal amino acid sequence", "PROTEIN", 103, 165], ["S1 protein", "PROTEIN", 169, 179], ["neuropilin-1 (NPR-1", "PROTEIN", 229, 248], ["SARS-Cov2 virus", "SPECIES", 73, 88], ["SARS", "PROBLEM", 73, 77], ["Cov2 virus", "PROBLEM", 78, 88], ["a polybasic ArgArg", "TEST", 101, 119], ["C-terminal amino acid sequence", "TEST", 135, 165], ["S1 protein", "TEST", 169, 179], ["neuropilin", "TEST", 229, 239], ["NPR", "TEST", 243, 246], ["a cell receptor", "TREATMENT", 251, 266], ["respiratory", "ANATOMY", 287, 298], ["olfactory epithelium", "OBSERVATION", 303, 323]]], ["In vitro and in vivo experiments suggest that this binding of SARS-Cov2 to NPR-1 receptor enhances the infectability of SARS-Cov2 in cell culture [32] and may be a significant contributing factor for enhanced tropism and infectability of SARS-Cov2 in humans, [33].", [["cell culture", "ANATOMY", 133, 145], ["SARS", "DISEASE", 62, 66], ["SARS", "DISEASE", 238, 242], ["SARS-Cov2", "GENE_OR_GENE_PRODUCT", 62, 71], ["NPR-1 receptor", "GENE_OR_GENE_PRODUCT", 75, 89], ["SARS-Cov2", "GENE_OR_GENE_PRODUCT", 120, 129], ["cell culture [32]", "CELL", 133, 150], ["SARS-Cov2", "GENE_OR_GENE_PRODUCT", 238, 247], ["humans", "ORGANISM", 251, 257], ["SARS-Cov2 to NPR-1 receptor", "PROTEIN", 62, 89], ["Cov2", "DNA", 125, 129], ["humans", "SPECIES", 251, 257], ["humans", "SPECIES", 251, 257], ["SARS", "PROBLEM", 62, 66], ["NPR", "TEST", 75, 78], ["SARS", "PROBLEM", 120, 124], ["Cov2 in cell culture", "TEST", 125, 145], ["enhanced tropism", "PROBLEM", 200, 216], ["SARS", "PROBLEM", 238, 242]]], ["Compared to previous corona viruses, this combination of high ACE2 receptor affinity and enhanced tropism due to the presence of a polybasic cleavage site in its spike protein enhances SARS-CoV-2's ability to infect multiple organs, including the heart.SARS-CoV-2 pathogenesis ::: IntroductionFurin itself is a ubiquitously expressed transmembrane protein and its function has been well- characterized in the heart [[34], [35], [36]].", [["organs", "ANATOMY", 225, 231], ["heart", "ANATOMY", 247, 252], ["transmembrane", "ANATOMY", 334, 347], ["heart", "ANATOMY", 409, 414], ["SARS", "DISEASE", 253, 257], ["IntroductionFurin", "CHEMICAL", 281, 298], ["corona viruses", "ORGANISM", 21, 35], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 185, 195], ["organs", "ORGAN", 225, 231], ["heart", "ORGAN", 247, 252], ["IntroductionFurin", "GENE_OR_GENE_PRODUCT", 281, 298], ["transmembrane", "CELLULAR_COMPONENT", 334, 347], ["heart", "ORGAN", 409, 414], ["ACE2 receptor", "PROTEIN", 62, 75], ["polybasic cleavage site", "PROTEIN", 131, 154], ["spike protein", "PROTEIN", 162, 175], ["ubiquitously expressed transmembrane protein", "PROTEIN", 311, 355], ["previous corona viruses", "PROBLEM", 12, 35], ["high ACE2 receptor affinity", "PROBLEM", 57, 84], ["enhanced tropism", "PROBLEM", 89, 105], ["a polybasic cleavage site", "PROBLEM", 129, 154], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["corona", "ANATOMY_MODIFIER", 21, 27], ["viruses", "OBSERVATION", 28, 35], ["polybasic cleavage", "OBSERVATION", 131, 149], ["heart", "ANATOMY", 247, 252], ["heart", "ANATOMY", 409, 414]]], ["In the case of COVID-19, protein-proofed single-cell RNA (pscRNA) profiling studies examining the effects of infection on expression of ACE2, TMPRSS2 or furin in the heart, revealed that cardiomyocytes are a critical target for infection by SARS-CoV-2, preceded only by lung alveolar type II (AT2) cells and macrophages [37].", [["heart", "ANATOMY", 166, 171], ["cardiomyocytes", "ANATOMY", 187, 201], ["lung alveolar type II (AT2) cells", "ANATOMY", 270, 303], ["macrophages", "ANATOMY", 308, 319], ["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 228, 237], ["SARS", "DISEASE", 241, 245], ["COVID-19", "GENE_OR_GENE_PRODUCT", 15, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 136, 140], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 142, 149], ["furin", "GENE_OR_GENE_PRODUCT", 153, 158], ["heart", "ORGAN", 166, 171], ["cardiomyocytes", "CELL", 187, 201], ["SARS-CoV-2", "ORGANISM", 241, 251], ["lung alveolar type II (AT2) cells", "CELL", 270, 303], ["macrophages", "CELL", 308, 319], ["COVID-19", "DNA", 15, 23], ["ACE2", "PROTEIN", 136, 140], ["TMPRSS2", "PROTEIN", 142, 149], ["furin", "PROTEIN", 153, 158], ["cardiomyocytes", "CELL_TYPE", 187, 201], ["lung alveolar type II (AT2) cells", "CELL_TYPE", 270, 303], ["macrophages", "CELL_TYPE", 308, 319], ["SARS-CoV", "SPECIES", 241, 249], ["COVID", "TEST", 15, 20], ["protein", "TEST", 25, 32], ["profiling studies", "TEST", 66, 83], ["infection", "PROBLEM", 109, 118], ["ACE2", "TEST", 136, 140], ["TMPRSS2", "PROBLEM", 142, 149], ["furin in the heart", "TEST", 153, 171], ["cardiomyocytes", "PROBLEM", 187, 201], ["infection", "PROBLEM", 228, 237], ["SARS", "TEST", 241, 245], ["CoV", "TEST", 246, 249], ["macrophages", "PROBLEM", 308, 319], ["infection", "OBSERVATION", 109, 118], ["heart", "ANATOMY", 166, 171], ["cardiomyocytes", "ANATOMY", 187, 201], ["infection", "OBSERVATION", 228, 237], ["lung", "ANATOMY", 270, 274], ["alveolar", "ANATOMY_MODIFIER", 275, 283]]], ["Two additional studies demonstrated that SARS-CoV-2 can enter the cell membrane and replicate in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).", [["cell membrane", "ANATOMY", 66, 79], ["pluripotent stem cell-derived cardiomyocytes", "ANATOMY", 111, 155], ["hiPSC-CMs", "ANATOMY", 157, 166], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["cell membrane", "CELLULAR_COMPONENT", 66, 79], ["human", "ORGANISM", 97, 102], ["pluripotent stem cell-derived cardiomyocytes", "CELL", 111, 155], ["hiPSC-CMs", "CELL", 157, 166], ["human induced pluripotent stem cell-derived cardiomyocytes", "CELL_LINE", 97, 155], ["hiPSC", "CELL_TYPE", 157, 162], ["CMs", "CELL_LINE", 163, 166], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["Two additional studies", "TEST", 0, 22], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["derived cardiomyocytes", "PROBLEM", 133, 155], ["SARS", "OBSERVATION", 41, 45], ["cell membrane", "OBSERVATION", 66, 79], ["pluripotent stem cell", "OBSERVATION", 111, 132], ["cardiomyocytes", "ANATOMY", 141, 155]]], ["Microscopy and immunofluorescence studies confirmed that the virus localizes in the perinuclear region and induces apoptosis in the infected hiPSC-CMs, suggesting a deleterious outcome for cardiac tissue in response to COVID-19 [38,39].", [["perinuclear region", "ANATOMY", 84, 102], ["hiPSC-CMs", "ANATOMY", 141, 150], ["cardiac tissue", "ANATOMY", 189, 203], ["COVID-19 [38,39", "CHEMICAL", 219, 234], ["COVID-19", "CHEMICAL", 219, 227], ["perinuclear region", "CELLULAR_COMPONENT", 84, 102], ["hiPSC-CMs", "CELL", 141, 150], ["cardiac tissue", "TISSUE", 189, 203], ["Microscopy", "TEST", 0, 10], ["immunofluorescence studies", "TEST", 15, 41], ["the virus", "PROBLEM", 57, 66], ["apoptosis", "PROBLEM", 115, 124], ["cardiac tissue", "PROBLEM", 189, 203], ["COVID", "TEST", 219, 224], ["virus", "OBSERVATION", 61, 66], ["perinuclear", "ANATOMY_MODIFIER", 84, 95], ["apoptosis", "OBSERVATION_MODIFIER", 115, 124], ["infected hiPSC", "OBSERVATION", 132, 146]]], ["Thus, entry receptor and proteases present good therapeutic targets to combat SARS-CoV-2 infection (Fig. 2).COVID-19 and cardiovascular burden ::: IntroductionDamage to cardiac tissue has been previously reported in response to the coronavirus outbreaks.", [["cardiovascular", "ANATOMY", 121, 135], ["cardiac tissue", "ANATOMY", 169, 183], ["SARS-CoV-2 infection", "DISEASE", 78, 98], ["coronavirus", "DISEASE", 232, 243], ["SARS-CoV-2", "ORGANISM", 78, 88], ["cardiac tissue", "TISSUE", 169, 183], ["coronavirus", "ORGANISM", 232, 243], ["entry receptor", "PROTEIN", 6, 20], ["proteases", "PROTEIN", 25, 34], ["SARS-CoV-2", "SPECIES", 78, 88], ["proteases", "TREATMENT", 25, 34], ["SARS", "PROBLEM", 78, 82], ["CoV-2 infection", "PROBLEM", 83, 98], ["COVID", "TEST", 108, 113], ["the coronavirus outbreaks", "PROBLEM", 228, 253], ["infection", "OBSERVATION", 89, 98], ["cardiac tissue", "ANATOMY", 169, 183], ["coronavirus", "OBSERVATION", 232, 243]]], ["Approximately 8% of all SARS patients had CVD comorbidities and the presence of CVD or diabetes mellitus in SARS-infected patients led to at least 12-fold increased death rate [40,41].", [["SARS", "DISEASE", 24, 28], ["CVD", "DISEASE", 42, 45], ["CVD", "DISEASE", 80, 83], ["diabetes mellitus", "DISEASE", 87, 104], ["SARS-infected", "DISEASE", 108, 121], ["death", "DISEASE", 165, 170], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 122, 130], ["CVD comorbidities", "PROBLEM", 42, 59], ["CVD", "PROBLEM", 80, 83], ["diabetes mellitus", "PROBLEM", 87, 104], ["SARS", "PROBLEM", 108, 112], ["fold increased death rate", "PROBLEM", 150, 175], ["diabetes", "OBSERVATION", 87, 95]]], ["CVD (30%) and hypertension (50%) comorbidities were also significantly associated with MERS (Badawi & Ryoo, 2016).", [["CVD", "DISEASE", 0, 3], ["hypertension", "DISEASE", 14, 26], ["CVD", "PROBLEM", 0, 3], ["hypertension", "PROBLEM", 14, 26], ["comorbidities", "PROBLEM", 33, 46], ["30%", "OBSERVATION_MODIFIER", 5, 8], ["hypertension", "OBSERVATION", 14, 26]]], ["Recent reports from Wuhan, Italy and US suggest that CVD is one of the most common comorbidities associated with COVID-19 [[42], [43], [44], [45]].", [["CVD", "DISEASE", 53, 56], ["COVID-19", "CHEMICAL", 113, 121], ["[42], [43], [44], [45]", "SIMPLE_CHEMICAL", 123, 145], ["CVD", "PROBLEM", 53, 56], ["COVID", "TEST", 113, 118]]], ["In addition, COVID-19 patients with CVD have a higher mortality rate (around 10.5%) as compared to other comorbidities such as hypertension (6%), diabetes (7.3%), or chronic respiratory disease (6.3%) [46].", [["respiratory", "ANATOMY", 174, 185], ["CVD", "DISEASE", 36, 39], ["hypertension", "DISEASE", 127, 139], ["diabetes", "DISEASE", 146, 154], ["chronic respiratory disease", "DISEASE", 166, 193], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["CVD", "PROBLEM", 36, 39], ["a higher mortality rate", "PROBLEM", 45, 68], ["other comorbidities", "PROBLEM", 99, 118], ["hypertension", "PROBLEM", 127, 139], ["diabetes", "PROBLEM", 146, 154], ["chronic respiratory disease", "PROBLEM", 166, 193], ["hypertension", "OBSERVATION", 127, 139], ["chronic", "OBSERVATION_MODIFIER", 166, 173], ["respiratory disease", "OBSERVATION", 174, 193]]], ["In a study of 416 hospitalized patients with confirmed COVID-19, approximately 20% had elevated hs-TnI levels, indicative of an increased pathological response in the heart.", [["heart", "ANATOMY", 167, 172], ["patients", "ORGANISM", 31, 39], ["hs-TnI", "GENE_OR_GENE_PRODUCT", 96, 102], ["heart", "ORGAN", 167, 172], ["TnI", "PROTEIN", 99, 102], ["patients", "SPECIES", 31, 39], ["a study", "TEST", 3, 10], ["COVID", "TEST", 55, 60], ["elevated hs-TnI levels", "PROBLEM", 87, 109], ["an increased pathological response in the heart", "PROBLEM", 125, 172], ["indicative of", "UNCERTAINTY", 111, 124], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["pathological response", "OBSERVATION", 138, 159], ["heart", "ANATOMY", 167, 172]]], ["Patients with these elevated cardiac injury biomarkers also had significantly higher mortality rates (~50%), as compared to those without heart injury (~4.5%) [45].", [["cardiac", "ANATOMY", 29, 36], ["heart", "ANATOMY", 138, 143], ["cardiac injury", "DISEASE", 29, 43], ["heart injury", "DISEASE", 138, 150], ["Patients", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 29, 36], ["heart", "ORGAN", 138, 143], ["Patients", "SPECIES", 0, 8], ["these elevated cardiac injury biomarkers", "PROBLEM", 14, 54], ["heart injury", "PROBLEM", 138, 150], ["elevated", "OBSERVATION_MODIFIER", 20, 28], ["cardiac", "ANATOMY", 29, 36], ["injury", "OBSERVATION", 37, 43], ["heart", "ANATOMY", 138, 143], ["injury", "OBSERVATION", 144, 150]]], ["Similar findings were reported in a separate independent study, where the mortality rate among patients with elevated Troponin T (TnT), another cardiac injury biomarker, was ~60%, whereas the mortality rate in patients with normal TnT levels was ~9% [47].", [["cardiac", "ANATOMY", 144, 151], ["cardiac injury", "DISEASE", 144, 158], ["patients", "ORGANISM", 95, 103], ["Troponin T", "GENE_OR_GENE_PRODUCT", 118, 128], ["TnT", "GENE_OR_GENE_PRODUCT", 130, 133], ["cardiac", "ORGAN", 144, 151], ["patients", "ORGANISM", 210, 218], ["TnT", "GENE_OR_GENE_PRODUCT", 231, 234], ["Troponin T", "PROTEIN", 118, 128], ["TnT", "PROTEIN", 130, 133], ["TnT", "PROTEIN", 231, 234], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 210, 218], ["a separate independent study", "TEST", 34, 62], ["the mortality rate", "TEST", 70, 88], ["elevated Troponin T (TnT", "PROBLEM", 109, 133], ["another cardiac injury biomarker", "PROBLEM", 136, 168], ["the mortality rate", "TEST", 188, 206], ["cardiac", "ANATOMY", 144, 151], ["injury", "OBSERVATION", 152, 158]]], ["Examination of additional cardiac injury biomarkers, including CRP and NT-proBNP, all consistently point towards a similar conclusion [48].COVID-19 and cardiovascular burden ::: IntroductionWhile there was an increase in multiple cardiac injury biomarkers, the physiological and pathological manifestation of COVID-19 infection in heart spans a broad spectrum.", [["cardiac", "ANATOMY", 26, 33], ["cardiovascular", "ANATOMY", 152, 166], ["cardiac", "ANATOMY", 230, 237], ["heart", "ANATOMY", 331, 336], ["cardiac injury", "DISEASE", 26, 40], ["cardiac injury", "DISEASE", 230, 244], ["COVID-19", "CHEMICAL", 309, 317], ["infection", "DISEASE", 318, 327], ["cardiac", "ORGAN", 26, 33], ["CRP", "GENE_OR_GENE_PRODUCT", 63, 66], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 71, 80], ["cardiac", "ORGAN", 230, 237], ["COVID-19", "GENE_OR_GENE_PRODUCT", 309, 317], ["heart", "ORGAN", 331, 336], ["CRP", "PROTEIN", 63, 66], ["Examination", "TEST", 0, 11], ["additional cardiac injury biomarkers", "TEST", 15, 51], ["CRP", "TEST", 63, 66], ["NT-proBNP", "TEST", 71, 80], ["COVID", "TEST", 139, 144], ["multiple cardiac injury biomarkers", "PROBLEM", 221, 255], ["COVID", "TEST", 309, 314], ["19 infection in heart spans", "PROBLEM", 315, 342], ["cardiac", "ANATOMY", 26, 33], ["injury", "OBSERVATION", 34, 40], ["increase", "OBSERVATION_MODIFIER", 209, 217], ["multiple", "OBSERVATION_MODIFIER", 221, 229], ["cardiac", "ANATOMY", 230, 237], ["injury", "OBSERVATION", 238, 244], ["infection", "OBSERVATION", 318, 327], ["heart", "ANATOMY", 331, 336], ["broad", "OBSERVATION_MODIFIER", 345, 350]]], ["In severe cases, direct acute myocardial injury characterized by concentric left ventricular hypertrophy with a dilated, severely hypokinetic right ventricle and cardiac amyloidosis has been reported [49]..Cardiac rhythm disorders have also been observed in patients with COVID-19.", [["myocardial", "ANATOMY", 30, 40], ["left ventricular", "ANATOMY", 76, 92], ["right ventricle", "ANATOMY", 142, 157], ["cardiac", "ANATOMY", 162, 169], ["Cardiac", "ANATOMY", 206, 213], ["myocardial injury", "DISEASE", 30, 47], ["left ventricular hypertrophy", "DISEASE", 76, 104], ["hypokinetic right ventricle", "DISEASE", 130, 157], ["cardiac amyloidosis", "DISEASE", 162, 181], ["Cardiac rhythm disorders", "DISEASE", 206, 230], ["COVID-19", "CHEMICAL", 272, 280], ["myocardial", "MULTI-TISSUE_STRUCTURE", 30, 40], ["ventricular", "MULTI-TISSUE_STRUCTURE", 81, 92], ["ventricle", "MULTI-TISSUE_STRUCTURE", 148, 157], ["cardiac", "ORGAN", 162, 169], ["Cardiac", "ORGAN", 206, 213], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["direct acute myocardial injury", "PROBLEM", 17, 47], ["concentric left ventricular hypertrophy", "PROBLEM", 65, 104], ["a dilated", "PROBLEM", 110, 119], ["severely hypokinetic right ventricle", "PROBLEM", 121, 157], ["cardiac amyloidosis", "PROBLEM", 162, 181], ["Cardiac rhythm disorders", "PROBLEM", 206, 230], ["COVID", "TEST", 272, 277], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["myocardial", "ANATOMY", 30, 40], ["injury", "OBSERVATION", 41, 47], ["concentric", "OBSERVATION_MODIFIER", 65, 75], ["left ventricular", "ANATOMY", 76, 92], ["hypertrophy", "OBSERVATION", 93, 104], ["dilated", "OBSERVATION", 112, 119], ["severely", "OBSERVATION_MODIFIER", 121, 129], ["hypokinetic", "OBSERVATION", 130, 141], ["right ventricle", "ANATOMY", 142, 157], ["cardiac", "ANATOMY", 162, 169], ["amyloidosis", "OBSERVATION", 170, 181], ["rhythm disorders", "OBSERVATION", 214, 230]]], ["Guo et al. reported an overall ventricular tachycardia (VT)/ventricular fibrillation (VF) incidence rate of 7% during hospitalization [47] However in a larger clinical trial involving 700 COVID-19 positive patients, only 1.3% of the patients had cardiac arrests, 3.6% had atrial fibrillation, 1.3% had significant bradyarrhythmia and 1.4% had nonsustained VT [50].", [["ventricular", "ANATOMY", 31, 42], ["ventricular", "ANATOMY", 60, 71], ["cardiac", "ANATOMY", 246, 253], ["atrial", "ANATOMY", 272, 278], ["ventricular tachycardia", "DISEASE", 31, 54], ["VT", "DISEASE", 56, 58], ["ventricular fibrillation", "DISEASE", 60, 84], ["VF", "DISEASE", 86, 88], ["cardiac arrests", "DISEASE", 246, 261], ["atrial fibrillation", "DISEASE", 272, 291], ["bradyarrhythmia", "DISEASE", 314, 329], ["ventricular", "ORGAN", 31, 42], ["ventricular", "MULTI-TISSUE_STRUCTURE", 60, 71], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 233, 241], ["cardiac", "ORGAN", 246, 253], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 233, 241], ["an overall ventricular tachycardia", "PROBLEM", 20, 54], ["ventricular fibrillation", "PROBLEM", 60, 84], ["VF", "PROBLEM", 86, 88], ["incidence rate", "TEST", 90, 104], ["COVID", "TEST", 188, 193], ["cardiac arrests", "PROBLEM", 246, 261], ["atrial fibrillation", "PROBLEM", 272, 291], ["significant bradyarrhythmia", "PROBLEM", 302, 329], ["nonsustained VT", "PROBLEM", 343, 358], ["et al", "OBSERVATION", 4, 9], ["ventricular", "ANATOMY", 31, 42], ["tachycardia", "OBSERVATION", 43, 54], ["ventricular", "ANATOMY", 60, 71], ["fibrillation", "OBSERVATION", 72, 84], ["cardiac", "ANATOMY", 246, 253], ["arrests", "OBSERVATION", 254, 261], ["atrial", "ANATOMY", 272, 278], ["fibrillation", "OBSERVATION", 279, 291], ["bradyarrhythmia", "OBSERVATION", 314, 329]]], ["Vascular complications of COVID-19 have also been reported including stroke, cutaneous lesions on the toes, and Kawasaki disease like systemic vasculitis in young children with severe COVID-19 [51,52].Preliminary autopsy and endocardial biopsy reports suggest low grade myocardial inflammation as evidenced by T-lymphocytic infiltration [53] and CD68+ macrophage infiltration in heart [13,54,55].", [["Vascular", "ANATOMY", 0, 8], ["cutaneous lesions", "ANATOMY", 77, 94], ["toes", "ANATOMY", 102, 106], ["endocardial biopsy", "ANATOMY", 225, 243], ["myocardial", "ANATOMY", 270, 280], ["T-lymphocytic", "ANATOMY", 310, 323], ["CD68+ macrophage", "ANATOMY", 346, 362], ["heart", "ANATOMY", 379, 384], ["COVID-19", "CHEMICAL", 26, 34], ["stroke", "DISEASE", 69, 75], ["cutaneous lesions on the toes", "DISEASE", 77, 106], ["Kawasaki disease", "DISEASE", 112, 128], ["systemic vasculitis", "DISEASE", 134, 153], ["myocardial inflammation", "DISEASE", 270, 293], ["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "CHEMICAL", 184, 192], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["COVID-19", "GENE_OR_GENE_PRODUCT", 26, 34], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 77, 94], ["toes", "ORGANISM_SUBDIVISION", 102, 106], ["children", "ORGANISM", 163, 171], ["myocardial", "MULTI-TISSUE_STRUCTURE", 270, 280], ["T-lymphocytic", "CANCER", 310, 323], ["CD68", "GENE_OR_GENE_PRODUCT", 346, 350], ["heart", "ORGAN", 379, 384], ["CD68", "PROTEIN", 346, 350], ["children", "SPECIES", 163, 171], ["Vascular complications of COVID", "PROBLEM", 0, 31], ["stroke", "PROBLEM", 69, 75], ["cutaneous lesions on the toes", "PROBLEM", 77, 106], ["Kawasaki disease", "PROBLEM", 112, 128], ["systemic vasculitis", "PROBLEM", 134, 153], ["severe COVID", "PROBLEM", 177, 189], ["Preliminary autopsy", "TEST", 201, 220], ["endocardial biopsy", "TEST", 225, 243], ["low grade myocardial inflammation", "PROBLEM", 260, 293], ["T-lymphocytic infiltration", "PROBLEM", 310, 336], ["CD68", "TEST", 346, 350], ["macrophage infiltration in heart", "PROBLEM", 352, 384], ["complications", "OBSERVATION", 9, 22], ["stroke", "OBSERVATION", 69, 75], ["cutaneous", "ANATOMY", 77, 86], ["lesions", "OBSERVATION", 87, 94], ["toes", "ANATOMY", 102, 106], ["Kawasaki", "ANATOMY", 112, 120], ["systemic", "OBSERVATION_MODIFIER", 134, 142], ["vasculitis", "OBSERVATION", 143, 153], ["endocardial", "ANATOMY", 225, 236], ["biopsy", "OBSERVATION", 237, 243], ["low grade", "OBSERVATION_MODIFIER", 260, 269], ["myocardial", "ANATOMY", 270, 280], ["inflammation", "OBSERVATION", 281, 293], ["lymphocytic infiltration", "OBSERVATION", 312, 336], ["macrophage infiltration", "OBSERVATION", 352, 375], ["heart", "ANATOMY", 379, 384]]], ["In addition, evidence of viral particles within vascular endothelial cells and diffuse vascular endothelial cell injury in lung, heart, and other organs have also been reported [56,57].", [["vascular endothelial cells", "ANATOMY", 48, 74], ["diffuse vascular endothelial cell", "ANATOMY", 79, 112], ["lung", "ANATOMY", 123, 127], ["heart", "ANATOMY", 129, 134], ["organs", "ANATOMY", 146, 152], ["vascular endothelial cells", "CELL", 48, 74], ["vascular endothelial cell", "CELL", 87, 112], ["lung", "ORGAN", 123, 127], ["heart", "ORGAN", 129, 134], ["organs", "ORGAN", 146, 152], ["vascular endothelial cells", "CELL_TYPE", 48, 74], ["viral particles within vascular endothelial cells", "PROBLEM", 25, 74], ["diffuse vascular endothelial cell injury in lung, heart, and other organs", "PROBLEM", 79, 152], ["evidence of", "UNCERTAINTY", 13, 24], ["viral particles", "OBSERVATION", 25, 40], ["vascular endothelial cells", "OBSERVATION", 48, 74], ["diffuse", "OBSERVATION_MODIFIER", 79, 86], ["vascular", "ANATOMY", 87, 95], ["endothelial cell injury", "OBSERVATION", 96, 119], ["lung", "ANATOMY", 123, 127], ["heart", "ANATOMY", 129, 134]]], ["Histological evidence of acute myocarditis in COVID-19 patients is limited and additional autopsy and endomyocardial biopsy studies are needed to differentiate the pattern and proportion of cardiac damage caused by acute myocarditis versus other mechanisms.COVID-19 and cardiovascular burden ::: IntroductionIn addition to being widely prevalent and at times, even being a prognostic comorbidity, CVD can also be triggered and caused by COVID-19 in patients with no prior history of heart disease.", [["endomyocardial", "ANATOMY", 102, 116], ["cardiac", "ANATOMY", 190, 197], ["cardiovascular", "ANATOMY", 270, 284], ["heart", "ANATOMY", 483, 488], ["myocarditis", "DISEASE", 31, 42], ["cardiac damage", "DISEASE", 190, 204], ["myocarditis", "DISEASE", 221, 232], ["CVD", "DISEASE", 397, 400], ["heart disease", "DISEASE", 483, 496], ["patients", "ORGANISM", 55, 63], ["endomyocardial biopsy", "MULTI-TISSUE_STRUCTURE", 102, 123], ["cardiac", "ORGAN", 190, 197], ["patients", "ORGANISM", 449, 457], ["heart", "ORGAN", 483, 488], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 449, 457], ["acute myocarditis", "PROBLEM", 25, 42], ["additional autopsy", "TEST", 79, 97], ["endomyocardial biopsy studies", "TEST", 102, 131], ["cardiac damage", "PROBLEM", 190, 204], ["acute myocarditis", "PROBLEM", 215, 232], ["COVID", "TEST", 257, 262], ["IntroductionIn", "TREATMENT", 296, 310], ["a prognostic comorbidity", "PROBLEM", 371, 395], ["CVD", "PROBLEM", 397, 400], ["COVID", "TEST", 437, 442], ["heart disease", "PROBLEM", 483, 496], ["evidence of", "UNCERTAINTY", 13, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["myocarditis", "OBSERVATION", 31, 42], ["cardiac", "ANATOMY", 190, 197], ["damage", "OBSERVATION", 198, 204], ["acute", "OBSERVATION_MODIFIER", 215, 220], ["myocarditis", "OBSERVATION", 221, 232], ["heart", "ANATOMY", 483, 488], ["disease", "OBSERVATION", 489, 496]]], ["In a specific case study of a patient without previous history of cardiovascular disease, elevated levels of cardiac injury biomarkers high-sensitivity troponin T and NT-proBNP, acute myopericarditis with increased wall thickness and severe left ventricular dysfunction were reported one week after the respiratory symptoms were completely resolved [55].", [["cardiovascular", "ANATOMY", 66, 80], ["cardiac", "ANATOMY", 109, 116], ["wall", "ANATOMY", 215, 219], ["left ventricular", "ANATOMY", 241, 257], ["respiratory", "ANATOMY", 303, 314], ["cardiovascular disease", "DISEASE", 66, 88], ["cardiac injury", "DISEASE", 109, 123], ["NT-proBNP", "CHEMICAL", 167, 176], ["myopericarditis", "DISEASE", 184, 199], ["left ventricular dysfunction", "DISEASE", 241, 269], ["patient", "ORGANISM", 30, 37], ["cardiovascular", "ANATOMICAL_SYSTEM", 66, 80], ["cardiac", "ORGAN", 109, 116], ["troponin T", "GENE_OR_GENE_PRODUCT", 152, 162], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 167, 176], ["wall", "TISSUE", 215, 219], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 241, 257], ["troponin T", "PROTEIN", 152, 162], ["patient", "SPECIES", 30, 37], ["cardiovascular disease", "PROBLEM", 66, 88], ["elevated levels", "PROBLEM", 90, 105], ["cardiac injury biomarkers", "PROBLEM", 109, 134], ["troponin T", "TEST", 152, 162], ["NT", "TEST", 167, 169], ["proBNP", "TEST", 170, 176], ["acute myopericarditis", "PROBLEM", 178, 199], ["increased wall thickness", "PROBLEM", 205, 229], ["severe left ventricular dysfunction", "PROBLEM", 234, 269], ["the respiratory symptoms", "PROBLEM", 299, 323], ["cardiovascular", "ANATOMY", 66, 80], ["disease", "OBSERVATION", 81, 88], ["cardiac", "ANATOMY", 109, 116], ["injury", "OBSERVATION", 117, 123], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["myopericarditis", "OBSERVATION", 184, 199], ["increased", "OBSERVATION_MODIFIER", 205, 214], ["wall", "ANATOMY_MODIFIER", 215, 219], ["thickness", "OBSERVATION_MODIFIER", 220, 229], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["left ventricular", "ANATOMY", 241, 257], ["dysfunction", "OBSERVATION", 258, 269]]], ["Although underlying disease mechanisms are not well understood, these findings suggest significant cardiac involvement in COVID-19.Potential disease mechanisms underlying COVID-19 induced cardiovascular dysfunction ::: Introduction", [["cardiac", "ANATOMY", 99, 106], ["cardiovascular", "ANATOMY", 188, 202], ["COVID-19", "CHEMICAL", 171, 179], ["cardiovascular dysfunction", "DISEASE", 188, 214], ["COVID-19", "CHEMICAL", 122, 130], ["COVID-19", "CHEMICAL", 171, 179], ["cardiac", "ORGAN", 99, 106], ["COVID-19", "GENE_OR_GENE_PRODUCT", 171, 179], ["cardiovascular", "ANATOMICAL_SYSTEM", 188, 202], ["underlying disease mechanisms", "PROBLEM", 9, 38], ["significant cardiac involvement", "PROBLEM", 87, 118], ["COVID", "TEST", 122, 127], ["Potential disease mechanisms", "PROBLEM", 131, 159], ["COVID", "TEST", 171, 176], ["cardiovascular dysfunction", "PROBLEM", 188, 214], ["disease", "OBSERVATION", 20, 27], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["cardiac", "ANATOMY", 99, 106], ["involvement", "OBSERVATION", 107, 118], ["disease", "OBSERVATION", 141, 148]]]], "bfb5b4d0320a87030cd2a3a7b0d8bd640377f54b": [["Renal transplantation has been available for treatment of end-stage renal failure in cats for fifteen years and has more recently become available for dogs.", [["Renal", "ANATOMY", 0, 5], ["renal", "ANATOMY", 68, 73], ["end-stage renal failure", "DISEASE", 58, 81], ["Renal", "ORGAN", 0, 5], ["renal", "ORGAN", 68, 73], ["cats", "ORGANISM", 85, 89], ["dogs", "ORGANISM", 151, 155], ["cats", "SPECIES", 85, 89], ["dogs", "SPECIES", 151, 155], ["Renal transplantation", "TREATMENT", 0, 21], ["treatment", "TREATMENT", 45, 54], ["end-stage renal failure", "PROBLEM", 58, 81], ["dogs", "PROBLEM", 151, 155], ["transplantation", "OBSERVATION", 6, 21], ["stage", "OBSERVATION_MODIFIER", 62, 67], ["renal", "ANATOMY", 68, 73], ["failure", "OBSERVATION", 74, 81]]], ["The role of infection in morbidity and mortality of human renal transplant recipients is well documented.", [["renal transplant", "ANATOMY", 58, 74], ["infection", "DISEASE", 12, 21], ["human", "ORGANISM", 52, 57], ["renal", "ORGAN", 58, 63], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["infection", "PROBLEM", 12, 21], ["morbidity", "PROBLEM", 25, 34], ["human renal transplant recipients", "TREATMENT", 52, 85], ["infection", "OBSERVATION", 12, 21], ["renal", "ANATOMY", 58, 63], ["transplant", "OBSERVATION", 64, 74]]], ["Studies on the incidence of infectious complications in feline and canine transplant recipients are lacking.", [["feline", "ORGANISM", 56, 62], ["canine", "ORGANISM", 67, 73], ["feline", "SPECIES", 56, 62], ["canine", "SPECIES", 67, 73], ["canine", "SPECIES", 67, 73], ["infectious complications in feline", "PROBLEM", 28, 62], ["canine transplant recipients", "TREATMENT", 67, 95], ["infectious", "OBSERVATION", 28, 38]]]], "1261039cf5fdbacaee9514a23f6a2efbf1069e95": [["Introduction.Guided by the principle of primum non nocere (first do no harm), we report a cautionary note on the potential fatal toxicity of chloroquine (CQ) or hydroxychloroquine (HCQ) in combination with anti-diabetic drug metformin.", [["toxicity", "DISEASE", 129, 137], ["chloroquine", "CHEMICAL", 141, 152], ["CQ", "CHEMICAL", 154, 156], ["hydroxychloroquine", "CHEMICAL", 161, 179], ["HCQ", "CHEMICAL", 181, 184], ["metformin", "CHEMICAL", 225, 234], ["chloroquine", "CHEMICAL", 141, 152], ["CQ", "CHEMICAL", 154, 156], ["hydroxychloroquine", "CHEMICAL", 161, 179], ["HCQ", "CHEMICAL", 181, 184], ["metformin", "CHEMICAL", 225, 234], ["chloroquine", "SIMPLE_CHEMICAL", 141, 152], ["CQ", "SIMPLE_CHEMICAL", 154, 156], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 161, 179], ["HCQ", "SIMPLE_CHEMICAL", 181, 184], ["metformin", "SIMPLE_CHEMICAL", 225, 234], ["chloroquine (CQ)", "TREATMENT", 141, 157], ["hydroxychloroquine (HCQ)", "TREATMENT", 161, 185], ["anti-diabetic drug metformin", "TREATMENT", 206, 234]]], ["We observed that the combination of CQ or HCQ and metformin, which were used in our studies as potential anti-cancer drugs, killed 30-40% of mice.", [["CQ", "CHEMICAL", 36, 38], ["HCQ", "CHEMICAL", 42, 45], ["metformin", "CHEMICAL", 50, 59], ["CQ", "CHEMICAL", 36, 38], ["HCQ", "CHEMICAL", 42, 45], ["metformin", "CHEMICAL", 50, 59], ["CQ", "SIMPLE_CHEMICAL", 36, 38], ["HCQ", "SIMPLE_CHEMICAL", 42, 45], ["metformin", "SIMPLE_CHEMICAL", 50, 59], ["mice", "ORGANISM", 141, 145], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 141, 145], ["CQ", "TREATMENT", 36, 38], ["HCQ", "TREATMENT", 42, 45], ["metformin", "TREATMENT", 50, 59], ["anti-cancer drugs", "TREATMENT", 105, 122]]], ["While our observations in mice may not translate to toxicity in humans, the reports that CQ or HCQ has anti-COVID-19 activity [1] , the use of CQ resulting in toxicity and at least one death, and the recent Emergency Use Authorization (EUA) for CQ and HCQ by the US Food and Drug Administration (FDA) prompted our report.", [["toxicity", "DISEASE", 52, 60], ["CQ", "CHEMICAL", 89, 91], ["HCQ", "CHEMICAL", 95, 98], ["CQ", "CHEMICAL", 143, 145], ["toxicity", "DISEASE", 159, 167], ["death", "DISEASE", 185, 190], ["CQ", "CHEMICAL", 245, 247], ["HCQ", "CHEMICAL", 252, 255], ["HCQ", "CHEMICAL", 95, 98], ["HCQ", "CHEMICAL", 252, 255], ["mice", "ORGANISM", 26, 30], ["humans", "ORGANISM", 64, 70], ["CQ", "SIMPLE_CHEMICAL", 89, 91], ["HCQ", "SIMPLE_CHEMICAL", 95, 98], ["anti-COVID-19", "GENE_OR_GENE_PRODUCT", 103, 116], ["CQ", "SIMPLE_CHEMICAL", 143, 145], ["HCQ", "SIMPLE_CHEMICAL", 252, 255], ["mice", "SPECIES", 26, 30], ["humans", "SPECIES", 64, 70], ["mice", "SPECIES", 26, 30], ["humans", "SPECIES", 64, 70], ["toxicity", "PROBLEM", 159, 167], ["CQ", "TREATMENT", 245, 247], ["HCQ", "TREATMENT", 252, 255]]], ["Here we report the lethality of CQ or HCQ in combination with metformin as a warning of its potential serious clinical toxicity.", [["CQ", "CHEMICAL", 32, 34], ["HCQ", "CHEMICAL", 38, 41], ["metformin", "CHEMICAL", 62, 71], ["toxicity", "DISEASE", 119, 127], ["CQ", "CHEMICAL", 32, 34], ["HCQ", "CHEMICAL", 38, 41], ["metformin", "CHEMICAL", 62, 71], ["CQ", "SIMPLE_CHEMICAL", 32, 34], ["HCQ", "SIMPLE_CHEMICAL", 38, 41], ["metformin", "SIMPLE_CHEMICAL", 62, 71], ["the lethality of CQ", "PROBLEM", 15, 34], ["HCQ", "TREATMENT", 38, 41], ["metformin", "TREATMENT", 62, 71], ["serious clinical toxicity", "PROBLEM", 102, 127]]], ["We hope that our report will be helpful to stimulate pharmacovigilance and monitoring of adverse drug reactions with the use of CQ or HCQ, particularly with metformin.Methods.", [["adverse drug reactions", "DISEASE", 89, 111], ["CQ", "CHEMICAL", 128, 130], ["HCQ", "CHEMICAL", 134, 137], ["metformin", "CHEMICAL", 157, 166], ["CQ", "CHEMICAL", 128, 130], ["HCQ", "CHEMICAL", 134, 137], ["metformin", "CHEMICAL", 157, 166], ["CQ", "SIMPLE_CHEMICAL", 128, 130], ["HCQ", "SIMPLE_CHEMICAL", 134, 137], ["metformin", "SIMPLE_CHEMICAL", 157, 166], ["adverse drug reactions", "PROBLEM", 89, 111], ["CQ", "TREATMENT", 128, 130], ["HCQ", "TREATMENT", 134, 137], ["metformin", "TREATMENT", 157, 166]]], ["Tumor bearing or nontumor bearing immunocompromised mice were injected with 100 \u00b5L of saline vehicle, chloroquine (CQ, 60 mg/kg), hydroxychloroquine (HCQ, 60 mg/kg) and/or metformin (250 mg/kg) once daily intraperitoneally daily for 4 weeks as described [2 3] .", [["Tumor", "ANATOMY", 0, 5], ["nontumor", "ANATOMY", 17, 25], ["intraperitoneally", "ANATOMY", 205, 222], ["chloroquine", "CHEMICAL", 102, 113], ["CQ", "CHEMICAL", 115, 117], ["hydroxychloroquine", "CHEMICAL", 130, 148], ["HCQ", "CHEMICAL", 150, 153], ["metformin", "CHEMICAL", 172, 181], ["chloroquine", "CHEMICAL", 102, 113], ["CQ", "CHEMICAL", 115, 117], ["hydroxychloroquine", "CHEMICAL", 130, 148], ["HCQ", "CHEMICAL", 150, 153], ["metformin", "CHEMICAL", 172, 181], ["Tumor", "CANCER", 0, 5], ["nontumor", "CANCER", 17, 25], ["mice", "ORGANISM", 52, 56], ["chloroquine", "SIMPLE_CHEMICAL", 102, 113], ["CQ", "SIMPLE_CHEMICAL", 115, 117], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 130, 148], ["HCQ", "SIMPLE_CHEMICAL", 150, 153], ["metformin", "SIMPLE_CHEMICAL", 172, 181], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["Tumor bearing", "PROBLEM", 0, 13], ["nontumor bearing immunocompromised mice", "TREATMENT", 17, 56], ["saline vehicle", "TREATMENT", 86, 100], ["chloroquine", "TREATMENT", 102, 113], ["hydroxychloroquine (HCQ", "TREATMENT", 130, 153], ["metformin", "TREATMENT", 172, 181]]], ["A combination of CQ and metformin in the above-mentioned dose and frequency was administered to animals in the combination treatment group.", [["CQ", "CHEMICAL", 17, 19], ["metformin", "CHEMICAL", 24, 33], ["CQ", "CHEMICAL", 17, 19], ["metformin", "CHEMICAL", 24, 33], ["CQ", "SIMPLE_CHEMICAL", 17, 19], ["metformin", "SIMPLE_CHEMICAL", 24, 33], ["CQ", "TREATMENT", 17, 19], ["metformin", "TREATMENT", 24, 33], ["the combination treatment group", "TREATMENT", 107, 138]]], ["In a separate study, non-tumor bearing immunocompromised and immunocompetent mice were treated with HCQ and metformin once daily in the abovementioned dose for 38 days.", [["non-tumor", "ANATOMY", 21, 30], ["HCQ", "CHEMICAL", 100, 103], ["metformin", "CHEMICAL", 108, 117], ["HCQ", "CHEMICAL", 100, 103], ["metformin", "CHEMICAL", 108, 117], ["non-tumor", "CANCER", 21, 30], ["mice", "ORGANISM", 77, 81], ["HCQ", "SIMPLE_CHEMICAL", 100, 103], ["metformin", "SIMPLE_CHEMICAL", 108, 117], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["a separate study", "TEST", 3, 19], ["non-tumor bearing immunocompromised", "PROBLEM", 21, 56], ["immunocompetent mice", "TREATMENT", 61, 81], ["HCQ", "TREATMENT", 100, 103], ["metformin", "TREATMENT", 108, 117]]], ["Blood was drawn for chemistry and hematology via cardiac puncture, and organs and tissues were harvested, examined and processed for transmission electron microscopy as described [3] .Methods.", [["Blood", "ANATOMY", 0, 5], ["cardiac", "ANATOMY", 49, 56], ["organs", "ANATOMY", 71, 77], ["tissues", "ANATOMY", 82, 89], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 49, 65], ["organs", "ORGAN", 71, 77], ["tissues", "TISSUE", 82, 89], ["Blood", "TEST", 0, 5], ["chemistry", "TEST", 20, 29], ["cardiac puncture", "TEST", 49, 65], ["transmission electron microscopy", "TEST", 133, 165], ["cardiac", "ANATOMY", 49, 56], ["puncture", "OBSERVATION", 57, 65], ["organs", "ANATOMY", 71, 77]]], ["Based on our previous findings that metformin and CQ or HCQ curbed the growth of human pancreatic xenografts in athymic nude mice [2 3], we sought to determine whether the combination of metformin, which inhibits mitochondrial Complex I, and CQ that inhibits autophagy could be synergistic as an anti-cancer metabolic cocktail.", [["pancreatic xenografts", "ANATOMY", 87, 108], ["mitochondrial", "ANATOMY", 213, 226], ["metformin", "CHEMICAL", 36, 45], ["CQ", "CHEMICAL", 50, 52], ["HCQ", "CHEMICAL", 56, 59], ["metformin", "CHEMICAL", 187, 196], ["CQ", "CHEMICAL", 242, 244], ["metformin", "CHEMICAL", 36, 45], ["CQ", "CHEMICAL", 50, 52], ["HCQ", "CHEMICAL", 56, 59], ["metformin", "CHEMICAL", 187, 196], ["metformin", "SIMPLE_CHEMICAL", 36, 45], ["CQ", "SIMPLE_CHEMICAL", 50, 52], ["HCQ", "SIMPLE_CHEMICAL", 56, 59], ["human", "ORGANISM", 81, 86], ["pancreatic xenografts", "CANCER", 87, 108], ["nude mice", "ORGANISM", 120, 129], ["metformin", "SIMPLE_CHEMICAL", 187, 196], ["mitochondrial", "CELLULAR_COMPONENT", 213, 226], ["Complex I", "GENE_OR_GENE_PRODUCT", 227, 236], ["CQ", "SIMPLE_CHEMICAL", 242, 244], ["mitochondrial Complex I", "PROTEIN", 213, 236], ["human", "SPECIES", 81, 86], ["mice", "SPECIES", 125, 129], ["human", "SPECIES", 81, 86], ["mice", "SPECIES", 125, 129], ["metformin", "TREATMENT", 36, 45], ["CQ", "TREATMENT", 50, 52], ["HCQ", "TREATMENT", 56, 59], ["human pancreatic xenografts", "TREATMENT", 81, 108], ["metformin", "TREATMENT", 187, 196], ["mitochondrial Complex I, and CQ", "PROBLEM", 213, 244], ["an anti-cancer metabolic cocktail", "TREATMENT", 293, 326], ["pancreatic", "ANATOMY", 87, 97]]], ["In contrast to single agent metformin or CQ, which have anti-tumor activity, we found that the combination of metformin and CQ was lethal in 40% of tumor bearing or non-tumor bearing mice ( Figure 1A) .Methods.", [["tumor", "ANATOMY", 148, 153], ["non-tumor", "ANATOMY", 165, 174], ["metformin", "CHEMICAL", 28, 37], ["CQ", "CHEMICAL", 41, 43], ["metformin", "CHEMICAL", 110, 119], ["CQ", "CHEMICAL", 124, 126], ["tumor", "DISEASE", 148, 153], ["metformin", "CHEMICAL", 28, 37], ["CQ", "CHEMICAL", 41, 43], ["metformin", "CHEMICAL", 110, 119], ["CQ", "CHEMICAL", 124, 126], ["metformin", "SIMPLE_CHEMICAL", 28, 37], ["CQ", "SIMPLE_CHEMICAL", 41, 43], ["anti-tumor", "CANCER", 56, 66], ["metformin", "SIMPLE_CHEMICAL", 110, 119], ["CQ", "SIMPLE_CHEMICAL", 124, 126], ["tumor", "CANCER", 148, 153], ["non-tumor", "CANCER", 165, 174], ["mice", "ORGANISM", 183, 187], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["single agent metformin", "TREATMENT", 15, 37], ["CQ", "TREATMENT", 41, 43], ["metformin", "TREATMENT", 110, 119], ["CQ", "TREATMENT", 124, 126], ["lethal", "PROBLEM", 131, 137]]], ["Animal experiments were conducted following approval by the Animal Care and UseTo determine whether HCQ is similarly lethal in combination with metformin, we tested the metformin+HCQ combination in non-tumor bearing nude mice, which showed a 40% mortality ( Figure 1B) .", [["non-tumor", "ANATOMY", 198, 207], ["HCQ", "CHEMICAL", 100, 103], ["metformin", "CHEMICAL", 144, 153], ["metformin", "CHEMICAL", 169, 178], ["HCQ", "CHEMICAL", 179, 182], ["HCQ", "CHEMICAL", 100, 103], ["metformin", "CHEMICAL", 144, 153], ["metformin", "CHEMICAL", 169, 178], ["HCQ", "CHEMICAL", 179, 182], ["HCQ", "SIMPLE_CHEMICAL", 100, 103], ["metformin", "SIMPLE_CHEMICAL", 144, 153], ["metformin", "SIMPLE_CHEMICAL", 169, 178], ["HCQ", "SIMPLE_CHEMICAL", 179, 182], ["non-tumor", "CANCER", 198, 207], ["nude mice", "ORGANISM", 216, 225], ["mice", "SPECIES", 221, 225], ["mice", "SPECIES", 221, 225], ["metformin", "TREATMENT", 144, 153], ["the metformin", "TREATMENT", 165, 178], ["HCQ", "TREATMENT", 179, 182]]], ["To determine whether immunocompromised nude mice were particularly sensitive to the combination, we treated immunocompetent C57BL/6 mice with the metformin+HCQ, which resulted in 30% lethality.Methods.", [["metformin", "CHEMICAL", 146, 155], ["HCQ", "CHEMICAL", 156, 159], ["metformin", "CHEMICAL", 146, 155], ["HCQ", "CHEMICAL", 156, 159], ["nude mice", "ORGANISM", 39, 48], ["C57BL/6 mice", "ORGANISM", 124, 136], ["metformin", "SIMPLE_CHEMICAL", 146, 155], ["HCQ", "SIMPLE_CHEMICAL", 156, 159], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 132, 136], ["immunocompromised nude mice", "PROBLEM", 21, 48], ["the metformin", "TREATMENT", 142, 155], ["HCQ", "TREATMENT", 156, 159]]], ["Animal experiments were conducted following approval by the Animal Care and UseWe then sought to determine the basis for the toxicity of metformin+HCQ combination in autopsy studies and found that body weights were not significantly different ( Table 1) among the different groups.", [["body", "ANATOMY", 197, 201], ["toxicity", "DISEASE", 125, 133], ["metformin", "CHEMICAL", 137, 146], ["HCQ", "CHEMICAL", 147, 150], ["metformin", "CHEMICAL", 137, 146], ["HCQ", "CHEMICAL", 147, 150], ["metformin", "SIMPLE_CHEMICAL", 137, 146], ["HCQ", "SIMPLE_CHEMICAL", 147, 150], ["body", "ORGANISM_SUBDIVISION", 197, 201], ["metformin", "TREATMENT", 137, 146], ["HCQ", "TREATMENT", 147, 150], ["autopsy studies", "TEST", 166, 181], ["body weights", "TEST", 197, 209]]], ["While organ weights were not different among the groups, we observed via transmission electron microscopy an increase in the number of autophagosomes in the heart, liver and kidneys of athymic nude mice treated with metformin+HCQ combination ( Figure 1C) .", [["organ", "ANATOMY", 6, 11], ["autophagosomes", "ANATOMY", 135, 149], ["heart", "ANATOMY", 157, 162], ["liver", "ANATOMY", 164, 169], ["kidneys", "ANATOMY", 174, 181], ["metformin", "CHEMICAL", 216, 225], ["HCQ", "CHEMICAL", 226, 229], ["metformin", "CHEMICAL", 216, 225], ["HCQ", "CHEMICAL", 226, 229], ["organ", "ORGAN", 6, 11], ["autophagosomes", "CELLULAR_COMPONENT", 135, 149], ["heart", "ORGAN", 157, 162], ["liver", "ORGAN", 164, 169], ["kidneys", "ORGAN", 174, 181], ["nude mice", "ORGANISM", 193, 202], ["metformin", "SIMPLE_CHEMICAL", 216, 225], ["HCQ", "SIMPLE_CHEMICAL", 226, 229], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 198, 202], ["organ weights", "TEST", 6, 19], ["transmission electron microscopy", "TEST", 73, 105], ["athymic nude mice", "TREATMENT", 185, 202], ["metformin", "TREATMENT", 216, 225], ["HCQ", "TREATMENT", 226, 229], ["increase", "OBSERVATION_MODIFIER", 109, 117], ["autophagosomes", "OBSERVATION", 135, 149], ["heart", "ANATOMY", 157, 162], ["liver", "ANATOMY", 164, 169], ["kidneys", "ANATOMY", 174, 181]]], ["While the hematological findings were not different among the groups, we found that lactate dehydrogenase (LDH) and creatine kinase (CK) levels were elevated in all treatment groups as compared to control vehicle treated group ( Table 1 ).Methods.", [["lactate", "CHEMICAL", 84, 91], ["creatine", "CHEMICAL", 116, 124], ["lactate", "CHEMICAL", 84, 91], ["creatine", "CHEMICAL", 116, 124], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 84, 105], ["LDH", "GENE_OR_GENE_PRODUCT", 107, 110], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 116, 131], ["CK", "GENE_OR_GENE_PRODUCT", 133, 135], ["lactate dehydrogenase", "PROTEIN", 84, 105], ["LDH", "PROTEIN", 107, 110], ["creatine kinase", "PROTEIN", 116, 131], ["CK", "PROTEIN", 133, 135], ["lactate dehydrogenase", "TEST", 84, 105], ["LDH", "TEST", 107, 110], ["creatine kinase", "TEST", 116, 131], ["CK) levels", "TEST", 133, 143], ["elevated", "OBSERVATION_MODIFIER", 149, 157]]], ["Between March 16 and 21, 2020, partly based on a non-randomized study using HCQ with azithromycin [4] , claims disseminated through Twitter and amplified by the media that CQ or HCQ could be a therapy for COVID-19.", [["HCQ", "CHEMICAL", 76, 79], ["azithromycin", "CHEMICAL", 85, 97], ["CQ", "CHEMICAL", 172, 174], ["HCQ", "CHEMICAL", 178, 181], ["HCQ", "CHEMICAL", 76, 79], ["azithromycin", "CHEMICAL", 85, 97], ["HCQ", "CHEMICAL", 178, 181], ["COVID-19", "CHEMICAL", 205, 213], ["HCQ", "SIMPLE_CHEMICAL", 76, 79], ["azithromycin", "SIMPLE_CHEMICAL", 85, 97], ["CQ", "SIMPLE_CHEMICAL", 172, 174], ["HCQ", "SIMPLE_CHEMICAL", 178, 181], ["a non-randomized study", "TEST", 47, 69], ["HCQ", "TREATMENT", 76, 79], ["azithromycin", "TREATMENT", 85, 97], ["HCQ", "TREATMENT", 178, 181], ["a therapy", "TREATMENT", 191, 200], ["COVID", "TEST", 205, 210]]], ["Many individuals have started to take this drug, resulting in chloroquine poisoning in Nigeria ( #COVID19Nigeria) and a death in Arizona.", [["chloroquine", "CHEMICAL", 62, 73], ["poisoning", "DISEASE", 74, 83], ["death", "DISEASE", 120, 125], ["chloroquine", "CHEMICAL", 62, 73], ["individuals", "ORGANISM", 5, 16], ["chloroquine", "SIMPLE_CHEMICAL", 62, 73], ["chloroquine poisoning", "PROBLEM", 62, 83]]], ["Notably, CQ and HCQ doses which are used for the treatment of rheumatic diseases, could lead to the development of hypoglycemia, cardiomyopathy and retinopathy [5] .Methods.", [["CQ", "CHEMICAL", 9, 11], ["HCQ", "CHEMICAL", 16, 19], ["rheumatic diseases", "DISEASE", 62, 80], ["hypoglycemia", "DISEASE", 115, 127], ["cardiomyopathy", "DISEASE", 129, 143], ["retinopathy", "DISEASE", 148, 159], ["CQ", "CHEMICAL", 9, 11], ["HCQ", "CHEMICAL", 16, 19], ["CQ", "SIMPLE_CHEMICAL", 9, 11], ["HCQ", "SIMPLE_CHEMICAL", 16, 19], ["CQ and HCQ doses", "TREATMENT", 9, 25], ["rheumatic diseases", "PROBLEM", 62, 80], ["hypoglycemia", "PROBLEM", 115, 127], ["cardiomyopathy", "PROBLEM", 129, 143], ["retinopathy", "PROBLEM", 148, 159], ["rheumatic", "OBSERVATION", 62, 71], ["hypoglycemia", "OBSERVATION", 115, 127], ["retinopathy", "OBSERVATION", 148, 159]]], ["Animal experiments were conducted following approval by the Animal Care and UseHere we report the lethality of metformin+CQ or +HCQ as a warning of its potential deadly toxicity, noting that the dosages in mice are similar to those in human with allometric scaling.Methods.", [["metformin", "CHEMICAL", 111, 120], ["CQ", "CHEMICAL", 121, 123], ["HCQ", "CHEMICAL", 128, 131], ["toxicity", "DISEASE", 169, 177], ["metformin", "CHEMICAL", 111, 120], ["CQ", "CHEMICAL", 121, 123], ["HCQ", "CHEMICAL", 128, 131], ["metformin", "SIMPLE_CHEMICAL", 111, 120], ["CQ", "SIMPLE_CHEMICAL", 121, 123], ["+HCQ", "SIMPLE_CHEMICAL", 127, 131], ["mice", "ORGANISM", 206, 210], ["human", "ORGANISM", 235, 240], ["mice", "SPECIES", 206, 210], ["human", "SPECIES", 235, 240], ["mice", "SPECIES", 206, 210], ["human", "SPECIES", 235, 240], ["metformin", "TREATMENT", 111, 120], ["CQ", "TREATMENT", 121, 123], ["HCQ", "TREATMENT", 128, 131]]], ["Animal experiments were conducted following approval by the Animal Care and UseConsistent with our findings, the combination of CQ and metformin resulted in CNS neuronal damage after cardiac arrest in rats [6] .", [["CNS neuronal", "ANATOMY", 157, 169], ["cardiac", "ANATOMY", 183, 190], ["CQ", "CHEMICAL", 128, 130], ["metformin", "CHEMICAL", 135, 144], ["neuronal damage", "DISEASE", 161, 176], ["cardiac arrest", "DISEASE", 183, 197], ["CQ", "CHEMICAL", 128, 130], ["metformin", "CHEMICAL", 135, 144], ["CQ", "SIMPLE_CHEMICAL", 128, 130], ["metformin", "SIMPLE_CHEMICAL", 135, 144], ["CNS neuronal", "CELL", 157, 169], ["cardiac", "ORGAN", 183, 190], ["rats", "ORGANISM", 201, 205], ["rats", "SPECIES", 201, 205], ["CQ", "TREATMENT", 128, 130], ["metformin", "TREATMENT", 135, 144], ["CNS neuronal damage", "PROBLEM", 157, 176], ["cardiac arrest", "PROBLEM", 183, 197], ["CNS", "ANATOMY", 157, 160], ["neuronal damage", "OBSERVATION", 161, 176], ["cardiac", "ANATOMY", 183, 190], ["arrest", "OBSERVATION", 191, 197]]]], "PMC7097130": [["MainThe study of cell biology and embryology in China stemmed from the generation of the eminent biologist Shizhang Bei, who returned to China from Germany in 1929.", [["cell", "ANATOMY", 17, 21], ["cell", "CELL", 17, 21], ["The study", "TEST", 4, 13]]], ["Landmark achievements of Chinese cell biologists in the 1960s and 1970s include the first demonstration of asexual reproduction in amphibians by Xi Zhu (Shanghai Institute of Cell Biology (SICB), CAS)1, and the establishment of the first human liver cancer cell line by Ruiming Chen at the same institute2.MainThe development of molecular and cell biology (MCB) in the subsequent two decades was compromised by the agenda and resources available in the country, as the nation spent its limited resources on areas tied to the nation's economy and interests.", [["cell", "ANATOMY", 33, 37], ["Cell", "ANATOMY", 175, 179], ["liver cancer cell line", "ANATOMY", 244, 266], ["cell", "ANATOMY", 343, 347], ["liver cancer", "DISEASE", 244, 256], ["Chinese cell", "CELL", 25, 37], ["Cell", "CELL", 175, 179], ["human", "ORGANISM", 238, 243], ["liver cancer cell line", "CELL", 244, 266], ["cell", "CELL", 343, 347], ["human liver cancer cell line", "CELL_LINE", 238, 266], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 238, 243], ["the first human liver cancer cell line", "TREATMENT", 228, 266], ["Chinese cell", "OBSERVATION", 25, 37], ["liver", "ANATOMY", 244, 249], ["cancer", "OBSERVATION", 250, 256], ["cell line", "OBSERVATION", 257, 266], ["molecular", "OBSERVATION_MODIFIER", 329, 338], ["cell", "OBSERVATION", 343, 347]]], ["The political movements also set all scientific research curricula back during this period, until China opened its door to the West in the 1980s.", [["political movements", "OBSERVATION", 4, 23]]], ["In the next two decades, a large population of Chinese students and scholars went abroad to study modern sciences, including MCB.", [["large", "OBSERVATION_MODIFIER", 27, 32], ["population", "OBSERVATION_MODIFIER", 33, 43]]], ["Although these scholars made great discoveries overseas, the development of MCB research in China remained slow-paced due to the lack of expertise, resources and financial support.MainDuring the past decade, many MCB-based research centres and programmes in China have made ground-breaking progress, which has attracted international collaborators and prompted the return of thousands of Chinese scientists from overseas.", [["slow-paced", "PROBLEM", 107, 117], ["financial support", "TREATMENT", 162, 179]]], ["The Chinese Society for Cell Biology (CSCB) was founded in 1980, and it currently has 7000 active members, which represents 20% of MCB researchers in China.", [["Cell", "ANATOMY", 24, 28], ["Cell", "CELL", 24, 28]]], ["The CSCB has played an increasingly important part in advancing MCB research in China by organizing biennial national meetings, sponsoring special conferences and workshops on selective topics and advocating the need for initiating specific research and funding programmes for emerging scientific areas.", [["CSCB", "CHEMICAL", 4, 8], ["CSCB", "CANCER", 4, 8], ["funding programmes", "TREATMENT", 254, 272]]], ["This Essay highlights the current organization of MCB research programmes in China, funding opportunities and application procedures, career development initiatives for Chinese scientists returning from abroad and for foreign scholars, as well as the opportunities for scientific collaborations.Organization of MCB researchThere are two main streams of MCB research in China, one of which is orchestrated by the CAS.", [["application procedures", "TREATMENT", 110, 132], ["MCB research", "OBSERVATION", 311, 323], ["two", "OBSERVATION_MODIFIER", 333, 336], ["main", "OBSERVATION_MODIFIER", 337, 341], ["streams", "OBSERVATION_MODIFIER", 342, 349], ["MCB", "OBSERVATION_MODIFIER", 353, 356], ["research", "OBSERVATION", 357, 365], ["CAS", "OBSERVATION", 412, 415]]], ["Twenty institutes that have MCB research as part of their research portfolios are under the wing of the CAS, and a number of key national laboratories are within and across these institutes.", [["CAS", "OBSERVATION", 104, 107]]], ["The institutes under the CAS are located throughout China, although a higher number of them are in Beijing and Shanghai.", [["CAS", "OBSERVATION", 25, 28], ["higher", "OBSERVATION_MODIFIER", 70, 76], ["number", "OBSERVATION_MODIFIER", 77, 83]]], ["Some of the institutes possessing active MCB programmes under the CAS are listed in Fig. 2, and a full list can be found on the CAS website.Organization of MCB researchThe second stream of MCB research is governed by the Chinese Ministry of Education (MOE).", [["active MCB programmes", "TREATMENT", 34, 55], ["MCB research", "OBSERVATION", 156, 168]]], ["Most research universities started building their MCB programmes around 5 years ago, and they have attracted a large number of young talents under central government initiatives such as the 'Thousand Talent' and 'Young Thousand Talent' projects.", [["large", "OBSERVATION_MODIFIER", 111, 116]]], ["Some of the major universities that conduct MCB research and have the relevant educational curriculum are shown in Fig. 2, and a full list can also be found on the MOE's website.Organization of MCB researchThe birth of the National Institute of Biological Sciences (NIBS) in Beijing in April 2003 represents a new model system for conducting world-class MCB research in China.", [["MCB research", "OBSERVATION", 194, 206]]], ["Today, the NIBS model has been adopted in other research units to help promote the career development of young scientists.Funding programmes for MCB in ChinaAn interactive, intellectual environment and funding programmes that provide an incentive to scientists are key to ensuring scientific advances and breakthroughs in MCB research in China.", [["the NIBS model", "TEST", 7, 21]]], ["There are several independent funding programmes in China (Table 1).", [["several", "OBSERVATION_MODIFIER", 10, 17], ["independent", "OBSERVATION_MODIFIER", 18, 29], ["funding", "OBSERVATION", 30, 37]]], ["For both basic and translational MCB research, the NSFC, a leading funding organization that was founded in 1986, is the major channel of financial support.", [["NSFC", "DISEASE", 51, 55], ["NSFC", "CANCER", 51, 55], ["financial support", "TREATMENT", 138, 155], ["financial support", "OBSERVATION", 138, 155]]], ["Funded projects cover almost all disciplines of MCB, and the recent funding invested by the government exhibits a typical annual growth of 20%.", [["funding", "OBSERVATION", 68, 75], ["growth", "OBSERVATION_MODIFIER", 129, 135]]], ["This has resulted in seminal findings and high-impact publications in recent years, which has argued convincingly for continued support for MCB research.", [["seminal", "ORGANISM_SUBSTANCE", 21, 28], ["seminal findings", "PROBLEM", 21, 37], ["MCB research", "TREATMENT", 140, 152], ["seminal", "ANATOMY", 21, 28], ["high", "OBSERVATION_MODIFIER", 42, 46]]], ["Recently, the NSFC joined the National Institutes of Health (NIH) in the United States to fund bilateral collaboration grants to promote scientific exchange and collaboration between the two nations (see below) (Table 1).Funding programmes for MCB in ChinaThe second avenue for funding basic and translational research in MCB is the MOST.", [["MOST", "DNA", 333, 337], ["funding basic", "TREATMENT", 278, 291]]], ["The new programme now includes several specific research areas such as protein sciences, stem cell research, reproductive biology and developmental biology.Funding programmes for MCB in ChinaOne of the major differences between NSFC and MOST grants is the application format.", [["stem cell", "ANATOMY", 89, 98], ["stem cell", "CELL", 89, 98], ["NSFC", "CANCER", 228, 232], ["new", "OBSERVATION_MODIFIER", 4, 7], ["stem cell", "OBSERVATION", 89, 98]]], ["MOH grants fund translational biology-based projects (such as the development of new drugs) that focus on the most prevalent diseases in China.", [["new drugs", "TREATMENT", 81, 90], ["most prevalent", "OBSERVATION_MODIFIER", 110, 124], ["diseases", "OBSERVATION", 125, 133]]], ["These grants primarily fund consortium efforts in which a large number of cross-disciplinary teams tackle problems associated with HIV infection and viral hepatitis, two major epidemic health threats in China.", [["HIV infection", "DISEASE", 131, 144], ["viral hepatitis", "DISEASE", 149, 164], ["HIV", "ORGANISM", 131, 134], ["HIV", "SPECIES", 131, 134], ["HIV", "SPECIES", 131, 134], ["HIV infection", "PROBLEM", 131, 144], ["viral hepatitis", "PROBLEM", 149, 164], ["large", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 135, 144], ["viral hepatitis", "OBSERVATION", 149, 164]]], ["This newly developed funding scheme is less organized and has recently been criticised.", [["funding", "OBSERVATION", 21, 28], ["less organized", "OBSERVATION_MODIFIER", 39, 53]]], ["In particular the depth of evaluation systems was subject to criticism, as the MOH has an underdeveloped peer-review system and is less experienced in grant administration.", [["evaluation systems", "TEST", 27, 45]]], ["With a new central government and its strategic creation of a big and interactive MOH (this is combined with a family planning policy), this funding channel is expected to be overhauled and optimized.Funding programmes for MCB in ChinaTypically, applications for funding from the NSFC and MOST are due once a year in March compared with three cycles per year for NIH funding.", [["NIH funding", "TREATMENT", 363, 374], ["new", "OBSERVATION_MODIFIER", 7, 10], ["central government", "OBSERVATION", 11, 29]]], ["Given the relatively short history of research funding administration in China and its fast pace of growth, optimizing the procedures involved will accelerate research and development in MCB in China.", [["research funding administration", "TREATMENT", 38, 69], ["the procedures", "TREATMENT", 119, 133]]], ["In addition, there is an internal funding pipeline within the CAS to support MCB research.", [["an internal funding pipeline", "PROBLEM", 22, 50], ["internal", "OBSERVATION_MODIFIER", 25, 33], ["funding pipeline", "OBSERVATION", 34, 50]]], ["However, there are no regular deadlines, and the programmes are orchestrated by specific requests for application.Funding programmes for MCB in ChinaIt is worth noting that the funding agencies in China are taking increasingly strict measures with regard to scientific ethics to minimize the issue of scientific misconduct that has occurred in China and could setback the fast-growing phase of scientific research and development.Attracting Chinese and foreign scholarsTalented researchers drive the fast-growing scientific development in MCB research in China.", [["no", "UNCERTAINTY", 19, 21], ["regular", "OBSERVATION_MODIFIER", 22, 29], ["deadlines", "OBSERVATION", 30, 39], ["foreign scholars", "OBSERVATION", 453, 469]]], ["The Hundred Talent scientists are generally provided with ample laboratory space, a solid start-up package and the position of Principal Investigator.", [["a solid start-up package", "TREATMENT", 82, 106]]], ["Today, many Hundred Talent recruits remain active in research and education in academic settings in CAS institutes and universities beyond this.", [["active", "OBSERVATION_MODIFIER", 43, 49]]], ["The Hundred Talent project also has a partnership with the Max Planck Society (MPS) in Germany, and Gang Pei returned from the USA as a CAS\u2013MPS junior group leader in 1995.Attracting Chinese and foreign scholarsIn 1998, Li Ka Shing, the president of Cheung Kong Holdings (a company that develops residential, office, retail, industrial and hotel properties in Hong Kong), worked with the MOE to build the 'Cheung Kong Scholars' programme for recruiting research scholars and professors from overseas, regardless of their nationalities, to universities nationwide to work for the MOE.", [["MPS", "DISEASE", 140, 143], ["Li", "CHEMICAL", 220, 222], ["foreign scholars", "OBSERVATION", 195, 211]]], ["Eminent haematologist and leukaemia cell biologist Zhu Chen was one of the first Cheung Kong Scholars.", [["leukaemia cell", "ANATOMY", 26, 40], ["leukaemia", "DISEASE", 26, 35], ["leukaemia cell", "CELL", 26, 40], ["leukaemia cell", "OBSERVATION", 26, 40]]], ["Today, many Cheung Kong Scholars are actively engaged in research, education and scientific administration nationwide.Attracting Chinese and foreign scholarsGiven the success of the aforementioned talent-recruiting strategies, the rapid development of the country's economy and the urgent need to recruit additional talents to encourage economic transformation, the central government initiated an ambitious Thousand Talent project in 2008.", [["economic transformation", "PROBLEM", 337, 360], ["foreign scholars", "OBSERVATION", 141, 157]]], ["In addition, they are offered a salary scale comparable to their earnings overseas.", [["a salary scale", "TREATMENT", 30, 44]]], ["Distinguished programmed cell death researcher Xiaodong Wang was one of the first Thousand Talent investigators, and he relocated to China from the United States.", [["cell", "ANATOMY", 25, 29], ["death", "DISEASE", 30, 35], ["cell", "CELL", 25, 29], ["cell death", "OBSERVATION", 25, 35]]], ["However, the overall full-time employment rate is far below the number of candidates who have been awarded one of these grants, as many successful candidates remain at the stage of negotiation and planning for their research projects in China.Attracting Chinese and foreign scholarsThe central government subsequently initiated the Young Thousand Talent recruitment programme (introduced above).", [["foreign scholars", "OBSERVATION", 266, 282], ["central", "ANATOMY_MODIFIER", 286, 293]]], ["So far, four groups of scientists have been selected under this project, which brought a total of 400 scholars to China, the majority of which are Chinese, while the fifth group is being reviewed.Attracting Chinese and foreign scholarsFinally, there are programmes similar to the Thousand Talent programme aiming to recruit tenured faculty members of foreign nationalities.", [["foreign scholars", "OBSERVATION", 219, 235], ["foreign nationalities", "OBSERVATION", 351, 372]]], ["All career development plan applications begin with the human resources department of the perspective institutes and/or universities.", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61]]], ["There is a dramatic increase in academic job advertisements from Chinese institutes in major scientific journals, such as Science and Nature, and on the institutes' websites.", [["dramatic", "OBSERVATION_MODIFIER", 11, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28]]], ["Recently, the NIH has jointly awarded grants with the NSFC for collaborative projects related to cancer, allergies, immunology and infectious diseases, using supplemental mechanisms that provide additional funding for joint studies (see NIH funding opportunities and notices).", [["cancer", "ANATOMY", 97, 103], ["cancer", "DISEASE", 97, 103], ["allergies", "DISEASE", 105, 114], ["infectious diseases", "DISEASE", 131, 150], ["NSFC", "CANCER", 54, 58], ["cancer", "CANCER", 97, 103], ["cancer", "PROBLEM", 97, 103], ["allergies", "PROBLEM", 105, 114], ["supplemental mechanisms", "TREATMENT", 158, 181], ["joint studies", "TEST", 218, 231], ["cancer", "OBSERVATION", 97, 103], ["joint", "ANATOMY", 218, 223]]], ["The timely and joint publication in high impact journals is essential for renewals.", [["joint", "ANATOMY", 15, 20], ["publication", "OBSERVATION", 21, 32]]], ["Typically, this is a 5-year grant with an annual budget of 100,000 US dollars to support expenses related to scientific exchange and technology transfer.", [["scientific exchange", "TREATMENT", 109, 128]]], ["In addition, bilateral collaboration grants are available that are awarded through a request for applications procedure.", [["applications procedure", "TREATMENT", 97, 119], ["bilateral", "ANATOMY_MODIFIER", 13, 22], ["collaboration grants", "OBSERVATION", 23, 43]]], ["For this type of grant, both the Chinese investigator and the foreign collaborator should write and submit their applications to the NSFC and the respective co-sponsoring agency in the country of the collaborator.", [["NSFC", "CANCER", 133, 137]]], ["In general, the NSFC provides funding support to the Chinese applicants and finances travel in both directions between the awardees and their foreign collaborators, while funding from the collaborators' country supports their research and travel expenses for scientific exchanges.", [["foreign collaborators", "OBSERVATION", 142, 163]]], ["The criteria for funding this type of joint venture are based on the merit of the collaboration, which is assessed individually on both sides by the respective funding agencies.", [["joint", "ANATOMY", 38, 43]]], ["The typical 5-year programme requires annual exchange visits, one scientific workshop or conference per funding cycle to train young scholars and joint peer-reviewed publications on the proposed project.", [["joint", "ANATOMY", 146, 151]]], ["This type of joint grant can be renewed upon its successful completion.", [["joint", "ANATOMY", 13, 18]]], ["Typically, guidelines for the aforementioned grant applications are published on the NSFC website in late December, with a due date for applications in mid-March of the following year.Publishing and exchanging MCBThere is a long list of scientific journals in China that publish MCB-related studies.", [["publish MCB", "TEST", 271, 282]]], ["In recent years, the initiative of developing China's own brand-name international journals has received increasing support from multiple parties, including governmental agencies, local institutions and the broad community of scientists.", [["increasing support", "TREATMENT", 105, 123]]], ["As a result, premium international journals are starting to emerge from China, a prominent example of which is Cell Research.", [["Cell", "ANATOMY", 111, 115], ["Cell", "CELL", 111, 115]]], ["This journal has an impact factor that is competitive with key international journals and it is co-sponsored by the Institute of Biochemistry and Cell Biology (IBCB), Shanghai Institutes for Biological Sciences (SIBS), CAS and CSCB.", [["Cell", "ANATOMY", 146, 150], ["CAS", "PROBLEM", 219, 222]]], ["There is no doubt that as scientific research continues to flourish in China, more good-quality journals will emerge from Chinese biological societies.Publishing and exchanging MCBScientific communication and conferences in China have also benefited from the rapid economic growth, as well as from intellectual input from scientists who return to China from overseas.", [["no doubt", "UNCERTAINTY", 9, 17]]], ["Traditionally, there have been few high-quality scientific conferences in China; one of these, the Xiangshan Science Conference (which covers select subjects) is sponsored by the CAS and NSFC.", [["NSFC", "CANCER", 187, 191], ["few", "OBSERVATION_MODIFIER", 31, 34], ["high", "OBSERVATION_MODIFIER", 35, 39], ["CAS", "OBSERVATION", 179, 182]]], ["However, a number of high-quality international conferences have taken place in China since 2008.", [["high", "OBSERVATION_MODIFIER", 21, 25]]], ["It has now developed into a biennial event that attracts world-renowned cell biologists from abroad (Fig. 3).", [["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["a biennial event", "PROBLEM", 26, 42], ["biennial", "OBSERVATION_MODIFIER", 28, 36]]], ["So far, CSHL Asia conferences are deemed to be very successful, aside from the high fees.Publishing and exchanging MCBIn addition to international conferences, the CSCB holds its biennial 'Mountain Meeting' series to present exciting unpublished advances on select topics.", [["the CSCB", "TREATMENT", 160, 168], ["successful", "OBSERVATION", 52, 62]]], ["Moreover, the CSCB also holds a biennial meeting that aims to be similar in scope to the American Society for Cell Biology (ASCB) meeting.", [["Cell", "ANATOMY", 110, 114], ["Cell", "CELL", 110, 114]]], ["The most recent meeting was held 19\u201321 April 2013 and featured distinguished plenary speakers from abroad.", [["plenary speakers", "OBSERVATION", 77, 93]]], ["It is also encouraging to see that the visa application procedures for Chinese scholars attending overseas symposiums, such as the ASCB annual meeting and Gordon Research Conferences, has been simplified over recent years.Enhancing MCB research in ChinaAlthough MCB research in China has evolved rapidly over the past decade, there is certainly room for improvement in the scientific environment and in scientific output.", [["Enhancing MCB research", "PROBLEM", 222, 244], ["MCB", "OBSERVATION_MODIFIER", 232, 235], ["research", "OBSERVATION", 236, 244], ["rapidly", "OBSERVATION_MODIFIER", 296, 303]]], ["Specifically, the molecular delineation of the general principles that govern cellular plasticity and dynamics often requires synergism among chemistry, photonics, physics, mathematics and biology.", [["cellular", "ANATOMY", 78, 86], ["cellular", "CELL", 78, 86], ["photonics", "TREATMENT", 153, 162], ["cellular plasticity", "OBSERVATION", 78, 97]]], ["Scientific committees consisting of distinguished international scientists could also be deployed to provide scientific input and evaluation every 3\u20135 years.", [["evaluation", "TEST", 130, 140]]], ["However, very few MCB programmes across the nation have an active international advisory committee.", [["active", "OBSERVATION_MODIFIER", 59, 65]]], ["The recently established Protein Science Centres in Shanghai and Beijing represent a great opportunity for achieving a more efficient organization of the country's scientific research programmes, as they are a great resource for supporting the MCB research community in China by providing visiting scholar programmes and core facilities.", [["Protein Science", "OBSERVATION", 25, 40]]], ["This would avoid a 1-year gap in funding for such researchers and also the time spent on the application process; funding sources such as the 973, 863 and NSFC key projects require a second level of peer-review which consists of giving an oral presentation in front of a scientific panel.", [["oral", "ANATOMY", 239, 243], ["oral", "ORGANISM_SUBDIVISION", 239, 243], ["a scientific panel", "TEST", 269, 287]]], ["In addition, it would be cost-effective and productive if a 1-year extension that does not require the award of any new funding could be granted to researchers so that they don't have to rush to spend the remaining funds towards the end of a 5-year grant.Enhancing MCB research in ChinaIt is also important to mentor young scientists at the early stages of their careers, as the scientific community needs 'new blood' to ensure that great scientific discoveries are made in the future.", [["blood", "ANATOMY", 411, 416], ["blood", "ORGANISM_SUBSTANCE", 411, 416], ["MCB", "OBSERVATION_MODIFIER", 265, 268], ["research", "OBSERVATION", 269, 277]]], ["It is interesting to note that the tenure-track system has begun to be launched at universities and institutes in China, such as Tsinghua University and the NIBS, to promote the career development of early stage and mid-stage scientists.", [["the NIBS", "TREATMENT", 153, 161], ["early stage and mid-stage scientists", "PROBLEM", 200, 236]]], ["Given the differences in research culture between the West and China, it will be very helpful for young principal investigators who have just started their own independent laboratories in China to be mentored by established early career scientists returning from abroad.", [["research culture", "TEST", 25, 41]]], ["Along the line of career development, fair merit-based evaluation will certainly strengthen scientific advances.Enhancing MCB research in ChinaTo promote scientific exchange, the CSCB has initiated collaborations with partner societies, such as the ASCB and the Asia Pacific Organization of Cell Biology, to co-sponsor conferences and workshops.", [["Cell", "ANATOMY", 291, 295], ["CSCB", "CHEMICAL", 179, 183], ["Cell", "CELL", 291, 295], ["based evaluation", "TEST", 49, 65], ["line", "OBSERVATION_MODIFIER", 10, 14]]], ["The CSCB will continue to improve research and training environments by organizing joint conferences with partner societies on specialized topics and providing low-fee access to graduate students and postdoctoral fellows.PerspectivesCells are a basic unit of life; all molecules play their parts on the cellular stage in order to participate in the spectacular complexity and diversity seen in a living organism.", [["Cells", "ANATOMY", 233, 238], ["cellular", "ANATOMY", 303, 311], ["Cells", "CELL", 233, 238], ["cellular", "CELL", 303, 311], ["The CSCB", "TREATMENT", 0, 8], ["a basic unit of life", "TREATMENT", 243, 263], ["a living organism", "PROBLEM", 394, 411], ["joint", "ANATOMY", 83, 88], ["cellular stage", "OBSERVATION_MODIFIER", 303, 317]]], ["Like all other basic scientific disciplines, MCB research demands not only quantitative, combinatory and systematic scientific approaches with experimental and conceptual novelty, but also the overhaul of infrastructures, funding mechanisms and, even more crucially, the culture, so that these parameters are comparable between countries.", [["the culture", "TEST", 267, 278]]], ["Cultural changes pose a more challenging task than changes in infrastructure or funding strategies, especially in a country with a history of several 1000 years like China.", [["Cultural changes", "PROBLEM", 0, 16]]], ["The scientific advances during the past two decades in China seem to provide good reason for optimism and confidence that the trend will continue for another 20 years, as long as it relies more on the power and creativity of each 'cell', the individual scientist.", [["cell", "ANATOMY", 231, 235], ["cell", "CELL", 231, 235]]]], "PMC7413663": [["IntroductionAt the writing of this manuscript, the United States has over 1.5 million confirmed cases and over 90,00 deaths related to the novel coronavirus 2019 (COVID-19).1 This pandemic has brought deep-seated inequities in the US health care system to the forefront of public consciousness.2,3 In the first month of the outbreak, evidence appeared that there would be a higher burden of COVID-19 infection, hospitalization, and mortality in black patients as compared to white patients.4 In New York City, the case rate was 1.6 times higher in black and 1.4 times higher in Latinx residents than white residents.5 Further, the death rate for each group is twice as high as in their white counterparts.", [["deaths", "DISEASE", 117, 123], ["2,3", "CHEMICAL", 294, 297], ["infection", "DISEASE", 400, 409], ["death", "DISEASE", 631, 636], ["2,3", "SIMPLE_CHEMICAL", 294, 297], ["patients", "ORGANISM", 451, 459], ["patients", "ORGANISM", 481, 489], ["patients", "SPECIES", 451, 459], ["patients", "SPECIES", 481, 489], ["the novel coronavirus", "PROBLEM", 135, 156], ["COVID", "TEST", 163, 168], ["a higher burden of COVID-19 infection", "PROBLEM", 372, 409], ["the case rate", "TEST", 510, 523], ["the death rate", "TEST", 627, 641], ["infection", "OBSERVATION", 400, 409]]]], "5b31a92b9c0bbc361c12fb2c00bcb17ff3fab61c": [["IntroductionMiddle East respiratory syndrome coronavirus (MERS-CoV) is an enveloped virus with a single-stranded RNA genome of positive polarity.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 12, 56], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 12, 56], ["MERS-CoV", "ORGANISM", 58, 66], ["single-stranded RNA genome", "DNA", 97, 123], ["Middle East respiratory syndrome coronavirus", "SPECIES", 12, 56], ["MERS-CoV", "SPECIES", 58, 66], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 12, 56], ["an enveloped virus", "PROBLEM", 71, 89], ["Middle", "ANATOMY_MODIFIER", 12, 18], ["respiratory syndrome", "OBSERVATION", 24, 44], ["virus", "OBSERVATION", 84, 89], ["positive polarity", "OBSERVATION", 127, 144]]], ["It belongs to the Coronaviridae family (genus Betacoronavirus), which is part of the order Nidovirales.", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 18, 31], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 46, 61]]], ["MERS-CoV was isolated in 2012 from the sputum of a 60 year old man suffering from acute pneumonia and renal failure in Saudi Arabia [1] .", [["sputum", "ANATOMY", 39, 45], ["renal", "ANATOMY", 102, 107], ["pneumonia", "DISEASE", 88, 97], ["renal failure", "DISEASE", 102, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["man", "ORGANISM", 63, 66], ["renal", "ORGAN", 102, 107], ["man", "SPECIES", 63, 66], ["MERS-CoV", "SPECIES", 0, 8], ["acute pneumonia", "PROBLEM", 82, 97], ["renal failure", "PROBLEM", 102, 115], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["pneumonia", "OBSERVATION", 88, 97], ["renal", "ANATOMY", 102, 107], ["failure", "OBSERVATION", 108, 115]]], ["Since its discovery, MERS-CoV has caused 2,442 human infections of which 842 (34.5%) had a fatal outcome (as of May, 2019) [2] .", [["infections", "DISEASE", 53, 63], ["MERS-CoV", "ORGANISM", 21, 29], ["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["MERS-CoV", "SPECIES", 21, 29], ["human", "SPECIES", 47, 52], ["human infections", "PROBLEM", 47, 63], ["a fatal outcome", "PROBLEM", 89, 104], ["infections", "OBSERVATION", 53, 63], ["fatal", "OBSERVATION_MODIFIER", 91, 96]]], ["Dromedary camels are reservoir hosts of MERS-CoV and display only common cold-like symptoms upon infection but constitute the main source of human infections.", [["infection", "DISEASE", 97, 106], ["infections", "DISEASE", 147, 157], ["MERS-CoV", "ORGANISM", 40, 48], ["human", "ORGANISM", 141, 146], ["human", "SPECIES", 141, 146], ["MERS-CoV", "SPECIES", 40, 48], ["human", "SPECIES", 141, 146], ["Dromedary camels", "PROBLEM", 0, 16], ["common cold-like symptoms", "PROBLEM", 66, 91], ["infection", "PROBLEM", 97, 106], ["human infections", "PROBLEM", 141, 157], ["infection", "OBSERVATION", 97, 106], ["infections", "OBSERVATION", 147, 157]]], ["Transmission to humans occurs via close contact to animals or contaminated animal products [3] [4] [5] [6] .", [["humans", "ORGANISM", 16, 22], ["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 91, 106], ["humans", "SPECIES", 16, 22], ["humans", "SPECIES", 16, 22]]], ["Human-to-human transmissions seem limited and were mainly observed in health care settings, leading to MERS outbreaks in hospitals [7] [8] [9] [10] [11] [12] .", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 9, 14], ["[7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 131, 157], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["Finally, differences in the tissue specific expression of the cellular receptor for MERS-CoV, DPP4, were recently suggested to account for the differences in MERS-CoV transmission and disease induction in camels and humans, respectively [13, 14] .IntroductionIn order to infect a host (cell) and replicate, MERS-CoV has to deliver its genome into the cellular cytoplasm for gene translation and genome replication.", [["tissue", "ANATOMY", 28, 34], ["cellular", "ANATOMY", 62, 70], ["cell", "ANATOMY", 286, 290], ["cellular cytoplasm", "ANATOMY", 351, 369], ["tissue", "TISSUE", 28, 34], ["cellular", "CELL", 62, 70], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["DPP4", "GENE_OR_GENE_PRODUCT", 94, 98], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 158, 166], ["camels", "ORGANISM", 205, 211], ["humans", "ORGANISM", 216, 222], ["cell", "CELL", 286, 290], ["MERS-CoV", "ORGANISM", 307, 315], ["cellular cytoplasm", "ORGANISM_SUBSTANCE", 351, 369], ["genome", "CELLULAR_COMPONENT", 395, 401], ["cellular receptor", "PROTEIN", 62, 79], ["MERS", "PROTEIN", 84, 88], ["CoV", "PROTEIN", 89, 92], ["DPP4", "PROTEIN", 94, 98], ["MERS", "PROTEIN", 307, 311], ["humans", "SPECIES", 216, 222], ["MERS-CoV", "SPECIES", 84, 92], ["MERS-CoV", "SPECIES", 158, 166], ["camels", "SPECIES", 205, 211], ["humans", "SPECIES", 216, 222], ["MERS-CoV", "SPECIES", 307, 315], ["DPP4", "TEST", 94, 98], ["disease induction", "TREATMENT", 184, 201], ["IntroductionIn", "TREATMENT", 247, 261], ["gene translation", "TREATMENT", 374, 390], ["genome replication", "TREATMENT", 395, 413]]], ["This process is facilitated by the viral spike (S) glycoprotein, a type-I transmembrane protein embedded in the viral envelope.", [["viral spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 35, 63], ["type-I", "GENE_OR_GENE_PRODUCT", 67, 73], ["viral spike (S) glycoprotein", "PROTEIN", 35, 63], ["type-I transmembrane protein", "PROTEIN", 67, 95], ["the viral spike (S) glycoprotein", "PROBLEM", 31, 63], ["a type-I transmembrane protein", "TREATMENT", 65, 95], ["the viral envelope", "PROBLEM", 108, 126], ["viral spike", "OBSERVATION", 35, 46], ["viral envelope", "OBSERVATION", 112, 126]]], ["For host cell entry, the surface unit, S1, of MERS-CoV S binds to the cellular type-II transmembrane protein dipeptidyl peptidase 4 (DPP4, CD26) [15] .", [["cell", "ANATOMY", 9, 13], ["surface unit", "ANATOMY", 25, 37], ["cellular", "ANATOMY", 70, 78], ["host cell", "CELL", 4, 13], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 46, 56], ["cellular", "CELL", 70, 78], ["type-II transmembrane", "GENE_OR_GENE_PRODUCT", 79, 100], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 109, 131], ["DPP4", "GENE_OR_GENE_PRODUCT", 133, 137], ["CD26", "GENE_OR_GENE_PRODUCT", 139, 143], ["S1", "PROTEIN", 39, 41], ["MERS-CoV S", "PROTEIN", 46, 56], ["cellular type-II transmembrane protein", "PROTEIN", 70, 108], ["dipeptidyl peptidase 4", "PROTEIN", 109, 131], ["DPP4", "PROTEIN", 133, 137], ["CD26", "PROTEIN", 139, 143], ["MERS-CoV", "SPECIES", 46, 54], ["MERS", "TEST", 46, 50], ["CoV S binds", "TEST", 51, 62], ["the cellular type", "TEST", 66, 83], ["transmembrane protein dipeptidyl peptidase", "TREATMENT", 87, 129], ["DPP4, CD26)", "TREATMENT", 133, 144], ["host cell entry", "OBSERVATION", 4, 19], ["S1", "ANATOMY", 39, 41]]], ["The structure of the interface between DPP4 and MERS-CoV-S was resolved on the atomic level and fifteen residues in DPP4 were found to make direct contact with residues in the viral S protein [16] .", [["DPP4", "GENE_OR_GENE_PRODUCT", 39, 43], ["DPP4", "GENE_OR_GENE_PRODUCT", 116, 120], ["DPP4", "PROTEIN", 39, 43], ["MERS-CoV-S", "PROTEIN", 48, 58], ["DPP4", "PROTEIN", 116, 120], ["viral S protein", "PROTEIN", 176, 191], ["DPP4", "TEST", 39, 43], ["the atomic level", "TEST", 75, 91], ["fifteen residues in DPP4", "PROBLEM", 96, 120], ["the viral S protein", "TEST", 172, 191]]], ["Upon DPP4 engagement, MERS-CoV S undergoes proteolytic activation through the cellular serine protease TMPRSS2 or the endosomal cysteine protease cathepsin L [17] [18] [19] , which allows the transmembrane unit, S2, of MERS-CoV S to fuse the viral membrane with cellular membranes.IntroductionDPP4 is a prolyl oligopeptidase that is expressed in various tissues [20] and involved in multiple biological processes including T-cell activation [21] , control of the activity of growth factors, chemokines and bioactive peptides [22] [23] [24] , and regulation of the glucose metabolism [25] .", [["cellular", "ANATOMY", 78, 86], ["endosomal", "ANATOMY", 118, 127], ["transmembrane unit", "ANATOMY", 192, 210], ["membrane", "ANATOMY", 248, 256], ["cellular membranes", "ANATOMY", 262, 280], ["tissues", "ANATOMY", 354, 361], ["T-cell", "ANATOMY", 423, 429], ["glucose", "CHEMICAL", 564, 571], ["serine", "CHEMICAL", 87, 93], ["cysteine", "CHEMICAL", 128, 136], ["prolyl", "CHEMICAL", 303, 309], ["glucose", "CHEMICAL", 564, 571], ["DPP4", "GENE_OR_GENE_PRODUCT", 5, 9], ["cellular", "CELL", 78, 86], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 103, 110], ["endosomal", "CELLULAR_COMPONENT", 118, 127], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 219, 229], ["membrane", "CELLULAR_COMPONENT", 248, 256], ["cellular membranes", "CELLULAR_COMPONENT", 262, 280], ["IntroductionDPP4", "GENE_OR_GENE_PRODUCT", 281, 297], ["tissues", "TISSUE", 354, 361], ["T-cell", "CELL", 423, 429], ["[22] [23] [24]", "SIMPLE_CHEMICAL", 525, 539], ["glucose", "SIMPLE_CHEMICAL", 564, 571], ["DPP4", "PROTEIN", 5, 9], ["cellular serine protease", "PROTEIN", 78, 102], ["TMPRSS2", "PROTEIN", 103, 110], ["endosomal cysteine protease", "PROTEIN", 118, 145], ["S2", "PROTEIN", 212, 214], ["MERS-CoV S", "PROTEIN", 219, 229], ["IntroductionDPP4", "PROTEIN", 281, 297], ["prolyl oligopeptidase", "PROTEIN", 303, 324], ["growth factors", "PROTEIN", 475, 489], ["chemokines", "PROTEIN", 491, 501], ["proteolytic activation", "TREATMENT", 43, 65], ["the cellular serine protease TMPRSS2", "TREATMENT", 74, 110], ["the endosomal cysteine protease cathepsin L", "TREATMENT", 114, 157], ["MERS-CoV S", "PROBLEM", 219, 229], ["cellular membranes", "PROBLEM", 262, 280], ["IntroductionDPP4", "TREATMENT", 281, 297], ["a prolyl oligopeptidase", "TREATMENT", 301, 324], ["T-cell activation", "TREATMENT", 423, 440], ["bioactive peptides", "TEST", 506, 524], ["the glucose metabolism", "TEST", 560, 582], ["viral membrane", "OBSERVATION", 242, 256], ["cellular membranes", "OBSERVATION", 262, 280]]], ["Mature DPP4 is embedded in the plasma membrane as a homodimer and each monomer consists of an N-terminal cytoplasmic domain, followed by a transmembrane domain and a large ectodomain, which can be further subdivided into a short stalk domain, a glycosylation-rich and a cysteine-rich region as well as the C-terminal catalytic domain (\u03b1/ \u03b2-hydrolase domain) [26] .", [["plasma membrane", "ANATOMY", 31, 46], ["cytoplasmic", "ANATOMY", 105, 116], ["transmembrane", "ANATOMY", 139, 152], ["N", "CHEMICAL", 94, 95], ["cysteine", "CHEMICAL", 270, 278], ["C", "CHEMICAL", 306, 307], ["DPP4", "GENE_OR_GENE_PRODUCT", 7, 11], ["plasma membrane", "CELLULAR_COMPONENT", 31, 46], ["cytoplasmic", "ORGANISM_SUBSTANCE", 105, 116], ["transmembrane", "CELLULAR_COMPONENT", 139, 152], ["DPP4", "PROTEIN", 7, 11], ["homodimer", "PROTEIN", 52, 61], ["N-terminal cytoplasmic domain", "PROTEIN", 94, 123], ["transmembrane domain", "PROTEIN", 139, 159], ["ectodomain", "PROTEIN", 172, 182], ["short stalk domain", "PROTEIN", 223, 241], ["cysteine-rich region", "PROTEIN", 270, 290], ["C-terminal catalytic domain", "PROTEIN", 306, 333], ["\u03b1", "PROTEIN", 335, 336], ["\u03b2-hydrolase domain", "PROTEIN", 338, 356], ["Mature DPP4", "PROBLEM", 0, 11], ["an N-terminal cytoplasmic domain", "PROBLEM", 91, 123], ["a transmembrane domain", "PROBLEM", 137, 159], ["a large ectodomain", "PROBLEM", 164, 182], ["a short stalk domain", "PROBLEM", 221, 241], ["a cysteine-rich region", "TREATMENT", 268, 290], ["the C-terminal catalytic domain (\u03b1/ \u03b2-hydrolase domain", "TREATMENT", 302, 356], ["DPP4", "OBSERVATION", 7, 11], ["cytoplasmic domain", "OBSERVATION", 105, 123], ["large", "OBSERVATION_MODIFIER", 166, 171], ["ectodomain", "OBSERVATION", 172, 182]]], ["Polymorphisms in the DPP4 gene were implicated in several diseases and conditions, including diabetes [27, 28] and myocardial infarction [29] but their potential impact on MERS-CoV infection has not been analyzed.IntroductionWe asked whether naturally-occurring amino acid polymorphisms in DPP4 residues making contact with MERS-CoV S have an impact on MERS-CoV entry.", [["myocardial", "ANATOMY", 115, 125], ["diabetes", "DISEASE", 93, 101], ["myocardial infarction", "DISEASE", 115, 136], ["infection", "DISEASE", 181, 190], ["amino acid", "CHEMICAL", 262, 272], ["amino acid", "CHEMICAL", 262, 272], ["DPP4", "GENE_OR_GENE_PRODUCT", 21, 25], ["myocardial", "MULTI-TISSUE_STRUCTURE", 115, 125], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 172, 180], ["amino acid", "AMINO_ACID", 262, 272], ["DPP4", "GENE_OR_GENE_PRODUCT", 290, 294], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 324, 334], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 353, 361], ["DPP4 gene", "DNA", 21, 30], ["DPP4", "PROTEIN", 290, 294], ["MERS-CoV S", "PROTEIN", 324, 334], ["MERS-CoV", "SPECIES", 172, 180], ["MERS-CoV", "SPECIES", 353, 361], ["Polymorphisms in the DPP4 gene", "PROBLEM", 0, 30], ["several diseases", "PROBLEM", 50, 66], ["diabetes", "PROBLEM", 93, 101], ["myocardial infarction", "PROBLEM", 115, 136], ["CoV infection", "PROBLEM", 177, 190], ["amino acid polymorphisms", "TREATMENT", 262, 286], ["DPP4 residues", "TREATMENT", 290, 303], ["several", "OBSERVATION_MODIFIER", 50, 57], ["diseases", "OBSERVATION", 58, 66], ["myocardial", "ANATOMY", 115, 125], ["infarction", "OBSERVATION", 126, 136], ["infection", "OBSERVATION", 181, 190]]], ["We identified fourteen polymorphisms by screening public databases and introduced the respective mutations into a DPP4 expression plasmid.", [["DPP4", "GENE_OR_GENE_PRODUCT", 114, 118], ["DPP4 expression plasmid", "DNA", 114, 137], ["screening public databases", "TEST", 40, 66], ["the respective mutations", "TREATMENT", 82, 106], ["a DPP4 expression plasmid", "TREATMENT", 112, 137]]], ["We identified four mutations that reduced MERS-CoV S binding to DPP4 and MERS-CoV S-driven host cell entry without affecting DPP4 expression at the cell surface.Analysis of total DPP4 expression by SDS-PAGE and immunoblot293T cells were transfected with expression vectors for WT or mutant DPP4, or empty expression vector (negative control).", [["cell", "ANATOMY", 96, 100], ["cell surface", "ANATOMY", 148, 160], ["293T cells", "ANATOMY", 221, 231], ["DPP4", "GENE_OR_GENE_PRODUCT", 64, 68], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 73, 83], ["host cell", "CELL", 91, 100], ["DPP4", "GENE_OR_GENE_PRODUCT", 125, 129], ["cell surface", "CELLULAR_COMPONENT", 148, 160], ["DPP4", "GENE_OR_GENE_PRODUCT", 179, 183], ["293T cells", "CELL", 221, 231], ["DPP4", "GENE_OR_GENE_PRODUCT", 290, 294], ["MERS", "PROTEIN", 42, 46], ["DPP4", "PROTEIN", 64, 68], ["DPP4", "PROTEIN", 125, 129], ["DPP4", "PROTEIN", 179, 183], ["immunoblot293T cells", "CELL_LINE", 211, 231], ["expression vectors", "DNA", 254, 272], ["mutant DPP4", "PROTEIN", 283, 294], ["empty expression vector", "DNA", 299, 322], ["four mutations", "PROBLEM", 14, 28], ["reduced MERS-CoV S binding", "PROBLEM", 34, 60], ["DPP4", "TEST", 64, 68], ["MERS", "TEST", 73, 77], ["CoV S", "PROBLEM", 78, 83], ["host cell entry", "TREATMENT", 91, 106], ["total DPP4 expression", "TREATMENT", 173, 194], ["SDS", "TEST", 198, 201], ["immunoblot293T cells", "TREATMENT", 211, 231], ["expression vectors", "TREATMENT", 254, 272], ["WT", "TEST", 277, 279], ["mutant DPP4", "TREATMENT", 283, 294], ["empty expression vector", "TREATMENT", 299, 322]]], ["At 16 h post transfection, the culture medium was replaced and the cells were further incubated for additional 32 h.", [["cells", "ANATOMY", 67, 72], ["cells", "CELL", 67, 72], ["transfection", "TREATMENT", 13, 25], ["the culture medium", "TEST", 27, 45], ["the cells", "PROBLEM", 63, 72]]], ["Then, the cells were washed with PBS and mixed with 2x SDS-sample buffer (0.03 M Tris-HCl, 10% glycerol, 2% SDS, 0.2% bromophenol blue, 1 mM EDTA).", [["cells", "ANATOMY", 10, 15], ["Tris-HCl", "CHEMICAL", 81, 89], ["glycerol", "CHEMICAL", 95, 103], ["bromophenol blue", "CHEMICAL", 118, 134], ["Tris-HCl", "CHEMICAL", 81, 89], ["glycerol", "CHEMICAL", 95, 103], ["bromophenol blue", "CHEMICAL", 118, 134], ["EDTA", "CHEMICAL", 141, 145], ["cells", "CELL", 10, 15], ["Tris-HCl", "SIMPLE_CHEMICAL", 81, 89], ["glycerol", "SIMPLE_CHEMICAL", 95, 103], ["bromophenol blue", "SIMPLE_CHEMICAL", 118, 134], ["EDTA", "SIMPLE_CHEMICAL", 141, 145], ["PBS", "TREATMENT", 33, 36], ["2x SDS", "TREATMENT", 52, 58], ["sample buffer", "TREATMENT", 59, 72], ["Tris", "TEST", 81, 85], ["glycerol", "TREATMENT", 95, 103], ["2% SDS", "TREATMENT", 105, 111], ["0.2% bromophenol blue", "TREATMENT", 113, 134]]], ["Cell lysis was achieved by incubating the samples for 10 min at room temperature followed by incubation at 96\u00b0C for an additional 10 min.", [["Cell", "ANATOMY", 0, 4], ["samples", "ANATOMY", 42, 49], ["Cell", "CELL", 0, 4], ["Cell lysis", "TREATMENT", 0, 10]]], ["The samples were further loaded on polyacrylamide gels and SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) was performed.", [["samples", "ANATOMY", 4, 11], ["SDS-PAGE", "CHEMICAL", 59, 67], ["sodium dodecyl sulfate", "CHEMICAL", 69, 91], ["polyacrylamide", "CHEMICAL", 35, 49], ["sodium dodecyl sulfate", "CHEMICAL", 69, 91], ["polyacrylamide", "CHEMICAL", 92, 106], ["SDS-PAGE", "SIMPLE_CHEMICAL", 59, 67], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 69, 91], ["The samples", "TEST", 0, 11], ["polyacrylamide gels", "TREATMENT", 35, 54], ["SDS", "TEST", 59, 62], ["sodium dodecyl sulfate", "TREATMENT", 69, 91], ["polyacrylamide gel electrophoresis", "TREATMENT", 92, 126]]], ["Next, the proteins were transferred onto nitrocellulose membranes (Hartenstein GmbH) by immunoblotting.", [["membranes", "ANATOMY", 56, 65], ["nitrocellulose", "CHEMICAL", 41, 55], ["membranes", "CELLULAR_COMPONENT", 56, 65], ["nitrocellulose membranes", "TREATMENT", 41, 65]]], ["The membranes were further blocked by incubation in PBS-T (PBS containing 0.5% Tween 20 and 5% skim milk powder) for 30 min at room temperature.", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 100, 104], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["T (PBS", "TREATMENT", 56, 62], ["5% skim milk powder", "TREATMENT", 92, 111]]], ["Afterwards, the membranes were incubated overnight at 4\u00b0C with undiluted supernatant of a hybridoma cell line secreting anti-cMYC antibody 9E10 (for DPP4 detection) or PBS-T containing anti-\u00df-actin (ACTB) antibody (mouse, 1:1,000, Sigma Aldrich).", [["membranes", "ANATOMY", 16, 25], ["supernatant", "ANATOMY", 73, 84], ["hybridoma cell line", "ANATOMY", 90, 109], ["membranes", "CELLULAR_COMPONENT", 16, 25], ["hybridoma cell line", "CELL", 90, 109], ["anti-cMYC antibody 9E10", "GENE_OR_GENE_PRODUCT", 120, 143], ["DPP4", "GENE_OR_GENE_PRODUCT", 149, 153], ["PBS-T", "SIMPLE_CHEMICAL", 168, 173], ["anti-\u00df-actin", "GENE_OR_GENE_PRODUCT", 185, 197], ["ACTB", "GENE_OR_GENE_PRODUCT", 199, 203], ["mouse", "ORGANISM", 215, 220], ["Sigma Aldrich", "ORGANISM", 231, 244], ["hybridoma cell line", "CELL_LINE", 90, 109], ["anti-cMYC antibody 9E10", "PROTEIN", 120, 143], ["DPP4", "PROTEIN", 149, 153], ["PBS-T containing anti-\u00df-actin (ACTB) antibody", "PROTEIN", 168, 213], ["mouse", "SPECIES", 215, 220], ["mouse", "SPECIES", 215, 220], ["a hybridoma cell line secreting anti-cMYC antibody", "TEST", 88, 138], ["DPP4 detection", "TEST", 149, 163], ["PBS", "TEST", 168, 171], ["anti-\u00df-actin (ACTB", "TREATMENT", 185, 203], ["hybridoma cell line", "OBSERVATION", 90, 109]]], ["Following three washing intervals with PBS-T, the membranes were further incubated with PBS-T containing horseradish peroxidaseconjugated anti-mouse antibody (goat, 1:5,000, Dianova) for 1 h at room temperature before an in house-prepared enhanced chemiluminescent solution (0.1 M Tris-HCl [pH 8.6], 250 \u00b5g/ml luminol, 1 mg/ ml para-hydroxycoumaric acid, 0.3% H 2 O 2 ) was added and signals were recorded using the ChemoCam imaging system and the ChemoStar Professional software (Intas Science Imaging Instruments GmbH).Analysis of total DPP4 expression by SDS-PAGE and immunoblotIn order to quantify the signal intensity of the protein bands, the program ImageJ (FIJI distribution) [30] was used.", [["membranes", "ANATOMY", 50, 59], ["Tris-HCl", "CHEMICAL", 281, 289], ["luminol", "CHEMICAL", 310, 317], ["para-hydroxycoumaric acid", "CHEMICAL", 328, 353], ["H 2 O", "CHEMICAL", 360, 365], ["Tris-HCl", "CHEMICAL", 281, 289], ["luminol", "CHEMICAL", 310, 317], ["para-hydroxycoumaric acid", "CHEMICAL", 328, 353], ["H 2 O 2", "CHEMICAL", 360, 367], ["membranes", "CELLULAR_COMPONENT", 50, 59], ["PBS-T", "SIMPLE_CHEMICAL", 88, 93], ["horseradish", "SIMPLE_CHEMICAL", 105, 116], ["goat", "ORGANISM", 159, 163], ["Tris-HCl", "SIMPLE_CHEMICAL", 281, 289], ["luminol", "SIMPLE_CHEMICAL", 310, 317], ["para-hydroxycoumaric acid", "SIMPLE_CHEMICAL", 328, 353], ["H 2 O 2", "SIMPLE_CHEMICAL", 360, 367], ["DPP4", "GENE_OR_GENE_PRODUCT", 539, 543], ["horseradish peroxidaseconjugated anti-mouse antibody", "PROTEIN", 105, 157], ["goat, 1:5,000, Dianova", "PROTEIN", 159, 181], ["DPP4", "PROTEIN", 539, 543], ["protein bands", "PROTEIN", 630, 643], ["horseradish", "SPECIES", 105, 116], ["anti-mouse", "SPECIES", 138, 148], ["goat", "SPECIES", 159, 163], ["goat", "SPECIES", 159, 163], ["PBS", "TEST", 39, 42], ["PBS", "TEST", 88, 91], ["prepared enhanced chemiluminescent solution", "TREATMENT", 230, 273], ["pH", "TEST", 291, 293], ["luminol", "TREATMENT", 310, 317], ["para-hydroxycoumaric acid", "TREATMENT", 328, 353], ["the ChemoCam imaging system", "TEST", 412, 439], ["total DPP4 expression", "TREATMENT", 533, 554], ["SDS", "TEST", 558, 561], ["immunoblot", "TEST", 571, 581], ["the protein bands", "TEST", 626, 643]]], ["To account for differences in the total protein content of the samples and variations, we normalized the DPP4 signals against the respective signals of the loading control (ACTB).Cell culture293T (human kidney cells, DSMZ no. ACC 635), BHK-21 (hamster kidney cells, DSMZ no. ACC 61) and Vero 76 (African green monkey kidney cells, kindly provided by Andrea Maisner, Philipps-University Marburg) were cultivated in Dulbecco's modified Eagle medium (PAN-Biotech) while Caco-2 cells (human colorectal adenocarcinoma cells) were cultivated in Minimum Essential Medium (ThermoFisher Scientific).", [["samples", "ANATOMY", 63, 70], ["Cell", "ANATOMY", 179, 183], ["kidney cells", "ANATOMY", 203, 215], ["DSMZ", "ANATOMY", 217, 221], ["BHK-21", "ANATOMY", 236, 242], ["hamster kidney cells", "ANATOMY", 244, 264], ["DSMZ", "ANATOMY", 266, 270], ["kidney cells", "ANATOMY", 317, 329], ["Caco-2 cells", "ANATOMY", 467, 479], ["colorectal adenocarcinoma cells", "ANATOMY", 487, 518], ["ACC 635", "CHEMICAL", 226, 233], ["BHK-21", "CHEMICAL", 236, 242], ["PAN", "CHEMICAL", 448, 451], ["colorectal adenocarcinoma", "DISEASE", 487, 512], ["DPP4", "GENE_OR_GENE_PRODUCT", 105, 109], ["Cell culture293T", "CELL", 179, 195], ["human", "ORGANISM", 197, 202], ["kidney cells", "CELL", 203, 215], ["DSMZ", "CELL", 217, 221], ["BHK-21", "CELL", 236, 242], ["hamster kidney cells", "CELL", 244, 264], ["DSMZ", "CELL", 266, 270], ["Vero 76", "CELL", 287, 294], ["monkey", "ORGANISM", 310, 316], ["kidney cells", "CELL", 317, 329], ["Caco-2 cells", "CELL", 467, 479], ["human", "ORGANISM", 481, 486], ["colorectal adenocarcinoma cells", "CELL", 487, 518], ["DPP4", "PROTEIN", 105, 109], ["Cell culture293T", "CELL_LINE", 179, 195], ["human kidney cells", "CELL_TYPE", 197, 215], ["DSMZ", "CELL_LINE", 217, 221], ["BHK-21", "CELL_LINE", 236, 242], ["hamster kidney cells", "CELL_LINE", 244, 264], ["DSMZ", "CELL_LINE", 266, 270], ["African green monkey kidney cells", "CELL_TYPE", 296, 329], ["Caco-2 cells", "CELL_LINE", 467, 479], ["human colorectal adenocarcinoma cells", "CELL_TYPE", 481, 518], ["human", "SPECIES", 197, 202], ["hamster", "SPECIES", 244, 251], ["human", "SPECIES", 481, 486], ["human", "SPECIES", 197, 202], ["hamster", "SPECIES", 244, 251], ["African green monkey", "SPECIES", 296, 316], ["human", "SPECIES", 481, 486], ["the DPP4 signals", "TEST", 101, 117], ["the loading control", "TREATMENT", 152, 171], ["Cell culture293T", "TEST", 179, 195], ["human kidney cells", "TEST", 197, 215], ["DSMZ", "TEST", 217, 221], ["ACC", "TEST", 226, 229], ["BHK", "TEST", 236, 239], ["hamster kidney cells", "TEST", 244, 264], ["ACC", "TEST", 275, 278], ["Vero", "TEST", 287, 291], ["Caco-2 cells (human colorectal adenocarcinoma cells", "TREATMENT", 467, 518], ["kidney", "ANATOMY", 203, 209], ["kidney cells", "ANATOMY", 252, 264], ["colorectal", "ANATOMY", 487, 497], ["adenocarcinoma cells", "OBSERVATION", 498, 518], ["Medium", "OBSERVATION_MODIFIER", 557, 563]]], ["The media were supplemented with 10% fetal bovine serum (Biochrom), 100 U/ml of penicillin and 0.1 mg/ml of streptomycin (PAN-Biotech).", [["fetal bovine serum", "ANATOMY", 37, 55], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 108, 120], ["PAN", "CHEMICAL", 122, 125], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 108, 120], ["PAN", "CHEMICAL", 122, 125], ["bovine", "ORGANISM", 43, 49], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["Biochrom", "ORGANISM_SUBSTANCE", 57, 65], ["penicillin", "SIMPLE_CHEMICAL", 80, 90], ["streptomycin", "SIMPLE_CHEMICAL", 108, 120], ["bovine", "SPECIES", 43, 49], ["bovine", "SPECIES", 43, 49], ["10% fetal bovine serum (Biochrom)", "TREATMENT", 33, 66], ["penicillin", "TREATMENT", 80, 90], ["streptomycin", "TREATMENT", 108, 120]]], ["All cell lines were incubated at 37\u00b0C and 5% CO2 in a humidified atmosphere.", [["cell lines", "ANATOMY", 4, 14], ["CO2", "CHEMICAL", 45, 48], ["CO2", "CHEMICAL", 45, 48], ["cell lines", "CELL", 4, 14], ["CO2", "SIMPLE_CHEMICAL", 45, 48], ["cell lines", "CELL_LINE", 4, 14], ["All cell lines", "TREATMENT", 0, 14], ["5% CO2", "TREATMENT", 42, 48], ["a humidified atmosphere", "TREATMENT", 52, 75], ["cell lines", "OBSERVATION", 4, 14]]], ["For subcultivation and seeding, cells were washed with phosphate-buffered saline (PBS) and detached by incubation with trypsin/ EDTA solution (PAN-Biotech) (BHK-21, Vero 76 and Caco-2) or by resuspending the cells in culture medium (293T).", [["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 208, 213], ["293T", "ANATOMY", 233, 237], ["phosphate", "CHEMICAL", 55, 64], ["trypsin/ EDTA", "CHEMICAL", 119, 132], ["PAN", "CHEMICAL", 143, 146], ["phosphate", "CHEMICAL", 55, 64], ["EDTA", "CHEMICAL", 128, 132], ["cells", "CELL", 32, 37], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 55, 80], ["trypsin", "SIMPLE_CHEMICAL", 119, 126], ["EDTA solution", "SIMPLE_CHEMICAL", 128, 141], ["PAN", "SIMPLE_CHEMICAL", 143, 146], ["BHK-21", "CELL", 157, 163], ["Vero 76", "CELL", 165, 172], ["Caco-2", "CELL", 177, 183], ["cells", "CELL", 208, 213], ["293T", "CELL", 233, 237], ["trypsin", "PROTEIN", 119, 126], ["subcultivation", "TREATMENT", 4, 18], ["phosphate-buffered saline (PBS", "TREATMENT", 55, 85], ["trypsin/ EDTA solution", "TREATMENT", 119, 141], ["BHK", "TEST", 157, 160], ["Vero", "TEST", 165, 169], ["Caco", "TEST", 177, 181], ["culture medium", "TEST", 217, 231]]], ["Transfection of 293T and BHK-21 cells was carried out by calcium-phosphate precipitation or with the help of ICAFectin-441 (In-Cell-Art) or FuGENE HD (Promega).Plasmids and generation of DPP4 mutantsAll DPP4 mutants were generated based on a pcDNA3.1/Zeo(+)-based expression vector in which the coding sequence for human DPP4 (GenBank: XM_005246371.3) containing an C-terminal cMYC epitope was inserted into via BamHI/EcoRI restriction sites.", [["293T", "ANATOMY", 16, 20], ["BHK-21 cells", "ANATOMY", 25, 37], ["calcium-phosphate", "CHEMICAL", 57, 74], ["ICAFectin-441", "CHEMICAL", 109, 122], ["calcium-phosphate", "CHEMICAL", 57, 74], ["ICAFectin-441", "CHEMICAL", 109, 122], ["C", "CHEMICAL", 366, 367], ["293T", "CELL", 16, 20], ["BHK-21 cells", "CELL", 25, 37], ["calcium", "SIMPLE_CHEMICAL", 57, 64], ["phosphate", "SIMPLE_CHEMICAL", 65, 74], ["ICAFectin-441", "SIMPLE_CHEMICAL", 109, 122], ["FuGENE", "ORGANISM", 140, 146], ["DPP4", "GENE_OR_GENE_PRODUCT", 187, 191], ["DPP4", "GENE_OR_GENE_PRODUCT", 203, 207], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 242, 248], ["Zeo", "GENE_OR_GENE_PRODUCT", 251, 254], ["human", "ORGANISM", 315, 320], ["DPP4", "GENE_OR_GENE_PRODUCT", 321, 325], ["BamHI", "GENE_OR_GENE_PRODUCT", 412, 417], ["EcoRI", "GENE_OR_GENE_PRODUCT", 418, 423], ["293T", "CELL_LINE", 16, 20], ["BHK-21 cells", "CELL_LINE", 25, 37], ["DPP4 mutants", "PROTEIN", 187, 199], ["DPP4", "PROTEIN", 203, 207], ["pcDNA3.1/Zeo(+)-based expression vector", "DNA", 242, 281], ["human DPP4", "PROTEIN", 315, 325], ["C-terminal cMYC epitope", "DNA", 366, 389], ["BamHI/EcoRI restriction sites", "DNA", 412, 441], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 315, 320], ["Transfection", "TEST", 0, 12], ["BHK", "TEST", 25, 28], ["calcium-phosphate precipitation", "TREATMENT", 57, 88], ["ICAFectin", "TEST", 109, 118], ["FuGENE HD (Promega)", "TREATMENT", 140, 159], ["Plasmids", "TREATMENT", 160, 168], ["DPP4 mutants", "TREATMENT", 187, 199], ["All DPP4 mutants", "TEST", 199, 215], ["a pcDNA3", "TREATMENT", 240, 248], ["an C-terminal cMYC epitope", "TREATMENT", 363, 389], ["BamHI/EcoRI restriction sites", "TREATMENT", 412, 441]]], ["The following aa (amino acid) substitutions were introduced via overlap-extension PCR: K267E, K267N, Q286K, T288I, T288S, A289V, A291P, A291V, R317K, Y322H, I346T, I346V and K392N .", [["amino acid", "CHEMICAL", 18, 28], ["amino acid", "CHEMICAL", 18, 28], ["amino acid", "AMINO_ACID", 18, 28], ["The following aa (amino acid) substitutions", "TREATMENT", 0, 43], ["extension PCR", "TEST", 72, 85], ["K267E", "TEST", 87, 92], ["K267N", "TEST", 94, 99], ["T288I", "TEST", 108, 113], ["T288S", "TEST", 115, 120], ["K392N", "TEST", 174, 179]]], ["In addition, a deletion mutant was generated that lacks aa residues 346-348 (\u0394346-348).", [["a deletion mutant", "PROBLEM", 13, 30]]], ["Information on DPP4 polymorphisms was retrieved from the Ensembl database (https://www.ensembl.org/index.html) [31] and the Single Nucleotide Polymorphism Database (dbSNP) of the National Center for Biotechnology Information (NCBI) (https://www.ncbi.nlm.nih.gov/snp) [32] , and is based on data provided by the gnomAD database (Genome Aggregation database, https://gnomad. broadinstitute.org/), TOPMed program (Trans-Omics for Precision Medicine, https://www.nhlbiwgs.org/), ExAC consortium (Exome Aggregation Consortium, http://exac.broadinstitute.org/) [33] and the 1000G project (1,000 genomes project, http://www. internationalgenome.org/) [34] (For detailed information see Supplementary Table 1) .Plasmids and generation of DPP4 mutantsWe further utilized pCAGGS-based expression vectors for vesicular stomatitis virus (VSV) glycoprotein (G), MERS-CoV S wildtype (WT) and MERS-CoV S (D510G) (the latter two either untagged or equipped with a C-terminal V5 epitope) that have been described elsewhere [35] [36] [37] .", [["vesicular stomatitis", "DISEASE", 798, 818], ["C", "CHEMICAL", 948, 949], ["DPP4", "GENE_OR_GENE_PRODUCT", 15, 19], ["DPP4", "GENE_OR_GENE_PRODUCT", 730, 734], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 762, 768], ["vesicular stomatitis virus", "ORGANISM", 798, 824], ["VSV", "ORGANISM", 826, 829], ["G", "GENE_OR_GENE_PRODUCT", 845, 846], ["MERS-CoV S wildtype", "ORGANISM", 849, 868], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 878, 888], ["DPP4", "PROTEIN", 15, 19], ["gnomAD database", "DNA", 311, 326], ["DPP4 mutants", "PROTEIN", 730, 742], ["pCAGGS", "DNA", 762, 768], ["vesicular stomatitis virus (VSV) glycoprotein", "PROTEIN", 798, 843], ["MERS", "PROTEIN", 849, 853], ["MERS", "PROTEIN", 878, 882], ["CoV S", "PROTEIN", 883, 888], ["C-terminal V5 epitope", "PROTEIN", 948, 969], ["stomatitis virus", "SPECIES", 808, 824], ["stomatitis virus", "SPECIES", 808, 824], ["VSV", "SPECIES", 826, 829], ["MERS-CoV", "SPECIES", 878, 886], ["DPP4 polymorphisms", "TREATMENT", 15, 33], ["Precision Medicine", "TREATMENT", 427, 445], ["Plasmids", "TREATMENT", 703, 711], ["DPP4 mutants", "TREATMENT", 730, 742], ["pCAGGS-based expression vectors", "TREATMENT", 762, 793], ["vesicular stomatitis virus", "PROBLEM", 798, 824], ["glycoprotein (G)", "TREATMENT", 831, 847], ["MERS-CoV S wildtype (WT)", "TREATMENT", 849, 873], ["MERS-CoV S (D510G)", "TREATMENT", 878, 896], ["a C-terminal V5 epitope", "TREATMENT", 946, 969]]], ["In addition, a previously described expression vector for angiotensin converting enzyme 2 was employed [38] .", [["angiotensin", "CHEMICAL", 58, 69], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 58, 89], ["angiotensin converting enzyme 2", "PROTEIN", 58, 89], ["a previously described expression vector", "TREATMENT", 13, 53], ["angiotensin converting enzyme", "TEST", 58, 87]]], ["Similar to the strategy used for the generation of DPP4 mutants, we employed the overlap-extension PCR technique to introduce a single mutation into the MERS-CoV S open reading frame, thus generating untagged and V5-tagged MERS-CoV S (D539N).Plasmids and generation of DPP4 mutantsSoluble S comprising the S1 subdomain of MERS-CoV S (aa residues: 1-747) fused to a human IgG Fc tag was generated by inserting the PCR-amplified S1 sequences into the pCG1Fc vector [39] (kindly provided by Georg Herrler, University of Veterinary Medicine Hannover) making use of the BamHI/SalI restriction sites.", [["DPP4", "GENE_OR_GENE_PRODUCT", 51, 55], ["V5", "GENE_OR_GENE_PRODUCT", 213, 215], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 223, 233], ["DPP4", "GENE_OR_GENE_PRODUCT", 269, 273], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 322, 330], ["human", "ORGANISM", 365, 370], ["IgG Fc tag", "GENE_OR_GENE_PRODUCT", 371, 381], ["pCG1Fc", "GENE_OR_GENE_PRODUCT", 449, 455], ["BamHI", "GENE_OR_GENE_PRODUCT", 565, 570], ["SalI", "GENE_OR_GENE_PRODUCT", 571, 575], ["DPP4 mutants", "PROTEIN", 51, 63], ["MERS-CoV S open reading frame", "DNA", 153, 182], ["V5", "PROTEIN", 213, 215], ["MERS", "PROTEIN", 223, 227], ["CoV S", "PROTEIN", 228, 233], ["DPP4 mutants", "PROTEIN", 269, 281], ["Soluble S", "PROTEIN", 281, 290], ["S1 subdomain", "PROTEIN", 306, 318], ["MERS-CoV S", "PROTEIN", 322, 332], ["human IgG Fc tag", "DNA", 365, 381], ["PCR-amplified S1 sequences", "DNA", 413, 439], ["BamHI/SalI restriction sites", "DNA", 565, 593], ["human", "SPECIES", 365, 370], ["MERS-CoV", "SPECIES", 153, 161], ["human", "SPECIES", 365, 370], ["the generation of DPP4 mutants", "TREATMENT", 33, 63], ["extension PCR technique", "TREATMENT", 89, 112], ["a single mutation", "TREATMENT", 126, 143], ["CoV S", "TEST", 158, 163], ["Plasmids", "TREATMENT", 242, 250], ["DPP4 mutants", "TREATMENT", 269, 281], ["CoV S (aa residues", "TEST", 327, 345], ["a human IgG Fc tag", "TREATMENT", 363, 381], ["the PCR", "TEST", 409, 416], ["the BamHI/SalI restriction sites", "TREATMENT", 561, 593]]], ["In addition, we generated an expression vector for the enhanced green fluorescent protein (eGFP) by inserting the eGFP coding sequence, which was PCR-amplified from the pEGFP-C1 vector (Clontech), into the pCAGGS plasmid using the EcoRI/XhoI restriction sites.Plasmids and generation of DPP4 mutantsAll PCR-amplified sequences were subjected to automated sequence analysis (Microsynth SeqLab) to verify their integrity.", [["plasmid", "ANATOMY", 213, 220], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 64, 89], ["eGFP", "GENE_OR_GENE_PRODUCT", 91, 95], ["eGFP", "GENE_OR_GENE_PRODUCT", 114, 118], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 169, 177], ["Clontech", "GENE_OR_GENE_PRODUCT", 186, 194], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 206, 212], ["EcoRI", "GENE_OR_GENE_PRODUCT", 231, 236], ["XhoI", "GENE_OR_GENE_PRODUCT", 237, 241], ["DPP4", "GENE_OR_GENE_PRODUCT", 287, 291], ["enhanced green fluorescent protein", "PROTEIN", 55, 89], ["eGFP", "PROTEIN", 91, 95], ["eGFP coding sequence", "DNA", 114, 134], ["pEGFP-C1 vector", "DNA", 169, 184], ["Clontech", "DNA", 186, 194], ["pCAGGS plasmid", "DNA", 206, 220], ["EcoRI/XhoI restriction sites", "DNA", 231, 259], ["DPP4 mutants", "PROTEIN", 287, 299], ["PCR-amplified sequences", "DNA", 303, 326], ["Microsynth SeqLab", "DNA", 374, 391], ["an expression vector", "TREATMENT", 26, 46], ["the eGFP coding sequence", "TEST", 110, 134], ["PCR", "TEST", 146, 149], ["the pCAGGS plasmid", "TREATMENT", 202, 220], ["the EcoRI/XhoI restriction sites", "TREATMENT", 227, 259], ["Plasmids", "TREATMENT", 260, 268], ["DPP4 mutants", "TREATMENT", 287, 299], ["All PCR", "TEST", 299, 306], ["amplified sequences", "TEST", 307, 326], ["automated sequence analysis", "TEST", 345, 372], ["XhoI restriction", "OBSERVATION", 237, 253]]], ["Sequences of primers used for cloning of the different constructs are available upon request.Plasmids and generation of DPP4 mutantsAnalysis of DPP4 surface expression by immunofluorescence analysis BHK-21 cells were grown on coverslips and transfected with the different DPP4 constructs or empty expression vector using ICAFectin-441 (In-Cell-Art) at 24 h post seeding according to the manufacturer's instructions.", [["surface", "ANATOMY", 149, 156], ["BHK-21 cells", "ANATOMY", 199, 211], ["ICAFectin-441", "CHEMICAL", 321, 334], ["ICAFectin-441", "CHEMICAL", 321, 334], ["DPP4", "GENE_OR_GENE_PRODUCT", 120, 124], ["DPP4", "GENE_OR_GENE_PRODUCT", 144, 148], ["BHK-21 cells", "CELL", 199, 211], ["DPP4", "GENE_OR_GENE_PRODUCT", 272, 276], ["ICAFectin-441", "SIMPLE_CHEMICAL", 321, 334], ["In-Cell-Art", "CELL", 336, 347], ["DPP4 mutants", "PROTEIN", 120, 132], ["DPP4", "PROTEIN", 144, 148], ["BHK-21 cells", "CELL_LINE", 199, 211], ["DPP4 constructs", "DNA", 272, 287], ["empty expression vector", "DNA", 291, 314], ["Sequences of primers", "TEST", 0, 20], ["Plasmids", "TREATMENT", 93, 101], ["DPP4 mutants", "TREATMENT", 120, 132], ["DPP4 surface expression", "TEST", 144, 167], ["immunofluorescence analysis", "TEST", 171, 198], ["BHK", "TEST", 199, 202], ["coverslips", "TEST", 226, 236], ["the different DPP4 constructs", "TREATMENT", 258, 287], ["empty expression vector", "TREATMENT", 291, 314], ["ICAFectin", "TEST", 321, 330], ["In-Cell-Art", "TREATMENT", 336, 347]]], ["After changing the culture medium at 4 h post transfection, the cells were incubated for additional 20 h.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["the culture medium", "TREATMENT", 15, 33]]], ["Then, the culture medium was aspirated and the cells were washed with PBS, before they were fixed by incubated with PBS containing 4% paraformaldehyde (PBS/PFA) for 15 min at room temperature.", [["cells", "ANATOMY", 47, 52], ["paraformaldehyde", "CHEMICAL", 134, 150], ["PFA", "CHEMICAL", 156, 159], ["cells", "CELL", 47, 52], ["paraformaldehyde", "SIMPLE_CHEMICAL", 134, 150], ["PBS", "SIMPLE_CHEMICAL", 152, 155], ["PFA", "SIMPLE_CHEMICAL", 156, 159], ["the culture medium", "TEST", 6, 24], ["PBS", "TREATMENT", 70, 73], ["PBS", "TREATMENT", 116, 119], ["4% paraformaldehyde (PBS/PFA", "TREATMENT", 131, 159]]], ["Subsequently, the cells were washed with 0.1 M glycine/ PBS solution followed by a washing step with PBS.", [["cells", "ANATOMY", 18, 23], ["glycine", "CHEMICAL", 47, 54], ["glycine", "CHEMICAL", 47, 54], ["cells", "CELL", 18, 23], ["glycine", "SIMPLE_CHEMICAL", 47, 54], ["the cells", "TREATMENT", 14, 23], ["0.1 M glycine/ PBS solution", "TREATMENT", 41, 68], ["a washing step with PBS", "TREATMENT", 81, 104]]], ["Next, the coverslips were incubated with anti-DPP4 antibody (mouse, diluted 1:200 in PBS containing 1% bovine serum albumin [PBS/BSA], Abcam) for 1 h at 4\u00b0C. For this, the coverslip was put on a drop (20 \u00b5l) of antibody solution that was added on a sheet of parafilm inside a humidity chamber (a glass dish in which the parafilm was placed on wet paper tissue).", [["coverslips", "ANATOMY", 10, 20], ["serum", "ANATOMY", 110, 115], ["parafilm", "ANATOMY", 320, 328], ["tissue", "ANATOMY", 353, 359], ["anti-DPP4", "GENE_OR_GENE_PRODUCT", 41, 50], ["mouse", "ORGANISM", 61, 66], ["bovine", "ORGANISM", 103, 109], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["albumin", "SIMPLE_CHEMICAL", 116, 123], ["BSA", "SIMPLE_CHEMICAL", 129, 132], ["Abcam", "GENE_OR_GENE_PRODUCT", 135, 140], ["parafilm", "SIMPLE_CHEMICAL", 258, 266], ["tissue", "TISSUE", 353, 359], ["anti-DPP4 antibody", "PROTEIN", 41, 59], ["mouse", "SPECIES", 61, 66], ["bovine", "SPECIES", 103, 109], ["mouse", "SPECIES", 61, 66], ["the coverslips", "TREATMENT", 6, 20], ["anti-DPP4 antibody", "TREATMENT", 41, 59], ["1% bovine serum albumin [PBS/BSA", "TREATMENT", 100, 132], ["Abcam", "TEST", 135, 140], ["antibody solution", "TREATMENT", 211, 228], ["a sheet of parafilm", "TREATMENT", 247, 266], ["a humidity chamber", "TREATMENT", 274, 292], ["a glass dish", "TREATMENT", 294, 306], ["the parafilm", "TREATMENT", 316, 328], ["humidity chamber", "OBSERVATION", 276, 292], ["glass dish", "OBSERVATION", 296, 306]]], ["Thereafter, the cells were washed 3x with PBS before incubation with AlexaFluor568-conjugated antimouse antibody (goat, 1:1000, diluted in PBS/BSA, ThermoFisher Scientific) for 30 min at 4\u00b0C was performed.", [["cells", "ANATOMY", 16, 21], ["AlexaFluor568", "CHEMICAL", 69, 82], ["AlexaFluor568", "CHEMICAL", 69, 82], ["cells", "CELL", 16, 21], ["AlexaFluor568", "SIMPLE_CHEMICAL", 69, 82], ["goat", "ORGANISM", 114, 118], ["BSA", "SIMPLE_CHEMICAL", 143, 146], ["antimouse antibody", "PROTEIN", 94, 112], ["goat", "SPECIES", 114, 118], ["goat", "SPECIES", 114, 118], ["PBS", "TREATMENT", 42, 45], ["incubation", "TEST", 53, 63], ["AlexaFluor568", "TREATMENT", 69, 82], ["conjugated antimouse antibody", "TREATMENT", 83, 112]]], ["Subsequently, the cells were washed 3x with PBS.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["the cells", "TREATMENT", 14, 23], ["PBS", "TREATMENT", 44, 47]]], ["Finally, the cells were incubated with DAPI (4',6-diamidino-2-phenylindole, Carl Roth) and mounted in ProLong Gold Antifade Mountant (Ther-moFisher Scientific) before they were analyzed using a Zeiss LSM800 (Zeiss) confocal laser scanning microscope and the ZEN imaging software (Zeiss).Plasmids and generation of DPP4 mutantsAnalysis of DPP4 surface expression by flow cytometry BHK-21 cells were transfected with expression vectors for WT or mutant DPP4, or empty expression vector (negative control).", [["cells", "ANATOMY", 13, 18], ["surface", "ANATOMY", 343, 350], ["BHK-21 cells", "ANATOMY", 380, 392], ["DAPI", "CHEMICAL", 39, 43], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 45, 74], ["ZEN", "CHEMICAL", 258, 261], ["DAPI", "CHEMICAL", 39, 43], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 45, 74], ["cells", "CELL", 13, 18], ["DAPI", "SIMPLE_CHEMICAL", 39, 43], ["4',6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 45, 74], ["DPP4", "GENE_OR_GENE_PRODUCT", 314, 318], ["DPP4", "GENE_OR_GENE_PRODUCT", 338, 342], ["BHK-21 cells", "CELL", 380, 392], ["DPP4", "GENE_OR_GENE_PRODUCT", 451, 455], ["DPP4 mutants", "PROTEIN", 314, 326], ["DPP4", "PROTEIN", 338, 342], ["21 cells", "CELL_LINE", 384, 392], ["mutant DPP4", "PROTEIN", 444, 455], ["empty expression vector", "DNA", 460, 483], ["DAPI", "TEST", 39, 43], ["diamidino", "TEST", 50, 59], ["confocal laser scanning microscope", "TEST", 215, 249], ["the ZEN imaging software", "TEST", 254, 278], ["Plasmids", "TREATMENT", 287, 295], ["DPP4 mutants", "TREATMENT", 314, 326], ["DPP4 surface expression", "TEST", 338, 361], ["flow cytometry", "TEST", 365, 379], ["BHK", "TEST", 380, 383], ["cells", "TEST", 387, 392], ["expression vectors", "TREATMENT", 415, 433], ["WT", "TEST", 438, 440], ["mutant DPP4", "TEST", 444, 455], ["empty expression vector", "TREATMENT", 460, 483]]], ["At 16 h post transfection, the culture medium was replaced and the cells were further incubated for additional 32 h.", [["cells", "ANATOMY", 67, 72], ["cells", "CELL", 67, 72], ["transfection", "TREATMENT", 13, 25], ["the culture medium", "TEST", 27, 45], ["the cells", "PROBLEM", 63, 72]]], ["Then, the cells were washed with PBS, resuspended in PBS/ BSA and pelleted by centrifugation (600 x g, 5 min, 4\u00b0C).", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["BSA", "SIMPLE_CHEMICAL", 58, 61], ["the cells", "TREATMENT", 6, 15], ["PBS", "TREATMENT", 33, 36], ["PBS/ BSA", "TREATMENT", 53, 61], ["BSA", "ANATOMY", 58, 61]]], ["After aspiration of the supernatant, the cells were resuspended in PBS/BSA containing anti-DPP4 antibody (mouse, diluted 1:100, Abcam) and incubated for 1 h at 4\u00b0C. Next, the cells were pelleted, washed with PBS/BSA, pelleted again, resuspended in PBS/BSA containing AlexaFluor488-conjugated anti-mouse antibody (donkey, diluted 1:500, Thermo-Fisher Scientific) and incubated for 1 h at 4\u00b0C. Subsequently, the cells were washed (as described above) and resuspended in PBS/PFA for 2 h at 4\u00b0C for fixation.", [["supernatant", "ANATOMY", 24, 35], ["cells", "ANATOMY", 41, 46], ["cells", "ANATOMY", 175, 180], ["cells", "ANATOMY", 410, 415], ["AlexaFluor488", "CHEMICAL", 267, 280], ["AlexaFluor488", "CHEMICAL", 267, 280], ["PFA", "CHEMICAL", 472, 475], ["cells", "CELL", 41, 46], ["BSA", "SIMPLE_CHEMICAL", 71, 74], ["anti-DPP4 antibody", "SIMPLE_CHEMICAL", 86, 104], ["mouse", "ORGANISM", 106, 111], ["Abcam", "GENE_OR_GENE_PRODUCT", 128, 133], ["cells", "CELL", 175, 180], ["BSA", "SIMPLE_CHEMICAL", 212, 215], ["BSA", "SIMPLE_CHEMICAL", 252, 255], ["AlexaFluor488", "SIMPLE_CHEMICAL", 267, 280], ["donkey", "ORGANISM", 313, 319], ["cells", "CELL", 410, 415], ["PFA", "SIMPLE_CHEMICAL", 472, 475], ["anti-DPP4 antibody", "PROTEIN", 86, 104], ["mouse, diluted 1:100, Abcam", "PROTEIN", 106, 133], ["AlexaFluor488-conjugated anti-mouse antibody", "PROTEIN", 267, 311], ["mouse", "SPECIES", 106, 111], ["donkey", "SPECIES", 313, 319], ["mouse", "SPECIES", 106, 111], ["aspiration of the supernatant", "TREATMENT", 6, 35], ["the cells", "TREATMENT", 37, 46], ["PBS/BSA", "TREATMENT", 67, 74], ["anti-DPP4 antibody", "TREATMENT", 86, 104], ["the cells", "TREATMENT", 171, 180], ["PBS/BSA", "TREATMENT", 208, 215], ["BSA", "TEST", 252, 255], ["AlexaFluor488", "TREATMENT", 267, 280], ["PBS/PFA", "TREATMENT", 468, 475], ["fixation", "TREATMENT", 495, 503], ["fixation", "OBSERVATION", 495, 503]]], ["Finally, the cells were washed (as described above) and resuspended in PBS/BSA for flow cytometric analysis using an LSR II flow cytometer and the FACS Diva software (both BD Biosciences).", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["BSA", "SIMPLE_CHEMICAL", 75, 78], ["LSR II", "PROTEIN", 117, 123], ["flow cytometric analysis", "TEST", 83, 107], ["an LSR II flow cytometer", "TREATMENT", 114, 138]]], ["Additional data analysis was carried out using the FCS Express 4 Flow research software (De Novo software).", [["Additional data analysis", "TEST", 0, 24]]], ["For quantification of DPP4 surface expression, the mean fluorescence intensity (MFI) value of the negative control was subtracted from all samples.", [["surface", "ANATOMY", 27, 34], ["samples", "ANATOMY", 139, 146], ["DPP4", "GENE_OR_GENE_PRODUCT", 22, 26], ["DPP4", "PROTEIN", 22, 26], ["DPP4 surface expression", "TREATMENT", 22, 45], ["the mean fluorescence intensity", "TEST", 47, 78]]], ["For normalization of DPP4 surface expression, values obtained for cells expressing DPP4 WT were set as 100% and the relative surface expression of the respective DPP4 mutants was calculated accordingly.Production of soluble MERS-CoV S and binding studiesIn order to generate soluble MERS-CoV S for binding studies, 293T cells were transfected with an expression vector for the S1 subunit of MERS-CoV S fused to the Fc fragment of human immunoglobulin G (solMERS-S1-Fc).", [["surface", "ANATOMY", 26, 33], ["cells", "ANATOMY", 66, 71], ["surface", "ANATOMY", 125, 132], ["293T cells", "ANATOMY", 315, 325], ["DPP4", "GENE_OR_GENE_PRODUCT", 21, 25], ["cells", "CELL", 66, 71], ["DPP4", "GENE_OR_GENE_PRODUCT", 83, 87], ["DPP4", "GENE_OR_GENE_PRODUCT", 162, 166], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 224, 234], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 283, 293], ["293T cells", "CELL", 315, 325], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 391, 401], ["human", "ORGANISM", 430, 435], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 436, 452], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 454, 467], ["DPP4", "PROTEIN", 21, 25], ["DPP4", "PROTEIN", 83, 87], ["DPP4 mutants", "PROTEIN", 162, 174], ["MERS-CoV S", "PROTEIN", 224, 234], ["MERS-CoV S", "PROTEIN", 283, 293], ["293T cells", "CELL_LINE", 315, 325], ["S1 subunit", "PROTEIN", 377, 387], ["MERS-CoV S", "PROTEIN", 391, 401], ["Fc fragment", "DNA", 415, 426], ["human immunoglobulin G", "PROTEIN", 430, 452], ["solMERS", "PROTEIN", 454, 461], ["S1", "PROTEIN", 462, 464], ["Fc", "PROTEIN", 465, 467], ["human", "SPECIES", 430, 435], ["MERS-CoV", "SPECIES", 391, 399], ["human", "SPECIES", 430, 435], ["DPP4 surface expression", "TEST", 21, 44], ["values", "TEST", 46, 52], ["cells", "TEST", 66, 71], ["DPP4 WT", "TEST", 83, 90], ["the respective DPP4 mutants", "TREATMENT", 147, 174], ["binding studies", "TEST", 239, 254], ["binding studies", "TEST", 298, 313], ["293T cells", "TREATMENT", 315, 325], ["an expression vector", "TREATMENT", 348, 368], ["CoV S", "PROBLEM", 396, 401], ["human immunoglobulin G", "TEST", 430, 452], ["solMERS", "TEST", 454, 461], ["soluble MERS-CoV", "OBSERVATION", 216, 232]]], ["At 24 h post transfection, the culture medium was exchanged and the cells were further incubated for 24 h before culture supernatants were harvested and freed from cellular debris by centrifugation (4,700 x g, 10 min, 4\u00b0C).", [["cells", "ANATOMY", 68, 73], ["supernatants", "ANATOMY", 121, 133], ["cellular debris", "ANATOMY", 164, 179], ["cells", "CELL", 68, 73], ["cellular", "CELL", 164, 172], ["transfection", "TREATMENT", 13, 25], ["the culture medium", "TEST", 27, 45], ["the cells", "PROBLEM", 64, 73], ["culture supernatants", "TEST", 113, 133], ["cellular debris", "PROBLEM", 164, 179], ["cellular debris", "OBSERVATION", 164, 179]]], ["The clarified supernatants were loaded on Vivaspin protein concentrator columns with a molecular weight cut-off of 30 kDa (Sartorius) and centrifuged at 4,700 x g at 4\u00b0C until the sample was 10-fold concentrated.Analysis of MERS-CoV S / DPP4 interaction with soluble MERS-CoV s1 by flow cytometryFor the binding studies with solMERS-S1-Fc, a similar protocol was followed as described for the analysis of DPP4 surface expression with the exceptions that sol-MERS-S1-Fc was used instead of the primary antibody (1:10 dilution in PBS/BSA) and that an AlexaFluor488conjugated anti-human antibody (goat, 1:500 dilution in PBS/BSA, ThermoFisher Scientific) was employed as the secondary antibody.", [["supernatants", "ANATOMY", 14, 26], ["sample", "ANATOMY", 180, 186], ["surface", "ANATOMY", 410, 417], ["AlexaFluor488", "CHEMICAL", 549, 562], ["Vivaspin", "SIMPLE_CHEMICAL", 42, 50], ["C", "GENE_OR_GENE_PRODUCT", 168, 169], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 224, 234], ["DPP4", "GENE_OR_GENE_PRODUCT", 237, 241], ["MERS-CoV s1", "GENE_OR_GENE_PRODUCT", 267, 278], ["DPP4", "GENE_OR_GENE_PRODUCT", 405, 409], ["BSA", "SIMPLE_CHEMICAL", 532, 535], ["AlexaFluor488", "SIMPLE_CHEMICAL", 549, 562], ["goat", "ORGANISM", 594, 598], ["BSA", "SIMPLE_CHEMICAL", 622, 625], ["MERS-CoV S", "PROTEIN", 224, 234], ["DPP4", "PROTEIN", 237, 241], ["soluble MERS-CoV s1", "PROTEIN", 259, 278], ["solMERS-S1-Fc", "PROTEIN", 325, 338], ["DPP4", "PROTEIN", 405, 409], ["sol-MERS-S1-Fc", "PROTEIN", 454, 468], ["primary antibody", "PROTEIN", 493, 509], ["AlexaFluor488conjugated anti-human antibody", "PROTEIN", 549, 592], ["secondary antibody", "PROTEIN", 672, 690], ["goat", "SPECIES", 594, 598], ["MERS-CoV", "SPECIES", 267, 275], ["goat", "SPECIES", 594, 598], ["Vivaspin protein concentrator columns", "TREATMENT", 42, 79], ["the sample", "TEST", 176, 186], ["Analysis", "TEST", 212, 220], ["MERS", "TEST", 224, 228], ["soluble MERS", "TEST", 259, 271], ["flow cytometry", "TEST", 282, 296], ["the binding studies", "TEST", 300, 319], ["a similar protocol", "TREATMENT", 340, 358], ["the analysis", "TEST", 389, 401], ["DPP4 surface expression", "TREATMENT", 405, 428], ["Fc", "TREATMENT", 466, 468], ["the primary antibody", "TREATMENT", 489, 509], ["PBS/BSA", "TREATMENT", 528, 535], ["an AlexaFluor", "TEST", 546, 559], ["anti-human antibody", "TEST", 573, 592], ["PBS/BSA", "TREATMENT", 618, 625], ["flow cytometry", "OBSERVATION", 282, 296], ["secondary antibody", "OBSERVATION", 672, 690]]], ["BHK-21 cells transfected with expression vectors for WT or mutant DPP4, ACE2 or empty expression vector (both negative controls) were analyzed by flow cytometry for solMERS-S1-Fc binding using an LSR II flow cytometer and the FACS Diva software (both BD Biosciences).", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["DPP4", "GENE_OR_GENE_PRODUCT", 66, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["BHK-21 cells", "CELL_LINE", 0, 12], ["mutant DPP4, ACE2 or empty expression vector", "DNA", 59, 103], ["solMERS", "PROTEIN", 165, 172], ["S1", "PROTEIN", 173, 175], ["Fc", "PROTEIN", 176, 178], ["LSR II", "PROTEIN", 196, 202], ["BHK", "TEST", 0, 3], ["expression vectors", "TREATMENT", 30, 48], ["WT", "TEST", 53, 55], ["empty expression vector", "TREATMENT", 80, 103], ["flow cytometry", "TEST", 146, 160], ["solMERS", "TEST", 165, 172], ["an LSR II flow cytometer", "TREATMENT", 193, 217], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["Additional data analysis was carried out using the FCS Express 4 Flow research software (De Novo software).", [["Additional data analysis", "TEST", 0, 24]]], ["For quantification of solMERS-S1-Fc binding, the MFI value obtained for cells transfected with empty expression vector was subtracted from all samples.", [["cells", "ANATOMY", 72, 77], ["samples", "ANATOMY", 143, 150], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 22, 35], ["cells", "CELL", 72, 77], ["solMERS", "PROTEIN", 22, 29], ["S1", "PROTEIN", 30, 32], ["Fc", "PROTEIN", 33, 35], ["MFI", "PROTEIN", 49, 52], ["empty expression vector", "DNA", 95, 118], ["quantification", "TEST", 4, 18], ["solMERS", "TEST", 22, 29], ["Fc binding", "PROBLEM", 33, 43], ["the MFI value", "TEST", 45, 58], ["cells", "PROBLEM", 72, 77], ["empty expression vector", "TREATMENT", 95, 118]]], ["Further, binding of solMERS-S1-Fc to cells expressing DPP4 WT was set as 100% and the relative binding efficiencies to cells expressing the respective DPP4 mutants or ACE2 were calculated accordingly.Analysis of MERS-CoV S / DPP4 interaction by coimmunoprecipitation293T cells (grown in 6-well plates) were cotransfected with expression plasmids coding for solMERS-S1-Fc and WT or mutant DPP4.", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 119, 124], ["293T cells", "ANATOMY", 266, 276], ["plasmids", "ANATOMY", 337, 345], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 20, 33], ["cells", "CELL", 37, 42], ["DPP4", "GENE_OR_GENE_PRODUCT", 54, 58], ["cells", "CELL", 119, 124], ["DPP4", "GENE_OR_GENE_PRODUCT", 151, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 212, 222], ["DPP4", "GENE_OR_GENE_PRODUCT", 225, 229], ["293T cells", "CELL", 266, 276], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 357, 370], ["DPP4", "GENE_OR_GENE_PRODUCT", 388, 392], ["solMERS", "PROTEIN", 20, 27], ["S1", "PROTEIN", 28, 30], ["Fc", "PROTEIN", 31, 33], ["DPP4", "PROTEIN", 54, 58], ["DPP4 mutants", "PROTEIN", 151, 163], ["ACE2", "PROTEIN", 167, 171], ["DPP4", "PROTEIN", 225, 229], ["coimmunoprecipitation293T cells", "CELL_LINE", 245, 276], ["expression plasmids", "DNA", 326, 345], ["solMERS", "PROTEIN", 357, 364], ["S1", "PROTEIN", 365, 367], ["Fc", "PROTEIN", 368, 370], ["WT", "PROTEIN", 375, 377], ["mutant DPP4", "PROTEIN", 381, 392], ["solMERS", "TEST", 20, 27], ["DPP4 WT", "TEST", 54, 61], ["the relative binding efficiencies", "PROBLEM", 82, 115], ["ACE2", "TEST", 167, 171], ["Analysis", "TEST", 200, 208], ["MERS", "PROBLEM", 212, 216], ["DPP4 interaction", "PROBLEM", 225, 241], ["coimmunoprecipitation293T cells", "TREATMENT", 245, 276], ["expression plasmids", "TREATMENT", 326, 345], ["solMERS", "TEST", 357, 364], ["mutant DPP4", "PROBLEM", 381, 392], ["binding efficiencies", "OBSERVATION", 95, 115]]], ["Cells transfected with empty expression vector instead of DPP4 or sol-MERS-S1-Fc (or both) served as controls.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DPP4", "GENE_OR_GENE_PRODUCT", 58, 62], ["sol-MERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 66, 80], ["empty expression vector", "DNA", 23, 46], ["DPP4", "PROTEIN", 58, 62], ["MERS", "PROTEIN", 70, 74], ["S1", "PROTEIN", 75, 77], ["Fc", "PROTEIN", 78, 80], ["empty expression vector", "TREATMENT", 23, 46], ["DPP4", "TEST", 58, 62]]], ["At 16 ,400 x g at 4\u00b0C, before 400 \u00b5l of the supernatant were mixed with 50 \u00b5l of protein A-sepharose (1 g protein A-sepharose [Sigma-Aldrich] in 4 ml PBS) while the residual 100 \u00b5l of the cell lysate were mixed with 100 \u00b5l 2x SDS-sample buffer and incubated for 15 min at 96\u00b0C (These samples were later analyzed to confirm comparable total protein levels [via detection of ACTB] as well as comparable DPP4 and solMERS-S1-Fc levels before the co-immunoprecipitation [co-IP] step.).", [["supernatant", "ANATOMY", 44, 55], ["cell lysate", "ANATOMY", 188, 199], ["samples", "ANATOMY", 284, 291], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 127, 140], ["cell lysate", "ORGANISM_SUBSTANCE", 188, 199], ["ACTB", "GENE_OR_GENE_PRODUCT", 373, 377], ["DPP4", "GENE_OR_GENE_PRODUCT", 401, 405], ["MERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 413, 423], ["protein A-sepharose", "PROTEIN", 81, 100], ["ACTB", "PROTEIN", 373, 377], ["DPP4", "PROTEIN", 401, 405], ["MERS", "PROTEIN", 413, 417], ["S1", "PROTEIN", 418, 420], ["Fc", "PROTEIN", 421, 423], ["the supernatant", "TREATMENT", 40, 55], ["protein A-sepharose", "TREATMENT", 81, 100], ["sepharose", "TEST", 116, 125], ["Sigma-Aldrich]", "TREATMENT", 127, 141], ["the residual", "TEST", 161, 173], ["the cell lysate", "TEST", 184, 199], ["sample buffer", "TREATMENT", 230, 243], ["These samples", "TEST", 278, 291], ["total protein levels", "TEST", 334, 354], ["ACTB", "TEST", 373, 377], ["DPP4", "TEST", 401, 405], ["solMERS", "TEST", 410, 417], ["Fc levels", "TEST", 421, 430], ["the co-immunoprecipitation", "TEST", 438, 464]]], ["Following incubation of the lysate/protein A-sepharose mixtures for 2 h at 4\u00b0C in an overhead shaker, the samples were centrifuged for 5 min at 16,400 x g at 4\u00b0C to pellet the protein A-sepharose/solMERS-S1-Fc/DPP4-complexes.", [["lysate", "ANATOMY", 28, 34], ["samples", "ANATOMY", 106, 113], ["DPP4", "GENE_OR_GENE_PRODUCT", 210, 214], ["protein A", "PROTEIN", 35, 44], ["protein A-sepharose", "PROTEIN", 176, 195], ["solMERS", "PROTEIN", 196, 203], ["S1", "PROTEIN", 204, 206], ["Fc", "PROTEIN", 207, 209], ["DPP4", "PROTEIN", 210, 214], ["the lysate/protein A-sepharose mixtures", "TREATMENT", 24, 63], ["sepharose", "TEST", 186, 195], ["solMERS", "TEST", 196, 203]]], ["After aspiration of the supernatant, 500 \u00b5l of NP40 lysis buffer (without protease inhibitors) were added and the cells were mixed by vortexing, before being centrifuged again.", [["supernatant", "ANATOMY", 24, 35], ["cells", "ANATOMY", 114, 119], ["NP40", "CHEMICAL", 47, 51], ["NP40", "SIMPLE_CHEMICAL", 47, 51], ["cells", "CELL", 114, 119], ["aspiration", "PROBLEM", 6, 16], ["the supernatant", "TREATMENT", 20, 35], ["NP40 lysis buffer", "TREATMENT", 47, 64], ["protease inhibitors", "TREATMENT", 74, 93], ["the cells", "TREATMENT", 110, 119]]], ["This washing routine was repeated three times, before finally 50 \u00b5l of 2x SDSsample buffer were added to the pelleted complexes and the samples were further incubated for 15 min at 96\u00b0C. Thereafter, the samples were subjected to SDS-PAGE and Western blot analysis (see above).", [["samples", "ANATOMY", 136, 143], ["samples", "ANATOMY", 203, 210], ["2x SDSsample buffer", "TREATMENT", 71, 90], ["the samples", "TEST", 132, 143], ["the samples", "TEST", 199, 210], ["blot analysis", "TEST", 250, 263]]], ["Detection of DPP4 (lysate and co-IP samples) and ACTB (lysate samples) was carried out as described above. solMERS-S1-Fc was detected (lysate and co-IP samples) by incubation with a peroxidase-conjugated anti-human antibody (goat, 1:5,000, Dianova).Analysis of MERS-CoV S / DPP4 interaction by coimmunoprecipitationSignal intensities of the protein bands were quantified as described above.", [["samples", "ANATOMY", 36, 43], ["lysate samples", "ANATOMY", 55, 69], ["lysate", "ANATOMY", 135, 141], ["samples", "ANATOMY", 152, 159], ["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["lysate", "ORGANISM_SUBSTANCE", 19, 25], ["ACTB", "GENE_OR_GENE_PRODUCT", 49, 53], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 107, 120], ["lysate", "ORGANISM_SUBSTANCE", 135, 141], ["peroxidase", "GENE_OR_GENE_PRODUCT", 182, 192], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 261, 271], ["DPP4", "GENE_OR_GENE_PRODUCT", 274, 278], ["DPP4", "PROTEIN", 13, 17], ["ACTB", "PROTEIN", 49, 53], ["solMERS", "PROTEIN", 107, 114], ["S1", "PROTEIN", 115, 117], ["Fc", "PROTEIN", 118, 120], ["peroxidase", "PROTEIN", 182, 192], ["anti-human antibody", "PROTEIN", 204, 223], ["goat, 1:5,000, Dianova", "PROTEIN", 225, 247], ["DPP4", "PROTEIN", 274, 278], ["goat", "SPECIES", 225, 229], ["DPP4", "TEST", 13, 17], ["lysate", "TEST", 19, 25], ["co-IP samples", "TEST", 30, 43], ["ACTB (lysate samples", "TEST", 49, 69], ["solMERS", "TEST", 107, 114], ["co-IP samples", "TEST", 146, 159], ["a peroxidase", "TEST", 180, 192], ["conjugated anti-human antibody", "TEST", 193, 223], ["MERS", "PROBLEM", 261, 265], ["DPP4 interaction", "PROBLEM", 274, 290], ["coimmunoprecipitation", "TEST", 294, 315], ["the protein bands", "TEST", 337, 354], ["S1", "ANATOMY", 115, 117], ["protein bands", "OBSERVATION", 341, 354]]], ["Further, signals obtained for DPP4 were normalized against the respective signals for solMERS-S1-Fc in order to account for variations in transfection efficiency and sample processing.Analysis of MERS-CoV S / DPP4 interaction using soluble DPP4 LigandFor the binding studies with soluble DPP4, a similar protocol was followed as described for the analysis of binding of solMERS-S1-Fc with the exceptions that a soluble DPP4 fused to the Fc region of human IgG (solDPP4-Fc, Acro Biosystems) was used instead of solMERS-S1-Fc (1:200 dilution in PBS/BSA) and that an AlexaFluor488-conjugated anti-human antibody (goat, 1:500 dilution in PBS/BSA, ThermoFisher Scientific) was employed as the secondary antibody.", [["sample", "ANATOMY", 166, 172], ["AlexaFluor488", "CHEMICAL", 564, 577], ["AlexaFluor488", "CHEMICAL", 564, 577], ["DPP4", "GENE_OR_GENE_PRODUCT", 30, 34], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 86, 99], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 196, 206], ["DPP4", "GENE_OR_GENE_PRODUCT", 209, 213], ["DPP4", "GENE_OR_GENE_PRODUCT", 240, 244], ["DPP4", "GENE_OR_GENE_PRODUCT", 288, 292], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 370, 383], ["DPP4", "GENE_OR_GENE_PRODUCT", 419, 423], ["human", "ORGANISM", 450, 455], ["IgG", "GENE_OR_GENE_PRODUCT", 456, 459], ["solDPP4-Fc", "GENE_OR_GENE_PRODUCT", 461, 471], ["BSA", "SIMPLE_CHEMICAL", 547, 550], ["AlexaFluor488", "SIMPLE_CHEMICAL", 564, 577], ["goat", "ORGANISM", 610, 614], ["BSA", "SIMPLE_CHEMICAL", 638, 641], ["DPP4", "PROTEIN", 30, 34], ["solMERS", "PROTEIN", 86, 93], ["S1", "PROTEIN", 94, 96], ["Fc", "PROTEIN", 97, 99], ["MERS-CoV S", "PROTEIN", 196, 206], ["DPP4", "PROTEIN", 209, 213], ["DPP4 Ligand", "PROTEIN", 240, 251], ["DPP4", "PROTEIN", 288, 292], ["solMERS", "PROTEIN", 370, 377], ["S1", "PROTEIN", 378, 380], ["Fc", "PROTEIN", 381, 383], ["DPP4", "PROTEIN", 419, 423], ["Fc region", "PROTEIN", 437, 446], ["human IgG", "PROTEIN", 450, 459], ["solDPP4", "PROTEIN", 461, 468], ["Fc", "PROTEIN", 469, 471], ["solMERS", "PROTEIN", 510, 517], ["S1", "PROTEIN", 518, 520], ["Fc", "PROTEIN", 521, 523], ["AlexaFluor488", "PROTEIN", 564, 577], ["anti-human antibody", "PROTEIN", 589, 608], ["secondary antibody", "PROTEIN", 688, 706], ["human", "SPECIES", 450, 455], ["goat", "SPECIES", 610, 614], ["human", "SPECIES", 450, 455], ["goat", "SPECIES", 610, 614], ["DPP4", "TEST", 30, 34], ["solMERS", "TEST", 86, 93], ["variations in transfection efficiency", "PROBLEM", 124, 161], ["sample processing", "TEST", 166, 183], ["MERS-CoV S", "PROBLEM", 196, 206], ["soluble DPP4 Ligand", "TREATMENT", 232, 251], ["the binding studies", "TEST", 255, 274], ["soluble DPP4", "TREATMENT", 280, 292], ["a similar protocol", "TREATMENT", 294, 312], ["the analysis", "TEST", 343, 355], ["solMERS", "TEST", 370, 377], ["a soluble DPP4", "TREATMENT", 409, 423], ["human IgG", "TEST", 450, 459], ["solMERS", "TEST", 510, 517], ["PBS/BSA", "TREATMENT", 543, 550], ["an AlexaFluor488-conjugated anti-human antibody", "TREATMENT", 561, 608], ["PBS/BSA", "TREATMENT", 634, 641], ["transfection efficiency", "OBSERVATION", 138, 161], ["human IgG", "ANATOMY", 450, 459], ["secondary antibody", "OBSERVATION", 688, 706]]], ["293T cells transfected with expression vectors for WT or mutant (D510G and D539N) MERS-CoV S, or empty expression vector (negative control) were analyzed by flow cytometry for solDPP4-Fc binding using an LSR II flow cytometer and the FACS Diva software (both BD Biosciences).", [["293T cells", "ANATOMY", 0, 10], ["293T cells", "CELL", 0, 10], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 82, 92], ["solDPP4-Fc", "GENE_OR_GENE_PRODUCT", 176, 186], ["293T cells", "CELL_LINE", 0, 10], ["mutant (D510G and D539N) MERS-CoV S", "DNA", 57, 92], ["empty expression vector", "DNA", 97, 120], ["solDPP4", "PROTEIN", 176, 183], ["Fc", "PROTEIN", 184, 186], ["LSR II", "PROTEIN", 204, 210], ["expression vectors", "TREATMENT", 28, 46], ["WT or mutant (D510G and D539N)", "TREATMENT", 51, 81], ["empty expression vector", "TREATMENT", 97, 120], ["flow cytometry", "TEST", 157, 171], ["an LSR II flow cytometer", "TREATMENT", 201, 225]]], ["Additional data analysis was carried out using the FCS Express 4 Flow research software (De Novo software).", [["Additional data analysis", "TEST", 0, 24]]], ["For quantification of solDPP4-Fc binding, the MFI value obtained for cells transfected with empty expression vector was subtracted from all samples.", [["cells", "ANATOMY", 69, 74], ["samples", "ANATOMY", 140, 147], ["solDPP4-Fc", "GENE_OR_GENE_PRODUCT", 22, 32], ["cells", "CELL", 69, 74], ["solDPP4", "PROTEIN", 22, 29], ["Fc", "PROTEIN", 30, 32], ["MFI", "PROTEIN", 46, 49], ["empty expression vector", "DNA", 92, 115], ["solDPP4-Fc binding", "PROBLEM", 22, 40], ["the MFI value", "TEST", 42, 55], ["cells", "PROBLEM", 69, 74], ["empty expression vector", "TREATMENT", 92, 115]]], ["Further, binding of solDPP4-Fc to cells expressing MERS-CoV S WT was set as 100% and the relative binding efficiencies to cells expressing the respective MERS-CoV S mutants were calculated accordingly.Generation of rhabdoviral pseudotypes and transduction studiesWe employed a previously described protocol for the generation of VSV pseudotype particles (VSVpp) that is based on a replication-deficient VSV vector that lacks the genetic information for VSV-G but instead contains the genetic information for eGFP and firefly luciferase (fLuc) as reporters of transduction efficiency (VSV\u0394G-fLuc for 1 h before being washed with PBS and further incubated for 16 h with culture medium that was supplemented with anti-VSV-G antibody (I1, mouse hybridoma supernatant from CRL-2700; ATCC) (except for cells expressing VSV-G).", [["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 122, 127], ["supernatant", "ANATOMY", 751, 762], ["ATCC", "ANATOMY", 778, 782], ["cells", "ANATOMY", 796, 801], ["CRL-2700", "CHEMICAL", 768, 776], ["solDPP4-Fc", "GENE_OR_GENE_PRODUCT", 20, 30], ["cells", "CELL", 34, 39], ["MERS-CoV S WT", "ORGANISM", 51, 64], ["cells", "CELL", 122, 127], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 154, 164], ["rhabdoviral pseudotypes", "ORGANISM", 215, 238], ["VSV", "ORGANISM", 329, 332], ["VSV", "ORGANISM", 403, 406], ["VSV-G", "GENE_OR_GENE_PRODUCT", 453, 458], ["eGFP", "GENE_OR_GENE_PRODUCT", 508, 512], ["luciferase", "GENE_OR_GENE_PRODUCT", 525, 535], ["fLuc", "GENE_OR_GENE_PRODUCT", 537, 541], ["anti-VSV-G antibody", "GENE_OR_GENE_PRODUCT", 710, 729], ["mouse", "ORGANISM", 735, 740], ["CRL-2700; ATCC", "CELL", 768, 782], ["cells", "CELL", 796, 801], ["VSV-G", "ORGANISM", 813, 818], ["solDPP4", "PROTEIN", 20, 27], ["Fc", "PROTEIN", 28, 30], ["MERS", "PROTEIN", 51, 55], ["MERS-CoV S mutants", "DNA", 154, 172], ["eGFP", "DNA", 508, 512], ["firefly luciferase", "PROTEIN", 517, 535], ["fLuc", "PROTEIN", 537, 541], ["anti-VSV", "PROTEIN", 710, 718], ["G antibody", "PROTEIN", 719, 729], ["I1", "PROTEIN", 731, 733], ["VSV-G", "PROTEIN", 813, 818], ["mouse", "SPECIES", 735, 740], ["MERS-CoV", "SPECIES", 154, 162], ["VSV pseudotype", "SPECIES", 329, 343], ["VSV", "SPECIES", 403, 406], ["VSV", "SPECIES", 453, 456], ["mouse", "SPECIES", 735, 740], ["solDPP4", "TEST", 20, 27], ["CoV S WT", "TEST", 56, 64], ["the relative binding efficiencies", "PROBLEM", 85, 118], ["CoV S mutants", "PROBLEM", 159, 172], ["rhabdoviral pseudotypes", "PROBLEM", 215, 238], ["transduction studies", "TEST", 243, 263], ["a previously described protocol", "TREATMENT", 275, 306], ["VSV pseudotype particles", "PROBLEM", 329, 353], ["a replication-deficient VSV vector", "TREATMENT", 379, 413], ["transduction efficiency", "PROBLEM", 559, 582], ["VSV\u0394G", "TEST", 584, 589], ["fLuc", "TREATMENT", 590, 594], ["PBS", "TREATMENT", 628, 631], ["culture medium", "TEST", 668, 682], ["anti-VSV", "TEST", 710, 718], ["G antibody", "TEST", 719, 729], ["mouse hybridoma", "TEST", 735, 750], ["CRL", "TEST", 768, 771], ["ATCC", "TEST", 778, 782], ["binding efficiencies", "OBSERVATION", 98, 118], ["rhabdoviral pseudotypes", "OBSERVATION", 215, 238]]], ["The produced VSVpp were inoculated onto BHK-21 cells expressing WT or mutant DPP4, or no DPP4 (empty expression vector, negative control) and incubated for 16-18 h before fLuc activity in cell lysates was quantified as an indicator for transduction efficiency using the Beetle-Juice kit (PJK) and a plate luminometer (Hidex) [41] .MERS-CoV infection and quantification of viral titersBHK-21 cells were transfected with expression vectors for wildtype or mutant DPP4 (K267E or A291P), or empty expression vector (negative control) using FuGENE HD (Promega) according to the manufacturer's instructions.", [["BHK-21 cells", "ANATOMY", 40, 52], ["cell lysates", "ANATOMY", 188, 200], ["titersBHK-21 cells", "ANATOMY", 378, 396], ["infection", "DISEASE", 340, 349], ["VSVpp", "GENE_OR_GENE_PRODUCT", 13, 18], ["BHK-21 cells", "CELL", 40, 52], ["DPP4", "GENE_OR_GENE_PRODUCT", 77, 81], ["DPP4", "GENE_OR_GENE_PRODUCT", 89, 93], ["fLuc", "GENE_OR_GENE_PRODUCT", 171, 175], ["cell lysates", "ORGANISM_SUBSTANCE", 188, 200], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 331, 339], ["titersBHK-21 cells", "CELL", 378, 396], ["DPP4", "GENE_OR_GENE_PRODUCT", 461, 465], ["FuGENE", "ORGANISM", 536, 542], ["VSVpp", "PROTEIN", 13, 18], ["BHK-21 cells", "CELL_LINE", 40, 52], ["mutant DPP4", "PROTEIN", 70, 81], ["DPP4", "PROTEIN", 89, 93], ["empty expression vector", "DNA", 95, 118], ["fLuc", "PROTEIN", 171, 175], ["Beetle-Juice kit", "PROTEIN", 270, 286], ["PJK", "PROTEIN", 288, 291], ["viral titersBHK-21 cells", "CELL_LINE", 372, 396], ["mutant DPP4", "PROTEIN", 454, 465], ["K267E", "PROTEIN", 467, 472], ["A291P", "PROTEIN", 476, 481], ["empty expression vector", "DNA", 487, 510], ["BHK-21", "SPECIES", 40, 46], ["BHK", "TEST", 40, 43], ["WT", "TEST", 64, 66], ["mutant DPP4", "TEST", 70, 81], ["DPP4 (empty expression vector", "TREATMENT", 89, 118], ["fLuc activity in cell lysates", "PROBLEM", 171, 200], ["transduction efficiency", "PROBLEM", 236, 259], ["the Beetle-Juice kit (PJK", "TREATMENT", 266, 291], ["a plate luminometer (Hidex)", "TREATMENT", 297, 324], ["CoV infection", "PROBLEM", 336, 349], ["viral titersBHK-21 cells", "PROBLEM", 372, 396], ["expression vectors", "TREATMENT", 419, 437], ["wildtype or mutant DPP4", "PROBLEM", 442, 465], ["empty expression vector", "TREATMENT", 487, 510], ["FuGENE HD (Promega)", "TREATMENT", 536, 555], ["CoV", "OBSERVATION_MODIFIER", 336, 339], ["infection", "OBSERVATION", 340, 349], ["viral", "OBSERVATION_MODIFIER", 372, 377]]], ["At 24 h posttransfection, the cells were infected with MERS-CoV (Human betacoronavirus 2c EMC/2012, MERS-CoV EMC-2012, GenBank accession number: JX869059) at a multiplicity of infection of 0.01 for 1 h.", [["cells", "ANATOMY", 30, 35], ["infection", "DISEASE", 176, 185], ["cells", "CELL", 30, 35], ["MERS-CoV", "ORGANISM", 55, 63], ["Human", "ORGANISM", 65, 70], ["betacoronavirus 2c EMC", "ORGANISM", 71, 93], ["MERS-CoV", "ORGANISM", 100, 108], ["Human", "SPECIES", 65, 70], ["MERS-CoV", "SPECIES", 55, 63], ["Human betacoronavirus 2c EMC/2012, MERS-CoV EMC-2012", "SPECIES", 65, 117], ["the cells", "PROBLEM", 26, 35], ["infection", "PROBLEM", 176, 185], ["infection", "OBSERVATION", 176, 185]]], ["Thereafter, the inoculum was removed and the cells were washed 3x with PBS before fresh medium was added and the first sample (time point 0 h postinfection) was taken.", [["cells", "ANATOMY", 45, 50], ["sample", "ANATOMY", 119, 125], ["cells", "CELL", 45, 50], ["the inoculum", "TREATMENT", 12, 24], ["the cells", "TREATMENT", 41, 50], ["PBS", "TREATMENT", 71, 74], ["fresh medium", "TREATMENT", 82, 94], ["inoculum", "OBSERVATION_MODIFIER", 16, 24]]], ["The cells were further incubated and additional samples were taken at 24 and 48 h postinfection.", [["cells", "ANATOMY", 4, 9], ["samples", "ANATOMY", 48, 55], ["cells", "CELL", 4, 9], ["additional samples", "TEST", 37, 55]]], ["Viral titers in the culture supernatant were analyzed by quantitative reversetranscriptase PCR, using the upE assay according to a published protocol [42] .", [["culture supernatant", "ANATOMY", 20, 39], ["Viral", "ORGANISM", 0, 5], ["Viral titers", "TEST", 0, 12], ["the culture supernatant", "TEST", 16, 39], ["quantitative reversetranscriptase PCR", "TEST", 57, 94], ["the upE assay", "TEST", 102, 115]]], ["In brief, viral RNA was isolated from cell culture supernatant using the NucleoSpin RNA Virus kit (Macherey-Nagel), reversetranscribed into cDNA using the Superscript III one step RT-PCR system (ThermoFisher Scientific) and analyzed on a LightCycler 480 qPCR cycler platform (Roche) with primers and conditions as specified for the upE assay [42] .", [["cell", "ANATOMY", 38, 42], ["supernatant", "ANATOMY", 51, 62], ["cell", "CELL", 38, 42], ["viral RNA", "RNA", 10, 19], ["Macherey", "PROTEIN", 99, 107], ["cDNA", "DNA", 140, 144], ["viral RNA", "PROBLEM", 10, 19], ["cell culture", "TEST", 38, 50], ["a LightCycler", "TEST", 236, 249], ["primers and conditions", "TREATMENT", 288, 310], ["the upE assay", "TEST", 328, 341], ["viral RNA", "OBSERVATION", 10, 19]]], ["In vitro-transcribed standard samples containing defined amounts of MERS-CoV fragments (10, 100, 1,000 and 10,000 copies) were included for absolute quantification as genome equivalents (GE).Protein structure visualizationThe DPP4 protein structure (4PV7) [43] and the structure of the complex formed by the MERS-CoV S receptor binding domain bound to DPP4 (4L72) [16] were retrieved from the Research Collaboratory for Structural Bioinformatics Protein Database (RSCB PDB, https://www.rcsb.org/).", [["samples", "ANATOMY", 30, 37], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 68, 76], ["DPP4", "GENE_OR_GENE_PRODUCT", 226, 230], ["MERS-CoV S receptor", "GENE_OR_GENE_PRODUCT", 308, 327], ["DPP4", "GENE_OR_GENE_PRODUCT", 352, 356], ["MERS-CoV fragments", "DNA", 68, 86], ["DPP4 protein structure", "PROTEIN", 226, 248], ["MERS-CoV S receptor binding domain", "PROTEIN", 308, 342], ["DPP4", "PROTEIN", 352, 356], ["4L72", "PROTEIN", 358, 362], ["MERS-CoV", "SPECIES", 68, 76], ["MERS-CoV fragments", "PROBLEM", 68, 86], ["Protein structure visualization", "TEST", 191, 222], ["The DPP4 protein structure", "TEST", 222, 248], ["CoV S receptor binding domain bound", "PROBLEM", 313, 348], ["DPP4", "TEST", 352, 356], ["amounts", "OBSERVATION_MODIFIER", 57, 64], ["CoV fragments", "OBSERVATION", 73, 86]]], ["Structure visualization and colorization was performed using the YASARA software (http://www.yasara.org/index.html) [44] and UCSF Chimera version 1.14 (developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco) [45] .Statistical analysisOne-way or two-way analysis of variance (ANOVA) with Dunnett's posttest was used to test for statistical significance.", [["the YASARA software", "TEST", 61, 80], ["UCSF Chimera version", "TEST", 125, 145], ["Visualization", "TEST", 196, 209], ["Statistical analysis", "TEST", 281, 301], ["Dunnett's posttest", "TEST", 354, 372]]], ["Only p values of 0.05 or lower were con-ResultsIdentification of polymorphisms in DPP4 that alter amino acid residues which make contact with MERS-CoV S The binding interface between MERS-CoV S and the cellular receptor DPP4 was resolved by Wang and colleagues using crystallography, revealing the interacting amino acid residues for each binding partner [16] : Fourteen residues of MERS-CoV S (Y499, N501, K502, L506, D510, R511, E513, D537 G538, D539, Y540, R542, W553 and V555) interact with a total of fifteen residues in DPP4 (K267, F269, Q286, T288, A289, A291, L294, I295, H298, R317, Y322, R336, Q344, I346 and K392) [16] , which are distributed over the glycosylation-rich domain and the cysteinerich domain ( Figure 1A-C) .ResultsIn order to identify polymorphic residues in DPP4 that contact MERS-CoV S, we screened public databases that provide information on polymorphic amino acid residues based on data derived from different bio projects (i.e. gnomAD, TOPMed, ExAC, 1000G; more information is given in the Materials and Methods section).", [["cellular", "ANATOMY", 202, 210], ["amino acid", "CHEMICAL", 98, 108], ["amino acid", "CHEMICAL", 310, 320], ["amino acid", "CHEMICAL", 884, 894], ["amino acid", "CHEMICAL", 98, 108], ["amino acid", "CHEMICAL", 310, 320], ["D537 G538, D539, Y540, R542, W553 and V555", "CHEMICAL", 437, 479], ["A289, A291, L294, I295, H298, R317, Y322, R336, Q344, I346 and K392", "CHEMICAL", 556, 623], ["amino acid", "CHEMICAL", 884, 894], ["DPP4", "GENE_OR_GENE_PRODUCT", 82, 86], ["amino acid", "AMINO_ACID", 98, 108], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 142, 152], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 183, 193], ["cellular", "CELL", 202, 210], ["DPP4", "GENE_OR_GENE_PRODUCT", 220, 224], ["amino acid", "AMINO_ACID", 310, 320], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 383, 391], ["DPP4", "GENE_OR_GENE_PRODUCT", 526, 530], ["DPP4", "GENE_OR_GENE_PRODUCT", 785, 789], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 803, 811], ["amino acid", "AMINO_ACID", 884, 894], ["DPP4", "PROTEIN", 82, 86], ["MERS-CoV S", "PROTEIN", 142, 152], ["MERS-CoV S", "PROTEIN", 183, 193], ["cellular receptor DPP4", "PROTEIN", 202, 224], ["MERS", "PROTEIN", 383, 387], ["V555", "PROTEIN", 475, 479], ["DPP4", "PROTEIN", 526, 530], ["glycosylation-rich domain", "PROTEIN", 663, 688], ["cysteinerich domain", "PROTEIN", 697, 716], ["Figure 1A-C", "PROTEIN", 719, 730], ["DPP4", "PROTEIN", 785, 789], ["MERS", "PROTEIN", 803, 807], ["ExAC", "PROTEIN", 976, 980], ["MERS-CoV", "SPECIES", 142, 150], ["MERS-CoV", "SPECIES", 803, 811], ["p values", "TEST", 5, 13], ["polymorphisms in DPP4", "PROBLEM", 65, 86], ["amino acid residues", "PROBLEM", 98, 117], ["MERS-CoV S", "PROBLEM", 183, 193], ["the cellular receptor DPP4", "TREATMENT", 198, 224], ["crystallography", "TEST", 267, 282], ["the interacting amino acid residues", "TREATMENT", 294, 329], ["CoV S", "TEST", 388, 393], ["K502", "TEST", 407, 411], ["DPP4", "TEST", 526, 530], ["K267", "TEST", 532, 536], ["the cysteinerich domain", "TEST", 693, 716], ["polymorphic residues in DPP4", "PROBLEM", 761, 789], ["polymorphic amino acid residues", "TREATMENT", 872, 903]]], ["By this method we found that nine out of the fifteen DPP4 residues interacting with MERS-CoV S are polymorphic (K267, Q286, T288, A289, A291, R317, Y322, I346 and K392) ( Figure 1C ).", [["DPP4", "GENE_OR_GENE_PRODUCT", 53, 57], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 84, 94], ["DPP4 residues", "PROTEIN", 53, 66], ["MERS-CoV S", "DNA", 84, 94], ["MERS-CoV", "SPECIES", 84, 92], ["CoV S", "TEST", 89, 94], ["polymorphic", "TEST", 99, 110], ["K267", "TEST", 112, 116], ["A289", "TEST", 130, 134], ["K392", "TEST", 163, 167]]], ["While five of these residues can be replaced by only a single different amino acid residue (Q286[K], A289 .", [["amino acid", "CHEMICAL", 72, 82], ["amino acid", "CHEMICAL", 72, 82], ["amino acid", "AMINO_ACID", 72, 82], ["a single different amino acid residue", "TREATMENT", 53, 90]]], ["Circles with sticks represent glycosylation sites, while small numbers indicate the amino acid residues.", [["amino acid", "CHEMICAL", 84, 94], ["amino acid", "CHEMICAL", 84, 94], ["amino acid", "AMINO_ACID", 84, 94], ["glycosylation sites", "PROTEIN", 30, 49], ["glycosylation sites", "PROBLEM", 30, 49], ["the amino acid residues", "PROBLEM", 80, 103], ["sticks", "OBSERVATION_MODIFIER", 13, 19], ["glycosylation sites", "OBSERVATION", 30, 49], ["small", "OBSERVATION_MODIFIER", 57, 62], ["amino acid residues", "OBSERVATION", 84, 103]]], ["Triangles below the domains highlight the positions of amino acid residues that directly interact with MERS-CoV S (grey triangles mark residues for which no polymorphism has been reported, while red triangles indicate polymorphic residues).", [["amino acid", "CHEMICAL", 55, 65], ["amino acid", "CHEMICAL", 55, 65], ["amino acid", "AMINO_ACID", 55, 65], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 103, 113], ["MERS-CoV S", "PROTEIN", 103, 113], ["Triangles", "TREATMENT", 0, 9], ["amino acid residues", "TREATMENT", 55, 74], ["CoV S (grey triangles mark residues", "TREATMENT", 108, 143], ["polymorphism", "PROBLEM", 157, 169], ["polymorphic residues", "PROBLEM", 218, 238], ["amino acid residues", "OBSERVATION", 55, 74], ["polymorphic residues", "OBSERVATION", 218, 238]]], ["(B) Side (left) and top (right) view of homodimeric DPP4 (the dotted line indicates the border between the two monomers and the cellular plasma membrane is schematically depicted below the side view model of DPP4).", [["cellular plasma membrane", "ANATOMY", 128, 152], ["DPP4", "GENE_OR_GENE_PRODUCT", 52, 56], ["cellular", "CELLULAR_COMPONENT", 128, 136], ["plasma membrane", "CELLULAR_COMPONENT", 137, 152], ["DPP4", "GENE_OR_GENE_PRODUCT", 208, 212], ["homodimeric DPP4", "PROTEIN", 40, 56], ["DPP4", "PROTEIN", 208, 212], ["(B) Side (left) and top (right)", "TREATMENT", 0, 31], ["homodimeric DPP4", "TREATMENT", 40, 56], ["the dotted line", "TREATMENT", 58, 73], ["left", "ANATOMY_MODIFIER", 10, 14], ["right", "ANATOMY_MODIFIER", 25, 30], ["plasma membrane", "OBSERVATION", 137, 152]]], ["The protein model was constructed on the published crystal structure (4PV7) deposited in RSCB PDB and the binding interface with MERS-CoV S has been highlighted (green).", [["RSCB PDB", "GENE_OR_GENE_PRODUCT", 89, 97], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 129, 139], ["PV7", "PROTEIN", 71, 74], ["RSCB PDB", "PROTEIN", 89, 97], ["MERS-CoV S", "PROTEIN", 129, 139], ["The protein model", "TEST", 0, 17], ["CoV S", "PROBLEM", 134, 139], ["RSCB PDB", "OBSERVATION", 89, 97]]], ["(C) Close-up on the DPP4 residues that directly interact with MERS-CoV S and for which no polymorphic (yellow) or polymorphic (red) residues have been reported.", [["DPP4", "GENE_OR_GENE_PRODUCT", 20, 24], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 62, 72], ["DPP4 residues", "PROTEIN", 20, 33], ["MERS-CoV S", "PROTEIN", 62, 72], ["MERS-CoV", "SPECIES", 62, 70], ["the DPP4 residues", "TREATMENT", 16, 33], ["CoV S", "TEST", 67, 72], ["polymorphic (yellow) or polymorphic (red) residues", "PROBLEM", 90, 140]]], ["In addition, the specific residues in DPP4 (regular letters and numbers), including the respective polymorphic residues (letters in brackets), and the corresponding interacting residues in MERS-CoV S (italicized letters and numbers) are indicated.", [["DPP4", "GENE_OR_GENE_PRODUCT", 38, 42], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 189, 199], ["DPP4", "PROTEIN", 38, 42], ["MERS", "PROTEIN", 189, 193], ["MERS-CoV", "SPECIES", 189, 197], ["DPP4", "TEST", 38, 42], ["the respective polymorphic residues (letters in brackets", "TREATMENT", 84, 140], ["residues", "OBSERVATION_MODIFIER", 26, 34], ["polymorphic residues", "OBSERVATION", 99, 119]]], ["(D) Frequency of polymorphic DPP4 residues in the human population.", [["DPP4", "GENE_OR_GENE_PRODUCT", 29, 33], ["human", "ORGANISM", 50, 55], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["polymorphic DPP4 residues", "PROBLEM", 17, 42], ["polymorphic", "OBSERVATION_MODIFIER", 17, 28], ["DPP4 residues", "OBSERVATION", 29, 42]]], ["Public databases (see Supplementary Table 1 and the materials and methods section for detailed information) were screened for the frequency of the polymorphic residues under study (y-axis).", [["Public databases", "TEST", 0, 16]]], ["Error bars indicate standard error of the mean (SEM) and refer to polymorphic residues found in more than one database.", [["polymorphic residues", "PROBLEM", 66, 86], ["standard error", "OBSERVATION", 20, 34]]], ["Finally, the frequency of these polymorphisms in the human population is low, ranging roughly from 1:19,000 (A289V) to 1:245,000 (T288I) ( Figure 1D and Supplementary Table 1 ).DPP4 polymorphisms are compatible with robust DPP4 expression and localization at the cell surfaceWe next introduced the polymorphisms in a DPP4 expression plasmid.", [["cell", "ANATOMY", 263, 267], ["human", "ORGANISM", 53, 58], ["DPP4", "GENE_OR_GENE_PRODUCT", 177, 181], ["DPP4", "GENE_OR_GENE_PRODUCT", 223, 227], ["cell", "CELL", 263, 267], ["DPP4", "GENE_OR_GENE_PRODUCT", 317, 321], ["DPP4", "PROTEIN", 177, 181], ["DPP4", "PROTEIN", 223, 227], ["DPP4 expression plasmid", "DNA", 317, 340], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["these polymorphisms", "TEST", 26, 45], ["the human population", "TEST", 49, 69], ["DPP4 polymorphisms", "PROBLEM", 177, 195], ["robust DPP4 expression", "TREATMENT", 216, 238], ["the cell surfaceWe", "TREATMENT", 259, 277], ["the polymorphisms", "PROBLEM", 294, 311], ["a DPP4 expression plasmid", "TREATMENT", 315, 340], ["polymorphisms", "OBSERVATION", 32, 45], ["low", "OBSERVATION_MODIFIER", 73, 76], ["compatible with", "UNCERTAINTY", 200, 215]]], ["Western blot analysis and signal quantification revealed that all resulting DPP4 variants were robustly expressed and total expression levels were comparable (Figure 2A-B) .", [["DPP4", "GENE_OR_GENE_PRODUCT", 76, 80], ["DPP4", "PROTEIN", 76, 80], ["Western blot analysis", "TEST", 0, 21], ["signal quantification", "TEST", 26, 47], ["all resulting DPP4 variants", "PROBLEM", 62, 89], ["total expression levels", "TEST", 118, 141]]], ["As DPP4 needs to be transported to the plasma membrane to be engaged by MERS-CoV S for host cell entry, we next investigated whether the presence of the polymorphic DPP4 residues has an impact on DPP4 cell surface localization.", [["plasma membrane", "ANATOMY", 39, 54], ["cell", "ANATOMY", 92, 96], ["cell surface", "ANATOMY", 201, 213], ["DPP4", "GENE_OR_GENE_PRODUCT", 3, 7], ["plasma membrane", "CELLULAR_COMPONENT", 39, 54], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 72, 82], ["host cell", "CELL", 87, 96], ["DPP4", "GENE_OR_GENE_PRODUCT", 165, 169], ["DPP4", "GENE_OR_GENE_PRODUCT", 196, 200], ["cell surface", "CELLULAR_COMPONENT", 201, 213], ["DPP4", "PROTEIN", 3, 7], ["MERS-CoV S", "PROTEIN", 72, 82], ["polymorphic DPP4 residues", "PROTEIN", 153, 178], ["DPP4", "PROTEIN", 196, 200], ["the polymorphic DPP4 residues", "PROBLEM", 149, 178], ["DPP4 cell surface localization", "TREATMENT", 196, 226]]], ["For this, we performed flow cytometry and confocal laser scanning microscopy, using transfected BHK-21 cells and an antibody targeting the DPP4 ectodomain.", [["BHK-21 cells", "ANATOMY", 96, 108], ["BHK-21 cells", "CELL", 96, 108], ["DPP4", "GENE_OR_GENE_PRODUCT", 139, 143], ["BHK-21 cells", "CELL_LINE", 96, 108], ["DPP4 ectodomain", "PROTEIN", 139, 154], ["BHK-21", "SPECIES", 96, 102], ["flow cytometry", "TEST", 23, 37], ["confocal laser scanning microscopy", "TEST", 42, 76], ["transfected BHK", "TEST", 84, 99], ["an antibody", "TEST", 113, 124], ["DPP4 ectodomain", "OBSERVATION", 139, 154]]], ["We found that all DPP4 variants but one, a deletion variant lacking amino acid residues 346-348 (\u0394346-348), displayed comparable cell surface expression levels ( Figure 3A-B) .Polymorphisms at positions 267 and 291 in DPP4 reduce S protein-driven host cell entry and replication of authentic MERS-CoVWe next investigated whether polymorphic DPP4 residues impact MERS-CoV host cell entry.", [["cell surface", "ANATOMY", 129, 141], ["cell", "ANATOMY", 252, 256], ["cell", "ANATOMY", 376, 380], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 68, 78], ["DPP4", "GENE_OR_GENE_PRODUCT", 18, 22], ["amino acid", "AMINO_ACID", 68, 78], ["cell surface", "CELLULAR_COMPONENT", 129, 141], ["DPP4", "GENE_OR_GENE_PRODUCT", 218, 222], ["S protein", "GENE_OR_GENE_PRODUCT", 230, 239], ["host cell", "CELL", 247, 256], ["DPP4", "GENE_OR_GENE_PRODUCT", 341, 345], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 362, 370], ["cell", "CELL", 376, 380], ["DPP4", "PROTEIN", 18, 22], ["DPP4", "PROTEIN", 218, 222], ["S protein", "PROTEIN", 230, 239], ["MERS-CoVWe", "DNA", 292, 302], ["MERS-CoV", "SPECIES", 362, 370], ["all DPP4 variants", "PROBLEM", 14, 31], ["a deletion variant", "PROBLEM", 41, 59], ["amino acid residues", "TEST", 68, 87], ["Polymorphisms at positions", "PROBLEM", 176, 202], ["DPP4", "TEST", 218, 222], ["S protein", "TEST", 230, 239], ["host cell entry", "TREATMENT", 247, 262], ["authentic MERS", "PROBLEM", 282, 296], ["CoVWe", "TREATMENT", 297, 302], ["polymorphic DPP4 residues", "PROBLEM", 329, 354], ["DPP4 variants", "OBSERVATION", 18, 31]]], ["For this, we made use of vesicular stomatitis virus (VSV) pseudotypes (VSVpp) bearing MERS-CoV S or VSV G, which does not bind to DPP4 and served as negative control [46] .", [["vesicular stomatitis", "DISEASE", 25, 45], ["vesicular stomatitis virus", "ORGANISM", 25, 51], ["VSV", "ORGANISM", 53, 56], ["pseudotypes", "ORGANISM", 58, 69], ["VSVpp", "CANCER", 71, 76], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 86, 96], ["VSV G", "ORGANISM", 100, 105], ["DPP4", "GENE_OR_GENE_PRODUCT", 130, 134], ["DPP4", "PROTEIN", 130, 134], ["stomatitis virus (VSV", "SPECIES", 35, 56], ["vesicular stomatitis virus", "SPECIES", 25, 51], ["VSV", "SPECIES", 53, 56], ["MERS-CoV", "SPECIES", 86, 94], ["VSV", "SPECIES", 100, 103], ["vesicular stomatitis virus", "PROBLEM", 25, 51], ["pseudotypes (VSVpp) bearing MERS", "PROBLEM", 58, 90], ["CoV S", "PROBLEM", 91, 96], ["VSV G", "TREATMENT", 100, 105], ["DPP4", "TEST", 130, 134], ["vesicular stomatitis", "ANATOMY", 25, 45]]], ["As expected, VSVpp harboring VSV G were able to efficiently transduce BHK-21 target cells irrespective of DPP4 expression.", [["BHK-21 target cells", "ANATOMY", 70, 89], ["VSVpp", "GENE_OR_GENE_PRODUCT", 13, 18], ["VSV G", "ORGANISM", 29, 34], ["BHK-21", "CELL", 70, 76], ["cells", "CELL", 84, 89], ["DPP4", "GENE_OR_GENE_PRODUCT", 106, 110], ["VSVpp", "PROTEIN", 13, 18], ["BHK-21 target cells", "CELL_LINE", 70, 89], ["DPP4", "PROTEIN", 106, 110], ["VSV", "SPECIES", 29, 32], ["VSVpp harboring VSV G", "PROBLEM", 13, 34], ["BHK", "TEST", 70, 73], ["DPP4 expression", "TREATMENT", 106, 121], ["DPP4 expression", "OBSERVATION", 106, 121]]], ["In contrast, transduction of BHK-21 cells mediated by MERS-CoV S critically depended on ectopic expression of human DPP4, in accordance with published findings [47] ( Figure 4) .", [["BHK-21 cells", "ANATOMY", 29, 41], ["BHK-21 cells", "CELL", 29, 41], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 54, 64], ["human", "ORGANISM", 110, 115], ["DPP4", "GENE_OR_GENE_PRODUCT", 116, 120], ["BHK-21 cells", "CELL_LINE", 29, 41], ["MERS-CoV S", "PROTEIN", 54, 64], ["human DPP4", "PROTEIN", 110, 120], ["human", "SPECIES", 110, 115], ["MERS-CoV", "SPECIES", 54, 62], ["human", "SPECIES", 110, 115], ["BHK", "TEST", 29, 32], ["ectopic expression of human DPP4", "TREATMENT", 88, 120]]], ["Notably, four DPP4 polymorphisms -K267E, K267N, A291P and \u0394346-348 -severely reduced MERS-CoV S-driven transduction compared to DPP4 WT (Figure 4 ).", [["DPP4", "GENE_OR_GENE_PRODUCT", 14, 18], ["\u0394346-348", "GENE_OR_GENE_PRODUCT", 58, 66], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 85, 95], ["DPP4", "GENE_OR_GENE_PRODUCT", 128, 132], ["DPP4", "PROTEIN", 14, 18], ["MERS-CoV S", "DNA", 85, 95], ["DPP4 WT", "PROTEIN", 128, 135], ["four DPP4 polymorphisms", "TEST", 9, 32], ["K267E", "TEST", 34, 39], ["K267N", "TEST", 41, 46], ["A291P", "TEST", 48, 53], ["severely reduced MERS", "PROBLEM", 68, 89], ["CoV S", "PROBLEM", 90, 95], ["driven transduction", "TREATMENT", 96, 115], ["DPP4 WT", "TEST", 128, 135]]], ["In order to analyze whether the reduction in MERS-CoV S-driven host cell entry would translate into attenuated MERS-CoV replication, we next investigated two DPP4 polymorphisms (K267E and A291P) in the context of infection with authentic MERS-CoV.", [["cell", "ANATOMY", 68, 72], ["infection", "DISEASE", 213, 222], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 45, 55], ["host cell", "CELL", 63, 72], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 111, 119], ["DPP4", "GENE_OR_GENE_PRODUCT", 158, 162], ["MERS-CoV", "ORGANISM", 238, 246], ["MERS-CoV S", "DNA", 45, 55], ["DPP4", "PROTEIN", 158, 162], ["MERS-CoV", "SPECIES", 111, 119], ["MERS-CoV", "SPECIES", 238, 246], ["the reduction in MERS", "PROBLEM", 28, 49], ["CoV S", "PROBLEM", 50, 55], ["CoV replication", "TREATMENT", 116, 131], ["two DPP4 polymorphisms", "PROBLEM", 154, 176], ["infection", "PROBLEM", 213, 222], ["infection", "OBSERVATION", 213, 222]]], ["When followed over a period of two days post infection it was observed that MERS-CoV replication in BHK-21 cells expressing human DPP4 was significantly reduced when DPP4 contained either K267E or A291P ( Figure 5 ).DPP4 polymorphisms K267E, K267N and A291P reduce MERS-CoV S binding efficiency to DPP4After the identification of DPP4 polymorphisms that reduce S-driven cellular entry of rhabdoviral vectors as well as MERS-CoV replication, we next sought to investigate whether the attenuating phenotype was due to reduced binding of MERS-CoV S to DPP4.", [["BHK-21 cells", "ANATOMY", 100, 112], ["cellular", "ANATOMY", 370, 378], ["infection", "DISEASE", 45, 54], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["BHK-21 cells", "CELL", 100, 112], ["human", "ORGANISM", 124, 129], ["DPP4", "GENE_OR_GENE_PRODUCT", 130, 134], ["DPP4", "GENE_OR_GENE_PRODUCT", 166, 170], ["DPP4", "GENE_OR_GENE_PRODUCT", 216, 220], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 265, 275], ["DPP4", "GENE_OR_GENE_PRODUCT", 330, 334], ["cellular", "CELL", 370, 378], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 419, 427], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 535, 545], ["DPP4", "GENE_OR_GENE_PRODUCT", 549, 553], ["BHK-21 cells", "CELL_LINE", 100, 112], ["human DPP4", "PROTEIN", 124, 134], ["DPP4", "PROTEIN", 166, 170], ["DPP4", "PROTEIN", 216, 220], ["DPP4", "PROTEIN", 330, 334], ["rhabdoviral vectors", "DNA", 388, 407], ["MERS-CoV S", "PROTEIN", 535, 545], ["DPP4", "PROTEIN", 549, 553], ["human", "SPECIES", 124, 129], ["MERS-CoV", "SPECIES", 76, 84], ["BHK-21", "SPECIES", 100, 106], ["human", "SPECIES", 124, 129], ["MERS-CoV", "SPECIES", 419, 427], ["MERS-CoV", "SPECIES", 535, 543], ["infection", "PROBLEM", 45, 54], ["MERS", "PROBLEM", 76, 80], ["CoV replication in BHK", "TREATMENT", 81, 103], ["human DPP4", "TEST", 124, 134], ["DPP4", "TEST", 166, 170], ["DPP4 polymorphisms", "TEST", 216, 234], ["K267E", "TEST", 235, 240], ["K267N", "TEST", 242, 247], ["MERS-CoV S binding efficiency", "PROBLEM", 265, 294], ["DPP4 polymorphisms", "PROBLEM", 330, 348], ["rhabdoviral vectors", "TREATMENT", 388, 407], ["CoV replication", "TREATMENT", 424, 439], ["the attenuating phenotype", "PROBLEM", 479, 504], ["reduced binding of MERS", "PROBLEM", 516, 539], ["DPP4", "TEST", 549, 553], ["infection", "OBSERVATION", 45, 54]]], ["For this, we used soluble MERS-CoV S, produced by fusing the S1 subunit, which contains the DPP4 binding domain, to the Fc portion of human immunoglobulin G (solMERS-S1-Fc).", [["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 26, 36], ["S1", "GENE_OR_GENE_PRODUCT", 61, 63], ["DPP4", "GENE_OR_GENE_PRODUCT", 92, 96], ["human", "ORGANISM", 134, 139], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 140, 156], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 158, 171], ["MERS", "PROTEIN", 26, 30], ["CoV S", "PROTEIN", 31, 36], ["S1 subunit", "PROTEIN", 61, 71], ["DPP4 binding domain", "PROTEIN", 92, 111], ["Fc portion", "PROTEIN", 120, 130], ["human immunoglobulin G", "PROTEIN", 134, 156], ["solMERS", "PROTEIN", 158, 165], ["S1", "PROTEIN", 166, 168], ["Fc", "PROTEIN", 169, 171], ["human", "SPECIES", 134, 139], ["MERS-CoV", "SPECIES", 26, 34], ["human", "SPECIES", 134, 139], ["soluble MERS", "TREATMENT", 18, 30], ["CoV S", "TREATMENT", 31, 36], ["the DPP4 binding domain", "TREATMENT", 88, 111], ["human immunoglobulin G", "TEST", 134, 156], ["solMERS", "TEST", 158, 165], ["S1", "ANATOMY", 61, 63]]], ["Co-immunoprecipitation analysis demonstrated that DPP4 variants harboring polymorphisms K267E, K267N or A291P, which were not compatible with efficient MERS-CoV S-driven host cell entry, displayed significantly reduced ability to interact with MERS-CoV S as indicated by weaker DPP4 signals upon protein A-sepharosemediated pull-down of DPP4/solMERS-S1-Fc (as compared to DPP4 WT, Figure 6A-B) .", [["cell", "ANATOMY", 175, 179], ["DPP4", "GENE_OR_GENE_PRODUCT", 50, 54], ["K267E", "GENE_OR_GENE_PRODUCT", 88, 93], ["K267N", "GENE_OR_GENE_PRODUCT", 95, 100], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 152, 162], ["host cell", "CELL", 170, 179], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 244, 254], ["DPP4", "GENE_OR_GENE_PRODUCT", 278, 282], ["DPP4", "GENE_OR_GENE_PRODUCT", 337, 341], ["solMERS-S1-Fc", "GENE_OR_GENE_PRODUCT", 342, 355], ["DPP4", "GENE_OR_GENE_PRODUCT", 372, 376], ["DPP4", "PROTEIN", 50, 54], ["MERS-CoV S", "DNA", 152, 162], ["MERS-CoV S", "PROTEIN", 244, 254], ["DPP4", "PROTEIN", 278, 282], ["DPP4", "PROTEIN", 337, 341], ["solMERS", "PROTEIN", 342, 349], ["S1", "PROTEIN", 350, 352], ["Fc", "PROTEIN", 353, 355], ["DPP4 WT", "PROTEIN", 372, 379], ["Figure 6A-B", "PROTEIN", 381, 392], ["MERS-CoV", "SPECIES", 244, 252], ["Co-immunoprecipitation analysis", "TEST", 0, 31], ["DPP4 variants harboring polymorphisms K267E", "PROBLEM", 50, 93], ["K267N", "TEST", 95, 100], ["efficient MERS", "PROBLEM", 142, 156], ["CoV S", "PROBLEM", 157, 162], ["significantly reduced ability", "PROBLEM", 197, 226], ["CoV S", "TEST", 249, 254], ["protein", "TEST", 296, 303], ["sepharosemediated pull", "TEST", 306, 328], ["DPP4", "TEST", 337, 341], ["solMERS", "TEST", 342, 349], ["DPP4", "TEST", 372, 376], ["WT", "TEST", 377, 379], ["Figure", "TEST", 381, 387]]], ["Notably, DPP4 variant \u0394346-348 could be as efficiently coimmunoprecipitated as DPP4 WT, indicating that its inefficient receptor function was solely due to its defect in proper surface transport.", [["surface", "ANATOMY", 177, 184], ["\u0394346-348", "CHEMICAL", 22, 30], ["DPP4", "GENE_OR_GENE_PRODUCT", 9, 13], ["\u0394346-348", "GENE_OR_GENE_PRODUCT", 22, 30], ["DPP4", "GENE_OR_GENE_PRODUCT", 79, 83], ["surface", "CELLULAR_COMPONENT", 177, 184], ["DPP4", "PROTEIN", 9, 13], ["DPP4 WT", "PROTEIN", 79, 86], ["DPP4 variant", "TEST", 9, 21], ["DPP4 WT", "TEST", 79, 86], ["its inefficient receptor function", "PROBLEM", 104, 137], ["its defect", "PROBLEM", 156, 166], ["defect", "OBSERVATION", 160, 166]]], ["The findings obtained by co-IP analysis were confirmed by flow cytometry.", [["co-IP analysis", "TEST", 25, 39], ["flow cytometry", "TEST", 58, 72], ["flow cytometry", "OBSERVATION", 58, 72]]], ["It was revealed that polymorphisms that reduced MERS-CoV S-driven host cell entry (K267E, K267N, A291P and \u0394346-348) and spread of authentic MERS-CoV (K267E and A291P) also reduced MERS-CoV S binding to cells expressing DPP4 on the cell surface ( Figure 6C ).", [["cell", "ANATOMY", 71, 75], ["cells", "ANATOMY", 203, 208], ["cell surface", "ANATOMY", 232, 244], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 48, 58], ["host cell", "CELL", 66, 75], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 141, 149], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 181, 191], ["cells", "CELL", 203, 208], ["DPP4", "GENE_OR_GENE_PRODUCT", 220, 224], ["cell surface", "CELLULAR_COMPONENT", 232, 244], ["MERS-CoV S", "DNA", 48, 58], ["MERS-CoV", "DNA", 141, 149], ["MERS-CoV S", "PROTEIN", 181, 191], ["DPP4", "PROTEIN", 220, 224], ["MERS-CoV", "SPECIES", 141, 149], ["polymorphisms", "PROBLEM", 21, 34], ["reduced MERS", "PROBLEM", 40, 52], ["CoV S", "TEST", 53, 58], ["K267E", "TEST", 83, 88], ["K267N", "TEST", 90, 95], ["A291P", "TEST", 97, 102], ["authentic MERS", "TEST", 131, 145], ["CoV (K267E", "TEST", 146, 156], ["reduced MERS-CoV S binding", "PROBLEM", 173, 199], ["DPP4", "TEST", 220, 224], ["MERS-CoV", "OBSERVATION", 181, 189]]], ["In addition, polymorphism A289V, which decreased MERS-CoV S-driven transduction to a lesser extent than the aforementioned polymorphisms (Figure 4) , also reduced MERS-CoV S binding to DPP4.", [["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 49, 59], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 163, 173], ["DPP4", "GENE_OR_GENE_PRODUCT", 185, 189], ["MERS-CoV S", "PROTEIN", 49, 59], ["DPP4", "PROTEIN", 185, 189], ["polymorphism A289V", "PROBLEM", 13, 31], ["reduced MERS", "PROBLEM", 155, 167], ["CoV S binding", "PROBLEM", 168, 181], ["DPP4", "TEST", 185, 189], ["lesser extent", "OBSERVATION_MODIFIER", 85, 98]]], ["Thus, DPP4 polymorphisms K267E, K267N and A291P reduce MERS-CoV S-driven host cell entry and MERS-CoV infection by diminishing MERS-CoV S binding to DPP4.DiscussionHost cell entry of MERS-CoV critically depends on the interaction between the viral S protein and the cellular receptor DPP4.", [["cell", "ANATOMY", 78, 82], ["cell", "ANATOMY", 169, 173], ["cellular", "ANATOMY", 266, 274], ["infection", "DISEASE", 102, 111], ["DPP4", "GENE_OR_GENE_PRODUCT", 6, 10], ["A291P", "GENE_OR_GENE_PRODUCT", 42, 47], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 55, 65], ["host cell", "CELL", 73, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 127, 137], ["DPP4", "GENE_OR_GENE_PRODUCT", 149, 153], ["Host cell", "CELL", 164, 173], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 183, 191], ["viral S protein", "GENE_OR_GENE_PRODUCT", 242, 257], ["cellular", "CELL", 266, 274], ["DPP4", "GENE_OR_GENE_PRODUCT", 284, 288], ["DPP4", "PROTEIN", 6, 10], ["MERS-CoV S", "PROTEIN", 127, 137], ["DPP4", "PROTEIN", 149, 153], ["MERS", "PROTEIN", 183, 187], ["viral S protein", "PROTEIN", 242, 257], ["cellular receptor", "PROTEIN", 266, 283], ["DPP4", "PROTEIN", 284, 288], ["MERS-CoV", "SPECIES", 93, 101], ["MERS-CoV", "SPECIES", 183, 191], ["DPP4 polymorphisms", "TEST", 6, 24], ["K267E", "TEST", 25, 30], ["K267N", "TEST", 32, 37], ["MERS", "TEST", 55, 59], ["CoV S", "PROBLEM", 60, 65], ["host cell entry", "PROBLEM", 73, 88], ["CoV infection", "PROBLEM", 98, 111], ["diminishing MERS-CoV S binding", "PROBLEM", 115, 145], ["DPP4", "TEST", 149, 153], ["the viral S protein", "TEST", 238, 257], ["the cellular receptor DPP4", "TREATMENT", 262, 288], ["CoV", "ANATOMY", 98, 101], ["infection", "OBSERVATION", 102, 111]]], ["A link between obesity or underlying diseases like diabetes mellitus, which both can affect DPP4 expression levels [48] , and the risk of fatal outcome of MERS-CoV infection has been made [49] .", [["obesity", "DISEASE", 15, 22], ["diabetes mellitus", "DISEASE", 51, 68], ["MERS-CoV infection", "DISEASE", 155, 173], ["DPP4", "GENE_OR_GENE_PRODUCT", 92, 96], ["MERS-CoV", "ORGANISM", 155, 163], ["DPP4", "PROTEIN", 92, 96], ["MERS-CoV", "SPECIES", 155, 163], ["obesity", "PROBLEM", 15, 22], ["underlying diseases", "PROBLEM", 26, 45], ["diabetes mellitus", "PROBLEM", 51, 68], ["DPP4 expression levels", "TEST", 92, 114], ["MERS", "PROBLEM", 155, 159], ["CoV infection", "PROBLEM", 160, 173], ["obesity", "OBSERVATION", 15, 22], ["diseases", "OBSERVATION", 37, 45], ["diabetes mellitus", "OBSERVATION", 51, 68], ["fatal", "OBSERVATION_MODIFIER", 138, 143]]], ["Moreover, alanine scanning mutagenesis identified DPP4 residues critical for MERS-CoV entry, including K267, L294, I295, R317 and R336 [50, 51] .", [["alanine", "CHEMICAL", 10, 17], ["alanine", "CHEMICAL", 10, 17], ["alanine", "AMINO_ACID", 10, 17], ["DPP4", "GENE_OR_GENE_PRODUCT", 50, 54], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 77, 85], ["DPP4", "PROTEIN", 50, 54], ["MERS", "PROTEIN", 77, 81], ["MERS-CoV", "SPECIES", 77, 85], ["alanine scanning mutagenesis", "TEST", 10, 38], ["DPP4 residues", "TEST", 50, 63], ["CoV entry", "TEST", 82, 91], ["K267", "TEST", 103, 107]]], ["However, the impact of natural-occurring variations on host cell entry of MERS-CoV has not been addressed so far.", [["cell", "ANATOMY", 60, 64], ["host cell", "CELL", 55, 64], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 74, 82], ["MERS-CoV", "SPECIES", 74, 82], ["host cell", "OBSERVATION_MODIFIER", 55, 64]]], ["We identified DPP4 polymorphisms that reduce S protein-driven host cell entry and replication of authentic MERS-CoV by lowering the binding efficiency of MERS-CoV S to DPP4, suggesting that the DPP4 phenotype may impact the course of MERS-CoV infection.DiscussionWestern blot analysis, flow cytometry and confocal laser scanning microscopy revealed that none of the polymorphisms studied, except deletion of amino acids 346-348, had a significant impact on total or cell surface expression of DPP4, at least in the context of DPP4 transfected cells.", [["cell", "ANATOMY", 67, 71], ["cell surface", "ANATOMY", 466, 478], ["cells", "ANATOMY", 543, 548], ["MERS-CoV infection", "DISEASE", 234, 252], ["amino acids 346-348", "CHEMICAL", 408, 427], ["amino acids", "CHEMICAL", 408, 419], ["DPP4", "GENE_OR_GENE_PRODUCT", 14, 18], ["S protein", "GENE_OR_GENE_PRODUCT", 45, 54], ["host cell", "CELL", 62, 71], ["MERS-CoV", "ORGANISM", 107, 115], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 154, 164], ["DPP4", "GENE_OR_GENE_PRODUCT", 168, 172], ["DPP4", "GENE_OR_GENE_PRODUCT", 194, 198], ["MERS-CoV", "ORGANISM", 234, 242], ["amino acids", "AMINO_ACID", 408, 419], ["346-348", "AMINO_ACID", 420, 427], ["cell surface", "CELLULAR_COMPONENT", 466, 478], ["DPP4", "GENE_OR_GENE_PRODUCT", 493, 497], ["DPP4", "GENE_OR_GENE_PRODUCT", 526, 530], ["cells", "CELL", 543, 548], ["DPP4", "PROTEIN", 14, 18], ["S protein", "PROTEIN", 45, 54], ["MERS-CoV S", "PROTEIN", 154, 164], ["DPP4", "PROTEIN", 168, 172], ["DPP4", "PROTEIN", 194, 198], ["amino acids 346-348", "PROTEIN", 408, 427], ["DPP4", "PROTEIN", 493, 497], ["DPP4 transfected cells", "CELL_LINE", 526, 548], ["MERS-CoV", "SPECIES", 107, 115], ["MERS-CoV", "SPECIES", 234, 242], ["DPP4 polymorphisms", "PROBLEM", 14, 32], ["S protein", "TEST", 45, 54], ["host cell entry", "TREATMENT", 62, 77], ["authentic MERS", "PROBLEM", 97, 111], ["CoV", "PROBLEM", 112, 115], ["MERS-CoV S", "PROBLEM", 154, 164], ["DPP4", "TEST", 168, 172], ["the DPP4 phenotype", "PROBLEM", 190, 208], ["MERS", "PROBLEM", 234, 238], ["CoV infection", "PROBLEM", 239, 252], ["blot analysis", "TEST", 271, 284], ["flow cytometry", "TEST", 286, 300], ["confocal laser scanning microscopy", "TEST", 305, 339], ["the polymorphisms studied", "PROBLEM", 362, 387], ["amino acids", "TEST", 408, 419], ["DPP4", "TEST", 493, 497], ["DPP4 transfected cells", "PROBLEM", 526, 548], ["infection", "OBSERVATION", 243, 252], ["significant", "OBSERVATION_MODIFIER", 435, 446], ["DPP4", "OBSERVATION", 526, 530], ["transfected cells", "OBSERVATION", 531, 548]]], ["Four polymorphisms located at three different sites in DPP4 (K267E, K267N, A291P and \u0394346-348) severely reduced S protein-driven host cell entry.", [["cell", "ANATOMY", 134, 138], ["DPP4", "GENE_OR_GENE_PRODUCT", 55, 59], ["S protein", "GENE_OR_GENE_PRODUCT", 112, 121], ["host cell", "CELL", 129, 138], ["DPP4", "PROTEIN", 55, 59], ["S protein", "PROTEIN", 112, 121], ["Four polymorphisms", "PROBLEM", 0, 18], ["DPP4", "TEST", 55, 59], ["K267E", "TEST", 61, 66], ["K267N", "TEST", 68, 73], ["A291P", "TEST", 75, 80], ["severely reduced S protein", "PROBLEM", 95, 121], ["three different", "OBSERVATION_MODIFIER", 30, 45], ["sites", "OBSERVATION_MODIFIER", 46, 51], ["DPP4", "ANATOMY", 55, 59], ["host cell entry", "OBSERVATION", 129, 144]]], ["As DPP4 \u0394346-348 was shown to be incompatible with robust cell surface transport but able to interact with MERS-CoV S in co-IP analysis, we conclude that the reduction in entry efficiency is solely due to insufficient DPP4 surface levels.", [["cell surface", "ANATOMY", 58, 70], ["surface", "ANATOMY", 223, 230], ["DPP4 \u0394346-348", "CHEMICAL", 3, 16], ["DPP4", "GENE_OR_GENE_PRODUCT", 3, 7], ["cell", "CELL", 58, 62], ["DPP4", "GENE_OR_GENE_PRODUCT", 218, 222], ["DPP4", "PROTEIN", 3, 7], ["MERS", "PROTEIN", 107, 111], ["-CoV S", "PROTEIN", 111, 117], ["-IP", "PROTEIN", 123, 126], ["DPP4", "PROTEIN", 218, 222], ["DPP4", "TEST", 3, 7], ["robust cell surface transport", "TREATMENT", 51, 80], ["co-IP analysis", "TEST", 121, 135], ["the reduction in entry efficiency", "PROBLEM", 154, 187], ["insufficient DPP4 surface levels", "PROBLEM", 205, 237], ["entry efficiency", "OBSERVATION", 171, 187]]], ["In contrast, reduction of host cell entry by K267E, K267N and A291P could not be explained by reduced DPP4 expression and these polymorphisms were thus further investigated.", [["cell", "ANATOMY", 31, 35], ["host cell", "CELL", 26, 35], ["K267E", "GENE_OR_GENE_PRODUCT", 45, 50], ["K267N", "GENE_OR_GENE_PRODUCT", 52, 57], ["A291P", "GENE_OR_GENE_PRODUCT", 62, 67], ["DPP4", "GENE_OR_GENE_PRODUCT", 102, 106], ["DPP4", "PROTEIN", 102, 106], ["host cell entry", "TEST", 26, 41], ["K267N", "TEST", 52, 57], ["reduced DPP4 expression", "PROBLEM", 94, 117], ["these polymorphisms", "PROBLEM", 122, 141], ["host cell entry", "OBSERVATION", 26, 41]]], ["MERS-CoV infection of BHK-21 cells transfected to express DPP4 WT and variants K267E or A291P revealed that K267E or A291P were not compatible with robust MERS-CoV replication.", [["BHK-21 cells", "ANATOMY", 22, 34], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["BHK-21 cells", "CELL", 22, 34], ["DPP4", "GENE_OR_GENE_PRODUCT", 58, 62], ["K267E", "GENE_OR_GENE_PRODUCT", 79, 84], ["A291P", "GENE_OR_GENE_PRODUCT", 88, 93], ["K267E", "GENE_OR_GENE_PRODUCT", 108, 113], ["A291P", "GENE_OR_GENE_PRODUCT", 117, 122], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 155, 163], ["BHK-21 cells", "CELL_LINE", 22, 34], ["DPP4 WT", "PROTEIN", 58, 65], ["BHK-21", "SPECIES", 22, 28], ["MERS-CoV", "SPECIES", 155, 163], ["CoV infection of BHK", "PROBLEM", 5, 25], ["DPP4 WT", "TEST", 58, 65], ["variants K267E", "TEST", 70, 84], ["K267E", "TEST", 108, 113], ["CoV replication", "TREATMENT", 160, 175], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18]]], ["Finally, co-IP analyses and binding studies with soluble MERS-CoV S showed that these DPP4 polymorphisms reduced S protein binding to DPP4.DiscussionWhen looking at the crystal structure of the complex consisting of the MERS-CoV S receptor binding domain bound to DPP4, these observations do not come as a surprise.", [["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 57, 67], ["DPP4", "GENE_OR_GENE_PRODUCT", 86, 90], ["DPP4", "GENE_OR_GENE_PRODUCT", 134, 138], ["DPP4", "GENE_OR_GENE_PRODUCT", 264, 268], ["-IP", "PROTEIN", 11, 14], ["MERS-CoV S", "PROTEIN", 57, 67], ["DPP4", "PROTEIN", 86, 90], ["S protein", "PROTEIN", 113, 122], ["DPP4", "PROTEIN", 134, 138], ["MERS-CoV S receptor binding domain", "PROTEIN", 220, 254], ["DPP4", "PROTEIN", 264, 268], ["co-IP analyses", "TEST", 9, 23], ["binding studies", "TEST", 28, 43], ["soluble MERS-CoV S", "TEST", 49, 67], ["these DPP4 polymorphisms reduced S protein binding", "PROBLEM", 80, 130], ["DPP4", "TEST", 134, 138], ["the MERS", "PROBLEM", 216, 224], ["CoV S receptor binding domain bound", "PROBLEM", 225, 260], ["DPP4", "TEST", 264, 268]]], ["DPP4 residue K267 has been reported to contact MERS-CoV S residues G538 and D539, including a salt bridge interaction with D539 [16] .", [["K267", "CHEMICAL", 13, 17], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["K267", "AMINO_ACID", 13, 17], ["D539", "AMINO_ACID", 76, 80], ["DPP4", "PROTEIN", 0, 4], ["MERS", "PROTEIN", 47, 51], ["DPP4 residue K267", "TEST", 0, 17], ["D539", "TREATMENT", 76, 80], ["a salt bridge interaction", "TREATMENT", 92, 117]]], ["The exchange of K267 to either glutamate (E) .", [["glutamate", "CHEMICAL", 31, 40], ["K267", "CHEMICAL", 16, 20], ["glutamate", "CHEMICAL", 31, 40], ["K267", "SIMPLE_CHEMICAL", 16, 20], ["glutamate", "SIMPLE_CHEMICAL", 31, 40], ["E", "SIMPLE_CHEMICAL", 42, 43], ["K267", "PROTEIN", 16, 20], ["The exchange of K267", "TREATMENT", 0, 20]]], ["Whole cell lysates (WCL) were prepared and analyzed for DPP4 expression by SDS-PAGE under non-reducing conditions and WB using a primary antibody targeting the C-terminal cMYC epitope and a peroxidase-conjugated secondary antibody.", [["Whole cell lysates", "ANATOMY", 0, 18], ["WCL", "ANATOMY", 20, 23], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["WCL", "CELL", 20, 23], ["DPP4", "GENE_OR_GENE_PRODUCT", 56, 60], ["peroxidase", "GENE_OR_GENE_PRODUCT", 190, 200], ["DPP4", "PROTEIN", 56, 60], ["primary antibody", "PROTEIN", 129, 145], ["C-terminal cMYC epitope", "PROTEIN", 160, 183], ["peroxidase-conjugated secondary antibody", "PROTEIN", 190, 230], ["Whole cell lysates", "TEST", 0, 18], ["WB", "TEST", 118, 120], ["a primary antibody", "TEST", 127, 145], ["the C-terminal cMYC epitope", "TREATMENT", 156, 183], ["a peroxidase", "TEST", 188, 200]]], ["Further, expression of beta-actin (ACTB) was analyzed as a loading control.", [["beta-actin", "GENE_OR_GENE_PRODUCT", 23, 33], ["ACTB", "GENE_OR_GENE_PRODUCT", 35, 39], ["beta-actin", "PROTEIN", 23, 33], ["ACTB", "PROTEIN", 35, 39], ["beta-actin (ACTB)", "TREATMENT", 23, 40], ["a loading control", "TREATMENT", 57, 74]]], ["Numbers at the left indicate the molecular weight in kilodalton (kDa).", [["kilodalton", "PROTEIN", 53, 63], ["left", "ANATOMY_MODIFIER", 15, 19]]], ["(B) Quantification of total DPP4 expression in WCL.", [["WCL", "ANATOMY", 47, 50], ["DPP4", "GENE_OR_GENE_PRODUCT", 28, 32], ["WCL", "CELL", 47, 50], ["DPP4", "PROTEIN", 28, 32], ["total DPP4 expression in WCL", "TREATMENT", 22, 50]]], ["After normalization of DPP4 band intensities with that of the corresponding ACTB bands.", [["DPP4", "GENE_OR_GENE_PRODUCT", 23, 27], ["ACTB", "GENE_OR_GENE_PRODUCT", 76, 80], ["DPP4", "PROTEIN", 23, 27], ["ACTB bands", "PROTEIN", 76, 86], ["DPP4 band intensities", "TEST", 23, 44], ["the corresponding ACTB bands", "PROBLEM", 58, 86], ["ACTB bands", "OBSERVATION", 76, 86]]], ["DPP4 WT expression was set as 100% and the relative expression of mutant DPP4 was calculated accordingly.", [["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["DPP4", "GENE_OR_GENE_PRODUCT", 73, 77], ["DPP4", "PROTEIN", 0, 4], ["mutant DPP4", "PROTEIN", 66, 77], ["DPP4 WT expression", "TEST", 0, 18], ["mutant DPP4", "PROBLEM", 66, 77]]], ["No statistical significance for differences in total expression between WT and mutant DPP4 was observed by one-way analysis of variance with Dunnett's posttest (p > 0.05, not significant [ns]). .", [["DPP4", "GENE_OR_GENE_PRODUCT", 86, 90], ["mutant DPP4", "PROTEIN", 79, 90], ["WT", "TEST", 72, 74], ["mutant DPP4", "TEST", 79, 90], ["Dunnett", "TEST", 141, 148]]], ["Surface expressed DPP4 was stained by subsequent incubation of the non-permeabilized cells with a primary antibody that targets the DPP4 ectodomain and an AlexaFluor488-conjugated secondary antibody.", [["cells", "ANATOMY", 85, 90], ["AlexaFluor488", "CHEMICAL", 155, 168], ["DPP4", "GENE_OR_GENE_PRODUCT", 18, 22], ["cells", "CELL", 85, 90], ["DPP4", "GENE_OR_GENE_PRODUCT", 132, 136], ["AlexaFluor488", "SIMPLE_CHEMICAL", 155, 168], ["DPP4", "PROTEIN", 18, 22], ["non-permeabilized cells", "CELL_LINE", 67, 90], ["primary antibody", "PROTEIN", 98, 114], ["DPP4 ectodomain", "PROTEIN", 132, 147], ["AlexaFluor488-conjugated secondary antibody", "PROTEIN", 155, 198], ["DPP4", "TEST", 18, 22], ["the non-permeabilized cells", "PROBLEM", 63, 90], ["a primary antibody", "PROBLEM", 96, 114], ["the DPP4 ectodomain", "TEST", 128, 147], ["an AlexaFluor488", "TEST", 152, 168]]], ["Fluorescent signals representing surface-expressed DPP4 were analyzed by flow cytometry and the mean fluorescence intensity (MFI) values for each sample were calculated.", [["surface", "ANATOMY", 33, 40], ["surface", "CELLULAR_COMPONENT", 33, 40], ["DPP4", "GENE_OR_GENE_PRODUCT", 51, 55], ["DPP4", "PROTEIN", 51, 55], ["Fluorescent signals", "TEST", 0, 19], ["DPP4", "TEST", 51, 55], ["flow cytometry", "TEST", 73, 87], ["the mean fluorescence intensity", "TEST", 92, 123], ["each sample", "TEST", 141, 152], ["surface", "OBSERVATION_MODIFIER", 33, 40]]], ["For normalization, the MFI value of the negative control was subtracted from all samples.", [["samples", "ANATOMY", 81, 88], ["MFI", "PROTEIN", 23, 26], ["the MFI value", "TEST", 19, 32]]], ["Further, surface expression of DPP4 WT was set as 100% and the relative surface expression of the DPP4 mutants was calculated accordingly.", [["surface", "ANATOMY", 9, 16], ["surface", "ANATOMY", 72, 79], ["surface", "CELLULAR_COMPONENT", 9, 16], ["DPP4", "GENE_OR_GENE_PRODUCT", 31, 35], ["DPP4", "GENE_OR_GENE_PRODUCT", 98, 102], ["DPP4", "PROTEIN", 31, 35], ["DPP4 mutants", "PROTEIN", 98, 110], ["DPP4 WT", "TEST", 31, 38], ["the DPP4 mutants", "TEST", 94, 110]]], ["Statistical significance for differences in surface expression between WT and mutant DPP4 was tested by one-way analysis of variance with Dunnett's posttest (p > 0.05, not significant; p \u2264 0.05, ; p \u2264 0.001, ; p \u2264 0.001, ***). aspartate residue at this position.", [["surface", "ANATOMY", 44, 51], ["aspartate", "CHEMICAL", 227, 236], ["aspartate", "CHEMICAL", 227, 236], ["surface", "CELLULAR_COMPONENT", 44, 51], ["DPP4", "GENE_OR_GENE_PRODUCT", 85, 89], ["aspartate", "SIMPLE_CHEMICAL", 227, 236], ["mutant DPP4", "PROTEIN", 78, 89], ["WT", "TEST", 71, 73], ["mutant DPP4", "TEST", 78, 89], ["Dunnett's posttest", "TEST", 138, 156], ["p", "TEST", 158, 159], ["aspartate residue", "PROBLEM", 227, 244], ["residue", "OBSERVATION", 237, 244]]], ["D539N reduced entry into cells expressing relatively low amounts of DPP4 but had no effect on entry into cells expressing high amounts of DPP4 (Supplementary Figure 2) .", [["cells", "ANATOMY", 25, 30], ["cells", "ANATOMY", 105, 110], ["D539N", "CHEMICAL", 0, 5], ["D539N", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 25, 30], ["DPP4", "GENE_OR_GENE_PRODUCT", 68, 72], ["cells", "CELL", 105, 110], ["DPP4", "GENE_OR_GENE_PRODUCT", 138, 142], ["D539N", "PROTEIN", 0, 5], ["DPP4", "PROTEIN", 68, 72], ["DPP4", "PROTEIN", 138, 142], ["relatively low amounts of DPP4", "PROBLEM", 42, 72], ["DPP4 (Supplementary Figure", "TREATMENT", 138, 164], ["relatively", "OBSERVATION_MODIFIER", 42, 52], ["low amounts", "OBSERVATION_MODIFIER", 53, 64]]], ["Moreover, and more interestingly, D539N slightly rescued MERS-CoV S-driven entry from the negative effect exerted by DPP4 polymorphism K267N (Supplementary Figure 2) .", [["D539N", "CHEMICAL", 34, 39], ["DPP4", "GENE_OR_GENE_PRODUCT", 117, 121], ["MERS-CoV S", "PROTEIN", 57, 67], ["DPP4", "PROTEIN", 117, 121], ["DPP4 polymorphism K267N", "TREATMENT", 117, 140]]], ["Similarly, residue 510 in MERS-CoV S, which is known to interact with DPP4 residues 317 and 322, was found to be polymorphic, and previous studies demonstrated that polymorphism D510G reduced DPP4 binding but also increased resistance to neutralizing antibodies [37] .", [["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 26, 36], ["DPP4", "GENE_OR_GENE_PRODUCT", 70, 74], ["DPP4", "GENE_OR_GENE_PRODUCT", 192, 196], ["MERS-CoV S", "DNA", 26, 36], ["DPP4", "PROTEIN", 70, 74], ["DPP4", "PROTEIN", 192, 196], ["neutralizing antibodies", "PROTEIN", 238, 261], ["MERS-CoV", "SPECIES", 26, 34], ["DPP4 residues", "TEST", 70, 83], ["previous studies", "TEST", 130, 146], ["polymorphism D510G reduced DPP4 binding", "PROBLEM", 165, 204], ["neutralizing antibodies", "TEST", 238, 261]]], ["Notably, D510G slightly increased entry via DPP4 harboring polymorphism Y322H and allowed MERS-CoV S to use DPP4 with polymorphism R317K with the same efficiency as WT DPP4.", [["DPP4", "GENE_OR_GENE_PRODUCT", 44, 48], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 90, 100], ["DPP4", "GENE_OR_GENE_PRODUCT", 108, 112], ["DPP4", "GENE_OR_GENE_PRODUCT", 168, 172], ["DPP4", "PROTEIN", 44, 48], ["MERS-CoV S", "DNA", 90, 100], ["DPP4", "PROTEIN", 108, 112], ["WT DPP4", "PROTEIN", 165, 172], ["MERS-CoV", "SPECIES", 90, 98], ["DPP4 harboring polymorphism Y322H", "TREATMENT", 44, 77], ["DPP4 with polymorphism R317K", "TREATMENT", 108, 136], ["WT DPP4", "TEST", 165, 172], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["It should be stated that none of these effects was statistically significant and that DPP4 and MERS-CoV S polymorphisms occur with low frequency.", [["DPP4", "GENE_OR_GENE_PRODUCT", 86, 90], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 95, 105], ["MERS-CoV", "SPECIES", 95, 103], ["DPP4", "TEST", 86, 90], ["CoV S polymorphisms", "PROBLEM", 100, 119], ["low frequency", "PROBLEM", 131, 144], ["low frequency", "OBSERVATION_MODIFIER", 131, 144]]], ["Although it is unlikely that the DPP4 polymorphisms have emerged as a result of evolutionary pressure from MERS-CoV infections, our results suggest that certain existing DPP4 polymorphism(s) might foster the emergence of MERS-CoV variants with altered biological properties.DiscussionThe polymorphisms studied here occur with relatively low frequencies of one per \u223c19,000 (A289V) to \u223c245,000 (T288I) individuals.", [["MERS-CoV infections", "DISEASE", 107, 126], ["DPP4", "GENE_OR_GENE_PRODUCT", 33, 37], ["MERS-CoV", "ORGANISM", 107, 115], ["DPP4", "GENE_OR_GENE_PRODUCT", 170, 174], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 221, 229], ["DPP4", "PROTEIN", 33, 37], ["DPP4", "PROTEIN", 170, 174], ["MERS-CoV", "SPECIES", 107, 115], ["MERS-CoV", "SPECIES", 221, 229], ["the DPP4 polymorphisms", "PROBLEM", 29, 51], ["evolutionary pressure", "PROBLEM", 80, 101], ["MERS", "PROBLEM", 107, 111], ["CoV infections", "PROBLEM", 112, 126], ["altered biological properties", "PROBLEM", 244, 273], ["The polymorphisms studied", "TEST", 284, 309], ["is unlikely", "UNCERTAINTY", 12, 23]]], ["Thus, DPP4 polymorphisms could contribute to the perplexing absence of MERS cases in Africa, where the virus circulates in camels [52] [53] [54] [55] [56] [57] .", [["DPP4", "GENE_OR_GENE_PRODUCT", 6, 10], ["[52] [53] [54] [55] [56] [57]", "SIMPLE_CHEMICAL", 130, 159], ["DPP4", "PROTEIN", 6, 10], ["DPP4 polymorphisms", "PROBLEM", 6, 24], ["the virus circulates", "TEST", 99, 119]]], ["However, recent evidence suggests that sequence variations between African and Arabian MERS-CoV might be a factor [53, 57] .", [["MERS-CoV", "ORGANISM", 87, 95], ["Arabian MERS-CoV", "SPECIES", 79, 95]]], ["More importantly, it remains to be analyzed how frequent DPP4 polymorphisms that affect S protein binding occur in the Middle East and whether they are associated with the clinical course of MERS.", [["MERS", "DISEASE", 191, 195], ["DPP4", "GENE_OR_GENE_PRODUCT", 57, 61], ["S protein", "GENE_OR_GENE_PRODUCT", 88, 97], ["DPP4", "PROTEIN", 57, 61], ["S protein", "PROTEIN", 88, 97], ["frequent DPP4 polymorphisms", "PROBLEM", 48, 75], ["S protein binding", "PROBLEM", 88, 105]]]], "PMC7158168": [["IMPORTANCE OF VETERINARIAN PARTICIPATION IN WILDLIFE CAREAs humans continue to encroach on previously undisturbed and pristine wild habitats, the frequency of wildlife-human encounters has increased.", [["humans", "ORGANISM", 60, 66], ["human", "ORGANISM", 168, 173], ["humans", "SPECIES", 60, 66], ["human", "SPECIES", 168, 173], ["humans", "SPECIES", 60, 66], ["human", "SPECIES", 168, 173], ["increased", "OBSERVATION_MODIFIER", 189, 198]]], ["These increased encounters have led to an increased need for veterinary participation in managing sick and injured animals.", [["increased", "OBSERVATION_MODIFIER", 42, 51]]], ["This does not necessarily suggest that veterinarians should consider themselves experts on all animal species, but that as professionals, they should develop an infrastructure of resources that enables them to provide medical and surgical care for those animals in need.", [["medical and surgical care", "TREATMENT", 218, 243]]], ["In addition, because many of these animals can serve as reservoirs for zoonotic diseases, veterinarians can play an important role in minimizing the risk of disease transmission between wildlife and concerned citizens.", [["zoonotic diseases", "DISEASE", 71, 88], ["zoonotic diseases", "PROBLEM", 71, 88], ["disease transmission", "PROBLEM", 157, 177]]], ["For some veterinarians, their role may require them to maintain a current list of veterinarians or wildlife rehabilitators capable of managing an injured wildlife patient and refer clients to these professionals.", [["patient", "ORGANISM", 163, 170], ["patient", "SPECIES", 163, 170]]], ["In many cases, the hospital will be expected to absorb the cost of treatment, although avenues for monetary compensation, including grants and public donations, do exist.", [["treatment", "TREATMENT", 67, 76], ["monetary compensation", "TEST", 99, 120]]], ["Accepting wildlife cases is often perceived by (prospective) clients as a positive reinforcement of a veterinarian's compassion toward animals and can serve, directly or indirectly, as a method of increasing a veterinarian's domestic and exotic pet caseload.", [["pet", "ORGANISM_SUBDIVISION", 245, 248], ["exotic pet caseload", "TREATMENT", 238, 257]]], ["One ethical consideration to make with these cases is deciding when intervention may interfere with a natural process occurring in a population.", [["intervention", "TREATMENT", 68, 80], ["a natural process", "PROBLEM", 100, 117]]], ["In some cases, euthanasia will certainly end suffering, whereas in others treatment may interfere with both natural selection and the disease status in a population.", [["euthanasia", "PROBLEM", 15, 25], ["treatment", "TREATMENT", 74, 83], ["the disease status", "PROBLEM", 130, 148]]], ["However, because the lives of humans have become so enmeshed with populations of wild animals, it is unavoidable that some, if not most, of the injuries or disease processes occurring in wildlife populations are the direct result of human contact.", [["injuries", "DISEASE", 144, 152], ["humans", "ORGANISM", 30, 36], ["human", "ORGANISM", 233, 238], ["humans", "SPECIES", 30, 36], ["human", "SPECIES", 233, 238], ["humans", "SPECIES", 30, 36], ["human", "SPECIES", 233, 238], ["the injuries", "PROBLEM", 140, 152], ["disease processes", "PROBLEM", 156, 173], ["injuries", "OBSERVATION", 144, 152]]], ["In these cases, there may be a strong moral (ethical) obligation to repair damage caused by the human species.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["a strong moral (ethical) obligation", "PROBLEM", 29, 64], ["repair damage", "PROBLEM", 68, 81], ["the human species", "PROBLEM", 92, 109], ["may be", "UNCERTAINTY", 22, 28], ["damage", "OBSERVATION", 75, 81]]], ["An early and rational assessment of the likely return to function for a patient is imperative to conserve the available resources for treatment and prevent undue suffering in the patient.", [["patient", "ORGANISM", 72, 79], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 72, 79], ["patient", "SPECIES", 179, 186], ["rational assessment", "TEST", 13, 32], ["treatment", "TREATMENT", 134, 143]]], ["Animals who are considered poor candidates for release or placement should be considered for euthanasia as soon as an assessment is made.", [["Animals", "ORGANISM", 0, 7], ["placement", "TREATMENT", 58, 67], ["euthanasia", "PROBLEM", 93, 103], ["an assessment", "TEST", 115, 128]]], ["Release candidates should be able to function appropriately within their natural habitat (including reproduction) and with conspecifics; otherwise, a disservice is rendered to both the animal and its population.DECIDING WHETHER OR NOT TO TREAT WILDLIFECertain factors should be weighed before deciding to accept wildlife cases to a practice.", [["Release candidates", "TREATMENT", 0, 18]]], ["The potential costs include those welfare expenses associated with captivity, treatment, release, and failure to reestablish the animal in the wild, as well as the welfare risks to conspecifics and other species through the possible introduction of infection or competition for resources and the upset in natural selection (e.g., treating animals that have increased susceptibility to disease may inadvertently select for less fit animals).", [["infection", "DISEASE", 249, 258], ["treatment", "TREATMENT", 78, 87], ["other species", "PROBLEM", 198, 211], ["infection", "PROBLEM", 249, 258], ["increased susceptibility to disease", "PROBLEM", 357, 392], ["infection", "OBSERVATION", 249, 258]]], ["The potential benefits associated with working with these animals include the emotional pleasure humans derive from helping a \u201clesser\u201d species, the potential to educate the public, and the opportunities this type of medicine provides for monitoring threats to wildlife and human populations.DECIDING WHETHER OR NOT TO TREAT WILDLIFEAssessing the balance or inherent value between welfare costs and benefits is often difficult.", [["humans", "ORGANISM", 97, 103], ["human", "ORGANISM", 273, 278], ["humans", "SPECIES", 97, 103], ["human", "SPECIES", 273, 278], ["humans", "SPECIES", 97, 103], ["human", "SPECIES", 273, 278]]], ["In addition to the unpredictability of responses between individual cases to treatment, there are few robust yardsticks for use in judging, for example, whether any stress or pain associated with captivity and treatment does or does not outweigh the potential welfare benefit to the animal.", [["pain", "DISEASE", 175, 179], ["treatment", "TREATMENT", 77, 86], ["any stress", "PROBLEM", 161, 171], ["pain", "PROBLEM", 175, 179], ["treatment", "TREATMENT", 210, 219], ["few", "OBSERVATION_MODIFIER", 98, 101]]], ["The task is not made easier by the scarcity of information on outcomes of wildlife rehabilitation cases, although more studies are being done.", [["wildlife rehabilitation", "TREATMENT", 74, 97]]], ["Veterinarians have an important role in these ethical assessments and in helping to design protocols that will best manage the welfare of these animals in both captive and wild settings.KNOWING THE REGULATIONSVeterinarians working with wildlife should become familiar with the regulations addressing the handling, transport, and treatment of these animals.", [["these ethical assessments", "TEST", 40, 65], ["treatment", "TREATMENT", 329, 338]]], ["These regulations have been enacted at the federal and state levels to ensure the protection of these animals against individuals that would otherwise exploit them (e.g., meat or fur).", [["meat", "ANATOMY", 171, 175], ["meat", "ORGANISM_SUBDIVISION", 171, 175], ["fur", "GENE_OR_GENE_PRODUCT", 179, 182]]], ["Historically, veterinarians were perceived as \u201cgood Samaritans,\u201d and it was just accepted that veterinarians would or could provide any medical and surgical care that a particular wildlife patient required.", [["patient", "ORGANISM", 189, 196], ["patient", "SPECIES", 189, 196], ["surgical care", "TREATMENT", 148, 161]]], ["Unfortunately, some veterinarians, like many unlicensed wildlife rehabilitators, will attempt to complete the rehabilitation process for their wildlife patients, even though they cannot meet their patient's husbandry, nutritional, or posttreatment rehabilitation needs.", [["patients", "ORGANISM", 152, 160], ["patient", "ORGANISM", 197, 204], ["patients", "SPECIES", 152, 160], ["patient", "SPECIES", 197, 204], ["posttreatment rehabilitation needs", "TREATMENT", 234, 268]]], ["Currently, federal and state governments are committed to maintaining veterinarians as an integral component to the care of injured wildlife and consider veterinarians to be the experts for providing medical and surgical care for these animals.", [["medical and surgical care", "TREATMENT", 200, 225]]], ["Because of this, federal and state agencies require veterinarians (without state and/or federal rehabilitation permits) to transfer these animals to licensed rehabilitators to complete the rehabilitation process.", [["federal rehabilitation", "TREATMENT", 88, 110]]], ["It is expected that a veterinarian will transfer any wildlife patient to a licensed wildlife rehabilitator within 24 hours of stabilizing the patient.", [["patient", "ORGANISM", 62, 69], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 62, 69], ["patient", "SPECIES", 142, 149]]], ["A stabilized patient is one that is no longer in dire need of veterinary medical care.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["veterinary medical care", "TREATMENT", 62, 85], ["stabilized", "OBSERVATION", 2, 12], ["no longer", "UNCERTAINTY", 36, 45]]], ["Patients that require medical treatment that can be administered via an experienced (trained) rehabilitator should be transferred.KNOWING THE REGULATIONSThe federal government is primarily invested in the protection of migratory birds and all other species that are listed federally as species of special concern, threatened, or endangered.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["medical treatment", "TREATMENT", 22, 39]]], ["State agencies also require rehabilitators to maintain permits to cover these same species, as well as mammals and other species (reptiles, amphibians, and fish) considered threatened or endangered at the state level.", [["fish", "ORGANISM_SUBDIVISION", 156, 160], ["rehabilitators", "TREATMENT", 28, 42], ["these same species", "PROBLEM", 72, 90]]], ["In our opinion, the knowledge base regarding wildlife medicine, more so than any other aspect of veterinary medicine, would benefit from more active participation by veterinarians.COMMON SPECIES PRESENTATIONSVeterinarians that publicize an interest in accepting wildlife cases may be surprised by the diversity of cases being presented to their hospitals.", [["wildlife medicine", "TREATMENT", 45, 62], ["veterinary medicine", "TREATMENT", 97, 116]]], ["Such a diverse caseload requires veterinarians to be adaptive to the different needs of these animals, both in their medical and surgical knowledge and in their ability to meet the rehabilitation needs (e.g., diet, environment) of the patient.", [["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242]]], ["It would also be helpful to have a list of other veterinarians on hand that do accept those species, so that those individuals can be referred to an appropriate facility.Staff Preparedness ::: PREPARING FOR WILDLIFE IN VETERINARY HOSPITALSWhen veterinarians accept wildlife cases into their hospitals, it is important that they have buy-in from their staff.", [["hand", "ANATOMY", 66, 70], ["hand", "ORGANISM_SUBDIVISION", 66, 70]]], ["Veterinarians that accept these types of cases on a moderate to large scale would certainly benefit from providing at least some of their staff an opportunity to obtain continuing education in wildlife rehabilitation.", [["wildlife rehabilitation", "TREATMENT", 193, 216]]], ["Membership in these organizations is also highly recommended, as they publish regular bulletins or journals and provide a real resource of potential personal contacts.Staff Preparedness ::: PREPARING FOR WILDLIFE IN VETERINARY HOSPITALSIt is important that veterinarians train their staff to avoid becoming emotionally attached to their wildlife patients.", [["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 346, 354]]], ["The time spent treating these patients should also be limited to necessary contact only.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Animals that become habituated to humans in captivity may be at greater risk of reinjury or death after release if they lose their fear of humans.", [["reinjury", "DISEASE", 80, 88], ["death", "DISEASE", 92, 97], ["Animals", "ORGANISM", 0, 7], ["humans", "ORGANISM", 34, 40], ["humans", "ORGANISM", 139, 145], ["humans", "SPECIES", 34, 40], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 34, 40], ["humans", "SPECIES", 139, 145], ["reinjury", "PROBLEM", 80, 88], ["death", "PROBLEM", 92, 97], ["reinjury", "OBSERVATION", 80, 88]]], ["Imprinting occurs when an animal recognizes a human as the \u201cparent\u201d animal.", [["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51]]], ["Imprinting can potentially lead to dangerous encounters for humans and wildlife, especially with mesopredators, carnivores, and raptors.", [["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["humans", "SPECIES", 60, 66]]], ["For this reason, it is important that only trained staff manage orphaned animals.Staff Preparedness ::: PREPARING FOR WILDLIFE IN VETERINARY HOSPITALSWhen accepting wildlife patients into a hospital, veterinarians must maintain a complete record for each patient.", [["patients", "ORGANISM", 174, 182], ["patient", "ORGANISM", 255, 262], ["patients", "SPECIES", 174, 182], ["patient", "SPECIES", 255, 262]]], ["The following information should be collected for each patient: the species, age (if known or adult/juvenile), gender (if known), date of presentation, location and date found, type of injury, medical treatment provided (if any), diet and husbandry provided (if any), and name and contact information of the person(s) presenting the animal.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["person", "SPECIES", 308, 314], ["injury", "PROBLEM", 185, 191], ["medical treatment", "TREATMENT", 193, 210], ["injury", "OBSERVATION", 185, 191]]], ["Each patient should also be thoroughly evaluated daily and the data recorded using a standard format (SOAP: subjective, objective, assessment, plan).", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["the data", "TEST", 59, 67]]], ["Maintaining this information in a computer database will allow for routine review and analysis of the data.", [["routine review", "TEST", 67, 81], ["analysis of the data", "TEST", 86, 106]]], ["This information can then be used to develop reference ranges for a particular species or area and can be published and presented to a wider audience.Equipment ::: PREPARING FOR WILDLIFE IN VETERINARY HOSPITALSMost of the medical and surgical equipment required for wildlife patients is already available in veterinary hospitals that treat domestic species.", [["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 275, 283], ["domestic species", "PROBLEM", 340, 356]]], ["A list of different equipment we consider important can be found in Box 19-1.BOX 19-1Specialty Equipment Required to Manage Wildlife at a Veterinary HospitalIncubatorsIncubators are thermostat-controlled microhabitats for small mammals, birds, reptiles, and amphibians.", [["different equipment", "TREATMENT", 10, 29], ["a Veterinary HospitalIncubatorsIncubators", "TREATMENT", 136, 177], ["small mammals", "PROBLEM", 222, 235], ["small mammals", "OBSERVATION", 222, 235]]], ["These enclosures should be capable of providing a range of environmental temperatures (80\u00b0\u2013100\u00b0).Oxygen CageBoth orphaned animals that aspirate during feeding and avian species with respiratory disease may benefit from placement in an oxygen cage.Ophthalmic LoupeA loupe can be used to provide better definition to small structures (e.g., blood vessels).Endoscopic EquipmentA 2.7-mm rigid endoscope can be used to perform exploratory coeliotomies in birds.", [["respiratory", "ANATOMY", 182, 193], ["blood vessels", "ANATOMY", 339, 352], ["Oxygen", "CHEMICAL", 97, 103], ["respiratory disease", "DISEASE", 182, 201], ["oxygen", "CHEMICAL", 235, 241], ["Oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 235, 241], ["Oxygen", "SIMPLE_CHEMICAL", 97, 103], ["oxygen", "SIMPLE_CHEMICAL", 235, 241], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 339, 352], ["birds", "ORGANISM", 450, 455], ["Oxygen CageBoth", "TREATMENT", 97, 112], ["avian species", "PROBLEM", 163, 176], ["respiratory disease", "PROBLEM", 182, 201], ["placement", "TREATMENT", 219, 228], ["an oxygen cage", "TREATMENT", 232, 246], ["Ophthalmic LoupeA loupe", "TREATMENT", 247, 270], ["small structures (e.g., blood vessels)", "PROBLEM", 315, 353], ["Endoscopic EquipmentA 2.7-mm rigid endoscope", "TREATMENT", 354, 398], ["exploratory coeliotomies", "TREATMENT", 422, 446], ["respiratory disease", "OBSERVATION", 182, 201], ["oxygen cage", "OBSERVATION", 235, 246], ["small", "OBSERVATION_MODIFIER", 315, 320], ["blood vessels", "ANATOMY", 339, 352]]], ["Sexing birds can also be done using this equipment.RadiosurgeryA radiosurgery unit can be used to control hemostasis.", [["this equipment", "TREATMENT", 36, 50], ["RadiosurgeryA radiosurgery unit", "TREATMENT", 51, 82]]], ["This can be especially important in small patients.Restraint MaterialsLeather gloves are required to restrain raptors and mesopredators.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Restraint MaterialsLeather gloves", "TREATMENT", 51, 84], ["mesopredators", "TREATMENT", 122, 135], ["small", "OBSERVATION_MODIFIER", 36, 41], ["Leather gloves", "OBSERVATION", 70, 84]]], ["Body wraps can be used for birds.", [["Body", "ANATOMY", 0, 4], ["birds", "ORGANISM", 27, 32], ["Body wraps", "TREATMENT", 0, 10]]], ["A rabies pole or pole-syringe can be used to handle mesopredators.Digital ScaleA scale or scales capable of measuring the variety of animals being presented to the facility are needed.", [["pole", "ANATOMY", 9, 13], ["pole-syringe", "TREATMENT", 17, 29], ["Digital ScaleA scale", "TEST", 66, 86], ["pole", "ANATOMY_MODIFIER", 17, 21]]], ["We suggest a scale capable of measuring 1-g increments.PASSERINES ::: Avian ::: HOUSINGThe most difficult aspects of providing housing for small birds is preventing escape and providing security.", [["Avian", "ORGANISM", 70, 75], ["Avian", "SPECIES", 70, 75], ["most difficult", "OBSERVATION_MODIFIER", 91, 105]]], ["Mesh or metal used to cover a cage must have a small diameter to prevent escape.", [["Mesh or metal", "TREATMENT", 0, 13], ["a cage", "TREATMENT", 28, 34], ["a small diameter", "TREATMENT", 45, 61], ["small diameter", "OBSERVATION_MODIFIER", 47, 61], ["escape", "OBSERVATION", 73, 79]]], ["The setup of feeding and water stations will vary greatly depending on the species.PIGEONS AND DOVES ::: Avian ::: HOUSINGFor short-term housing, any container, such as a dog or cat kennel, is sufficient.", [["Avian", "ORGANISM", 105, 110], ["dog", "ORGANISM", 171, 174], ["cat", "ORGANISM", 178, 181], ["Avian", "SPECIES", 105, 110], ["dog", "SPECIES", 171, 174], ["The setup of feeding and water stations", "TREATMENT", 0, 39]]], ["Because pigeons and doves are reservoirs for various avian pathogens, it is always best to isolate them from other species to limit the potential for disease transmission.", [["pigeons", "ORGANISM", 8, 15], ["doves", "ORGANISM", 20, 25], ["pigeons", "SPECIES", 8, 15], ["reservoirs", "TREATMENT", 30, 40], ["various avian pathogens", "PROBLEM", 45, 68], ["disease transmission", "PROBLEM", 150, 170]]], ["For longer periods in captivity, these birds may be best housed in an aviary.GAMEBIRDS ::: Avian ::: HOUSINGPrinciples of short-term and long-term housing are the same for these birds as was described for pigeons and doves, although the size of the cage may need to be increased for larger specimens.", [["specimens", "ANATOMY", 290, 299], ["birds", "ORGANISM", 39, 44], ["birds", "ORGANISM", 178, 183], ["pigeons", "ORGANISM", 205, 212], ["long-term housing", "TREATMENT", 137, 154], ["larger specimens", "PROBLEM", 283, 299], ["size", "OBSERVATION_MODIFIER", 237, 241]]], ["No perching materials need to be provided for short-term housing but should be provided if the bird is kept for a longer period of time to allow roosting at night.1 Substrate should be easily disinfected, to prevent foot disease (e.g., Astroturf is a good substrate).WATERFOWL ::: Avian ::: HOUSINGFor short-term waterfowl care, the principles are the same as with those previously mentioned, with the exception of providing water in a container large enough for the bird to stand in.", [["foot", "ANATOMY", 216, 220], ["bird", "ORGANISM", 95, 99], ["foot", "ORGANISM_SUBDIVISION", 216, 220], ["Avian", "SPECIES", 281, 286], ["perching materials", "PROBLEM", 3, 21], ["short-term housing", "TREATMENT", 46, 64], ["foot disease", "PROBLEM", 216, 228], ["short-term waterfowl care", "TREATMENT", 302, 327], ["materials", "OBSERVATION", 12, 21], ["foot", "ANATOMY", 216, 220], ["disease", "OBSERVATION", 221, 228]]], ["For long-term care, adequate housing will require the addition of a large pool or pond, which may not be feasible in a general practice setting.WADERS ::: Avian ::: HOUSINGShort-term housing for waders should be tall enough to enable the animal to stand naturally.", [["long-term care", "TREATMENT", 4, 18]]], ["The cage should also be kept dark and quiet with moist, nonslip flooring (e.g., moist sand or newspaper).2 Water should be provided in a shallow container.", [["Water", "TREATMENT", 107, 112], ["a shallow container", "TREATMENT", 135, 154], ["cage", "ANATOMY", 4, 8]]], ["For long-term housing, a shallow pond or pool and suitable natural cover should be provided.", [["long-term housing", "TREATMENT", 4, 21], ["a shallow pond", "PROBLEM", 23, 37], ["suitable natural cover", "TREATMENT", 50, 72]]], ["As with waterfowl, this may be difficult for general practitioners to provide.SEABIRDS ::: Avian ::: HOUSINGSeabirds have special requirements in captivity that may make rehabilitation difficult, especially for beginners.", [["Avian", "SPECIES", 91, 96], ["general practitioners", "TREATMENT", 45, 66]]], ["Some species of seabird are gregarious and do better when housed in groups.", [["Some species of seabird", "PROBLEM", 0, 23], ["gregarious", "PROBLEM", 28, 38], ["species", "OBSERVATION_MODIFIER", 5, 12], ["seabird", "OBSERVATION_MODIFIER", 16, 23], ["gregarious", "OBSERVATION_MODIFIER", 28, 38]]], ["Seabirds are sensitive to sudden noises and should be kept in a quiet environment.", [["sudden noises", "PROBLEM", 26, 39]]], ["A soft substrate that is easy to clean, such as Astroturf, rubber mats, or deep layers of wood shavings, should be used.", [["A soft substrate", "PROBLEM", 0, 16], ["Astroturf, rubber mats", "PROBLEM", 48, 70], ["wood shavings", "TREATMENT", 90, 103], ["soft substrate", "OBSERVATION_MODIFIER", 2, 16], ["clean", "OBSERVATION", 33, 38], ["rubber mats", "OBSERVATION", 59, 70], ["deep layers", "OBSERVATION_MODIFIER", 75, 86], ["wood shavings", "OBSERVATION", 90, 103]]], ["Animals left on firm substrates (metal flooring or concrete) can develop pododermatitis.", [["pododermatitis", "DISEASE", 73, 87], ["Animals", "ORGANISM", 0, 7], ["firm substrates (metal flooring", "TREATMENT", 16, 47], ["pododermatitis", "PROBLEM", 73, 87], ["left", "ANATOMY_MODIFIER", 8, 12], ["firm", "OBSERVATION", 16, 20]]], ["Straw or hay bedding should never be used, as they can be a source of fungal spores.", [["spores", "ANATOMY", 77, 83], ["Straw", "TREATMENT", 0, 5], ["fungal spores", "PROBLEM", 70, 83], ["fungal spores", "OBSERVATION", 70, 83]]], ["It is important to provide ample ventilation to minimize the risk of respiratory disease.", [["respiratory", "ANATOMY", 69, 80], ["respiratory disease", "DISEASE", 69, 88], ["ample ventilation", "TREATMENT", 27, 44], ["respiratory disease", "PROBLEM", 69, 88], ["respiratory disease", "OBSERVATION", 69, 88]]], ["For stable patients in medium- to long-term captivity, a water source (e.g., pool or pond) must be provided.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["stable", "OBSERVATION_MODIFIER", 4, 10]]], ["This water source should be cleaned regularly to prevent autoinfection.RAPTORS ::: Avian ::: HOUSINGAll of the general principles for housing apply to raptors.", [["autoinfection", "DISEASE", 57, 70], ["This water source", "TREATMENT", 0, 17], ["autoinfection", "PROBLEM", 57, 70]]], ["In addition, it is extremely important to provide an environment that will prevent any self-induced trauma.", [["trauma", "DISEASE", 100, 106], ["any self-induced trauma", "PROBLEM", 83, 106]]], ["Raptors are prone to damaging their feathers, wings, talons, and cere in captivity.", [["feathers", "ANATOMY", 36, 44], ["feathers", "ORGANISM_SUBDIVISION", 36, 44], ["wings", "ORGANISM_SUBDIVISION", 46, 51]]], ["Injuries to any of these body parts can delay the rehabilitation process and should be avoided at all costs.", [["body", "ANATOMY", 25, 29], ["Injuries", "DISEASE", 0, 8], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["Injuries", "PROBLEM", 0, 8]]], ["The best cage materials to use for housing raptors are those that do not bend or damage the feathers.", [["feathers", "ORGANISM_SUBDIVISION", 92, 100], ["The best cage materials", "TREATMENT", 0, 23], ["housing raptors", "TREATMENT", 35, 50]]], ["Because most veterinary hospitals maintain chain-link fence kennels or stainless steel cages, housing for raptors may be limited.", [["stainless steel cages", "TREATMENT", 71, 92]]], ["Covering the cage with a soft mesh can help diminish the amount of feather damage done to hospitalized raptors.", [["feather", "ORGANISM_SUBDIVISION", 67, 74], ["a soft mesh", "TREATMENT", 23, 34], ["feather damage", "PROBLEM", 67, 81], ["cage", "ANATOMY", 13, 17], ["soft mesh", "OBSERVATION", 25, 34]]], ["Tailguards made out of old radiograph film can be used to reduce tail feather damage.", [["tail feather", "ANATOMY", 65, 77], ["feather damage", "DISEASE", 70, 84], ["tail feather", "ORGANISM_SUBDIVISION", 65, 77], ["old radiograph film", "TEST", 23, 42], ["tail feather damage", "PROBLEM", 65, 84]]], ["Perches can also be used to help limit the amount of damage done to the tail feathers.", [["tail feathers", "ANATOMY", 72, 85], ["Perches", "TREATMENT", 0, 7], ["tail", "ANATOMY", 72, 76]]], ["The perch should be positioned so that the tail feathers do not touch the base of the cage and the flight feathers have minimal contact with the sides of the cage.", [["tail feathers", "ANATOMY", 43, 56], ["perch", "ORGANISM", 4, 9], ["feathers", "ORGANISM_SUBDIVISION", 106, 114], ["the tail feathers", "TEST", 39, 56], ["perch", "OBSERVATION", 4, 9], ["base", "ANATOMY_MODIFIER", 74, 78], ["cage", "ANATOMY", 86, 90], ["minimal", "OBSERVATION_MODIFIER", 120, 127], ["contact", "OBSERVATION", 128, 135], ["cage", "ANATOMY", 158, 162]]], ["For extended hospitalization, raptors should be housed in an appropriately sized aviary.", [["raptors", "TREATMENT", 30, 37]]], ["Whereas groups of some species can be housed together, mixing raptors is not recommended.", [["some species", "PROBLEM", 18, 30]]], ["An easily disinfected substrate, such as Astroturf or gravel, can be used for the aviary.", [["An easily disinfected substrate", "PROBLEM", 0, 31], ["disinfected", "OBSERVATION", 10, 21]]], ["Multiple perches should be provided.", [["Multiple perches", "TREATMENT", 0, 16], ["perches", "OBSERVATION", 9, 16]]], ["If the bird is not a solid flier, the perches should be maintained close to the ground.", [["solid flier", "CANCER", 21, 32], ["the perches", "TREATMENT", 34, 45]]], ["Covering the perches with a rough surface (e.g., Astroturf) will minimize the likelihood of a bird developing pododermatitis.", [["surface", "ANATOMY", 34, 41], ["pododermatitis", "DISEASE", 110, 124], ["pododermatitis", "CANCER", 110, 124], ["a bird developing pododermatitis", "PROBLEM", 92, 124], ["perches", "OBSERVATION_MODIFIER", 13, 20], ["bird", "OBSERVATION_MODIFIER", 94, 98], ["developing", "OBSERVATION_MODIFIER", 99, 109], ["pododermatitis", "OBSERVATION", 110, 124]]], ["Multiple diameter and textured perches should be placed in the cage; however, the diameter should not be so small that the talons puncture the plantar surface of the foot.3 The perches should be cleaned regularly to minimize the likelihood of fecal contamination.", [["plantar surface", "ANATOMY", 143, 158], ["foot", "ANATOMY", 166, 170], ["fecal", "ANATOMY", 243, 248], ["fecal contamination", "DISEASE", 243, 262], ["plantar surface", "MULTI-TISSUE_STRUCTURE", 143, 158], ["foot", "ORGANISM_SUBDIVISION", 166, 170], ["fecal", "ORGANISM_SUBSTANCE", 243, 248], ["Multiple diameter and textured perches", "TREATMENT", 0, 38], ["The perches", "TREATMENT", 173, 184], ["fecal contamination", "PROBLEM", 243, 262], ["diameter", "OBSERVATION_MODIFIER", 9, 17], ["textured", "OBSERVATION_MODIFIER", 22, 30], ["perches", "OBSERVATION", 31, 38], ["cage", "ANATOMY", 63, 67], ["diameter", "OBSERVATION_MODIFIER", 82, 90], ["should not be", "UNCERTAINTY", 91, 104], ["small", "OBSERVATION_MODIFIER", 108, 113], ["talons", "OBSERVATION_MODIFIER", 123, 129], ["puncture", "OBSERVATION", 130, 138], ["plantar", "ANATOMY_MODIFIER", 143, 150], ["surface", "ANATOMY_MODIFIER", 151, 158], ["foot", "ANATOMY", 166, 170], ["fecal", "ANATOMY", 243, 248], ["contamination", "OBSERVATION", 249, 262]]], ["As with other species, hay or straw should not be used because of the potential for exposure to Aspergillus spp. spores.", [["spores", "ANATOMY", 113, 119], ["Aspergillus spp", "DISEASE", 96, 111], ["Aspergillus spp", "ORGANISM", 96, 111], ["Aspergillus spp", "SPECIES", 96, 111], ["straw", "TREATMENT", 30, 35], ["Aspergillus spp", "PROBLEM", 96, 111], ["spores", "PROBLEM", 113, 119], ["Aspergillus spp", "OBSERVATION", 96, 111]]], ["For adult rodents, wood, some plastics, and aluminum caging materials are not recommended.", [["wood", "ANATOMY", 19, 23], ["aluminum", "CHEMICAL", 44, 52], ["aluminum", "CHEMICAL", 44, 52], ["wood", "ORGANISM_SUBDIVISION", 19, 23], ["some plastics", "TREATMENT", 25, 38], ["aluminum caging materials", "TREATMENT", 44, 69]]], ["Galvanized or stainless steel are more appropriate, as they can handle chewing and are easier to disinfect.", [["stainless steel", "OBSERVATION_MODIFIER", 14, 29]]], ["For short-term housing, adult rodents can be housed in stainless steel hospital kennels.", [["rodents", "ORGANISM", 30, 37]]], ["Within the enclosure, a nest box should be provided, which can be made from wood or cardboard.", [["wood", "ANATOMY", 76, 80], ["wood", "ORGANISM_SUBDIVISION", 76, 80], ["a nest box", "TREATMENT", 22, 32], ["enclosure", "OBSERVATION_MODIFIER", 11, 20]]], ["Tree limbs and other natural substances are also recommended and will provide the animals a surface to chew on.", [["Tree limbs", "ANATOMY", 0, 10], ["surface", "ANATOMY", 92, 99], ["limbs", "ORGANISM_SUBDIVISION", 5, 10], ["limbs", "ANATOMY", 5, 10]]], ["Orphaned animals or nonchewing species (e.g., bats) can be housed in clip-top plastic containers.", [["Orphaned animals", "PROBLEM", 0, 16], ["nonchewing species", "PROBLEM", 20, 38]]], ["It is important to drill a sufficient number of holes in the container to provide ventilation.", [["ventilation", "TREATMENT", 82, 93]]], ["Newspaper or towels can be used as a substrate for these cages.", [["towels", "TREATMENT", 13, 19], ["a substrate for these cages", "TREATMENT", 35, 62]]], ["For long-term rehabilitation, larger portable cages are recommended.", [["long-term rehabilitation", "TREATMENT", 4, 28], ["larger portable cages", "TREATMENT", 30, 51]]], ["Galvanized wire is probably the least expensive material for constructing these cages.", [["Galvanized wire", "TREATMENT", 0, 15], ["probably the", "UNCERTAINTY", 19, 31], ["least", "OBSERVATION_MODIFIER", 32, 37], ["expensive", "OBSERVATION_MODIFIER", 38, 47], ["material", "OBSERVATION", 48, 56]]], ["It is best to secure these cages to protect against predation.LAGOMORPHS ::: Mammals ::: HOUSINGLagomorphs are extremely sensitive and prone to stress, so maintaining a quiet, predator-free environment is essential.", [["these cages", "TREATMENT", 21, 32], ["HOUSINGLagomorphs", "TREATMENT", 89, 106], ["extremely sensitive", "PROBLEM", 111, 130]]], ["Care must be taken to make the enclosure escape-proof.", [["Care", "TREATMENT", 0, 4]]], ["Covering the cage will increase the feeling of security for the animal.", [["cage", "ANATOMY", 13, 17]]], ["A hay bedding or false floor can be used to simulate a burrow.", [["A hay bedding", "TREATMENT", 0, 13]]], ["The cage types described for rodents can also be used for lagomorphs.MESOPREDATORS ::: Mammals ::: HOUSINGMesopredators can be housed in standard domestic animals stainless steel cages; however, this is not without its limitations.", [["lagomorphs", "PROBLEM", 58, 68], ["HOUSINGMesopredators", "TREATMENT", 99, 119], ["standard domestic animals stainless steel cages", "TREATMENT", 137, 184], ["cage types", "OBSERVATION_MODIFIER", 4, 14], ["not without", "UNCERTAINTY", 203, 214]]], ["For animals that are difficult to manage, anesthesia is highly recommended.", [["anesthesia", "TREATMENT", 42, 52]]], ["A pole-syringe capable of being inserted between the cage bars can be used to safely deliver an appropriate anesthetic.", [["A pole-syringe", "TREATMENT", 0, 14], ["the cage bars", "TREATMENT", 49, 62], ["an appropriate anesthetic", "TREATMENT", 93, 118], ["pole", "OBSERVATION_MODIFIER", 2, 6]]], ["Shifting these animals to outdoor cages is highly recommended.", [["outdoor cages", "TREATMENT", 26, 39]]], ["Chain-link cages can be used to house these animals, but they must be constructed to be escape-proof.", [["Chain-link cages", "TREATMENT", 0, 16]]], ["Whether inside or outside, the cage should be provided with a shelter box and an area for a latrine.DEER ::: Mammals ::: HOUSINGFor short-term hospitalization, fawns can be kept in an isolation area or any area that is away from the noise of humans and other animals.", [["humans", "ORGANISM", 242, 248], ["humans", "SPECIES", 242, 248], ["humans", "SPECIES", 242, 248], ["a shelter box", "TREATMENT", 60, 73], ["a latrine", "TREATMENT", 90, 99]]], ["Large deer can be kept for short periods of time in a stable or outhouse with a deep layer of straw.", [["deer", "ORGANISM", 6, 10], ["Large deer", "SPECIES", 0, 10], ["a deep layer of straw", "TREATMENT", 78, 99], ["deer", "OBSERVATION", 6, 10], ["stable", "OBSERVATION_MODIFIER", 54, 60]]], ["As for the size of the enclosure, a maximum of 1.5 \u00d7 1.8 m and 2 \u00d7 3 m for fawns and adult deer, respectively, is recommended.4 The enclosure should not have windows, and ventilation should be provided through slats at the top of the walls or ceiling.", [["walls", "ANATOMY", 234, 239], ["ventilation", "TREATMENT", 171, 182], ["size", "OBSERVATION_MODIFIER", 11, 15], ["enclosure", "OBSERVATION_MODIFIER", 23, 32], ["walls", "ANATOMY_MODIFIER", 234, 239]]], ["A door that is divided into a stable-door arrangement, with the top portion only 0.5 m high, is preferred.", [["stable", "OBSERVATION_MODIFIER", 30, 36]]], ["It is best if the door can be swung inward, so that it can be used as a restraint device for the deer.", [["a restraint device", "TREATMENT", 70, 88]]], ["The top portion of the door should be opened for access only from above.", [["top", "OBSERVATION_MODIFIER", 4, 7]]], ["Deer who will be kept in captivity for longer periods of time should be transferred to an experienced rehabilitator who has appropriate pens.Reptiles and Amphibians ::: HOUSINGThe housing needs of reptiles and amphibians will vary greatly depending on species.", [["Deer", "ORGANISM", 0, 4]]], ["Some examples of reptile groupings by environment include those that are aquatic, semiaquatic, arboreal, or terrestrial.", [["aquatic", "OBSERVATION_MODIFIER", 73, 80]]], ["Of the terrestrial reptiles, subgroups include those that are fossorial (burrowing), thigmotactic (prefer to wedge themselves into rocky crevices when not basking), and those that live on the surface of the soil.", [["surface", "ANATOMY", 192, 199], ["terrestrial reptiles", "OBSERVATION", 7, 27]]], ["Reptiles can also be grouped according to the time of day that they are active: diurnal, nocturnal, and crepuscular (active during dusk or dawn).", [["active", "OBSERVATION", 72, 78]]], ["Species habits must be known before appropriate housing can be provided.", [["Species habits", "PROBLEM", 0, 14]]], ["For example, terrestrial species kept in moist cages may develop integumentary disease, whereas aquatic species housed in dry habitats will become dehydrated.", [["integumentary disease", "DISEASE", 65, 86], ["terrestrial species", "PROBLEM", 13, 32], ["moist cages", "TREATMENT", 41, 52], ["integumentary disease", "PROBLEM", 65, 86], ["aquatic species", "PROBLEM", 96, 111], ["dehydrated", "PROBLEM", 147, 157], ["terrestrial species", "OBSERVATION", 13, 32], ["integumentary", "ANATOMY", 65, 78], ["disease", "OBSERVATION", 79, 86]]], ["Arboreal reptiles must be provided with branches, reptiles adapted to saline or brackish water should be furnished with water of the appropriate salinity, fossorial species must be provided substrate to burrow in, and secretive reptiles must be provided hiding places.", [["saline", "SIMPLE_CHEMICAL", 70, 76], ["Arboreal reptiles", "TREATMENT", 0, 17], ["saline", "TREATMENT", 70, 76], ["brackish water", "TREATMENT", 80, 94], ["fossorial species", "PROBLEM", 155, 172]]], ["Water should be provided in the form in which the animal is used to imbibing it.", [["Water", "TREATMENT", 0, 5]]], ["Many lizards drink from rain or dewdrops on foliage and will not drink from dishes.", [["foliage", "ORGANISM_SUBDIVISION", 44, 51]]], ["Tortoises should be provided with a shallow bowl of water.", [["Tortoises", "TREATMENT", 0, 9], ["a shallow bowl of water", "TREATMENT", 34, 57]]], ["For additional information regarding the specific husbandry needs of reptiles, see the appropriate chapters in this text.QUARANTINEQuarantine is an important consideration when practicing wildlife medicine in a domestic species veterinary hospital.", [["QUARANTINEQuarantine", "CHEMICAL", 121, 141], ["QUARANTINEQuarantine", "CHEMICAL", 121, 141], ["QUARANTINEQuarantine", "TREATMENT", 121, 141]]], ["Because wildlife can harbor various bacterial, fungal, viral, and parasitic diseases that can be transmitted to domestic pets, it is important to minimize and restrict both direct and indirect contact between these animals.", [["fungal, viral, and parasitic diseases", "DISEASE", 47, 84], ["various bacterial, fungal, viral, and parasitic diseases", "PROBLEM", 28, 84], ["fungal", "OBSERVATION", 47, 53], ["parasitic diseases", "OBSERVATION", 66, 84]]], ["A foot bath with a disinfectant (e.g., sodium hypochlorite) should be placed outside the doorway and used after exiting the room to minimize the likelihood of tracking infectious diseases throughout the hospital.", [["sodium hypochlorite", "CHEMICAL", 39, 58], ["infectious diseases", "DISEASE", 168, 187], ["sodium hypochlorite", "CHEMICAL", 39, 58], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 39, 58], ["A foot bath", "TREATMENT", 0, 11], ["a disinfectant (e.g., sodium hypochlorite", "TREATMENT", 17, 58], ["tracking infectious diseases", "PROBLEM", 159, 187], ["foot", "ANATOMY", 2, 6], ["infectious", "OBSERVATION", 168, 178]]], ["The disinfectant should be changed daily, or as often as needed, to minimize the amount of organic debris in the solution.", [["The disinfectant", "TREATMENT", 0, 16], ["organic debris in the solution", "PROBLEM", 91, 121], ["disinfectant", "OBSERVATION", 4, 16], ["organic debris", "OBSERVATION", 91, 105]]], ["Organic debris renders many disinfectants useless.", [["Organic debris", "PROBLEM", 0, 14], ["debris", "OBSERVATION", 8, 14], ["many", "OBSERVATION_MODIFIER", 23, 27], ["disinfectants", "OBSERVATION", 28, 41]]], ["Laboratory coats, or preferably jumpsuits that totally cover clothing, should be placed in the wildlife ward and worn when working with the animals.", [["clothing", "TREATMENT", 61, 69]]], ["These clothing materials should be taken out of the room only for washing.", [["These clothing materials", "TREATMENT", 0, 24], ["washing", "TREATMENT", 66, 73]]], ["Any materials being removed from the ward should be placed in a garbage bag and carried through the hospital in these bags to minimize the likelihood of disseminating disease through the hospital.", [["Any materials", "PROBLEM", 0, 13], ["a garbage bag", "TREATMENT", 62, 75], ["these bags", "TREATMENT", 112, 122], ["disseminating disease", "PROBLEM", 153, 174]]], ["A hand-washing station should be placed within the room.", [["hand", "ANATOMY", 2, 6], ["A hand-washing station", "TREATMENT", 0, 22]]], ["Signs should be posted on the wildlife ward door to alert staff and clients about the presence of wildlife and the need to maintain a strict quarantine protocol.ZOONOSESZoonotic diseases should always be a concern for those individuals working with wildlife, as many of these animals can harbor a variety of bacterial, viral, fungal and parasitic zoonotic agents (Box 19-2).", [["ZOONOSESZoonotic diseases", "DISEASE", 161, 186], ["animals", "ORGANISM", 276, 283], ["a strict quarantine protocol", "TREATMENT", 132, 160], ["ZOONOSESZoonotic diseases", "PROBLEM", 161, 186], ["bacterial, viral, fungal", "PROBLEM", 308, 332], ["parasitic zoonotic agents", "TREATMENT", 337, 362]]], ["Because of this, children and individuals with compromised immune systems should not be allowed to work with wildlife.", [["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["compromised immune systems", "PROBLEM", 47, 73]]], ["Staff should not be allowed to eat, drink, or smoke near any wildlife patients, and food and drink items should not be allowed near any of the places where diagnostic samples are held.", [["samples", "ANATOMY", 167, 174], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["diagnostic samples", "TEST", 156, 174]]], ["We strongly recommend wearing examination gloves when handling wildlife.", [["examination", "TEST", 30, 41]]], ["Wearing gloves will help minimize the likelihood of introducing pathogens into cuts or abrasions on practitioners\u2019 and staff's hands.", [["abrasions", "DISEASE", 87, 96], ["hands", "ORGANISM_SUBDIVISION", 127, 132], ["gloves", "TREATMENT", 8, 14], ["introducing pathogens into cuts", "PROBLEM", 52, 83], ["abrasions", "PROBLEM", 87, 96], ["hands", "ANATOMY", 127, 132]]], ["For those cases where an aerosolized pathogen is suspected, a protective mask and eyeglasses should be worn.", [["an aerosolized pathogen", "PROBLEM", 22, 45], ["a protective mask", "TREATMENT", 60, 77], ["eyeglasses", "TREATMENT", 82, 92], ["aerosolized", "OBSERVATION_MODIFIER", 25, 36], ["pathogen", "OBSERVATION", 37, 45]]], ["Individuals who develop an illness after working with wildlife should be examined by a health care specialist immediately.", [["illness", "OBSERVATION", 27, 34]]], ["Zoonoses and Communicable Diseases Common to Man and Animals (ed 3), coedited by P. N. Acha and B. Szyfres and published by the Pan American Health Organization (Washington DC), is an excellent reference for obtaining additional information on zoonotic diseases associated with wildlife.BOX 19-2A partial List of Common Zoonotic Diseases Associated with WildlifeBacterial", [["Zoonoses", "DISEASE", 0, 8], ["Communicable Diseases", "DISEASE", 13, 34], ["zoonotic diseases", "DISEASE", 244, 261], ["Zoonotic Diseases", "DISEASE", 320, 337], ["Man", "SPECIES", 45, 48], ["zoonotic diseases", "PROBLEM", 244, 261], ["Common Zoonotic Diseases", "PROBLEM", 313, 337]]]], "PMC7334749": [], "PMC7188438": [["Since December 2019, countries have quickly shifted from spectators to victims of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak.", [["acute respiratory syndrome coronavirus", "DISEASE", 93, 131], ["SARS-CoV-2", "ORGANISM", 135, 145], ["severe acute respiratory syndrome coronavirus", "SPECIES", 86, 131], ["SARS-CoV-2", "SPECIES", 135, 145], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 82, 131], ["SARS", "TEST", 135, 139], ["outbreak", "PROBLEM", 147, 155], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119]]], ["The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed healthcare systems and crippled economies around the world, including the United States.", [["coronavirus disease", "DISEASE", 4, 23], ["COVID-19", "CHEMICAL", 30, 38], ["coronavirus", "ORGANISM", 4, 15], ["COVID-19", "ORGANISM", 30, 38], ["coronavirus disease 2019 (COVID-19", "SPECIES", 4, 38], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["coronavirus disease", "OBSERVATION", 4, 23]]], ["Countless hours and sleepless nights from academics around the world have resulted in a united front to mitigate morbidity and mortality from COVID-19.", [["COVID", "TEST", 142, 147]]], ["Despite these concerted efforts, another pandemic, in its own right, threatens to destroy the meticulously built scientific juggernaut surrounding COVID-19.", [["juggernaut", "CANCER", 124, 134], ["COVID-19", "CELL", 147, 155], ["COVID-19", "DNA", 147, 155], ["another pandemic", "PROBLEM", 33, 49], ["right", "ANATOMY_MODIFIER", 62, 67]]], ["This commentary uses a recent study of hydroxychloroquine to demonstrate the dire need for randomized clinical trials, but more importantly, to explore the potential consequences of misinformation, how fear fuels its impact, and offer guidance to maintain scientific integrity without relinquishing hope.", [["hydroxychloroquine", "CHEMICAL", 39, 57], ["hydroxychloroquine", "CHEMICAL", 39, 57], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 39, 57], ["a recent study", "TEST", 21, 35], ["hydroxychloroquine", "TREATMENT", 39, 57], ["randomized clinical trials", "TREATMENT", 91, 117]]]], "2394f46086f9125174094bc1ca712cdbd404ce16": [["IntroductionTaura syndrome virus (TSV) and yellow head virus (YHV) are the two most important RNA viruses of penaeid shrimp (Penaeus sp.)", [["IntroductionTaura syndrome", "DISEASE", 0, 26], ["IntroductionTaura syndrome virus", "ORGANISM", 0, 32], ["yellow head virus", "ORGANISM", 43, 60], ["penaeid shrimp", "ORGANISM", 109, 123], ["Penaeus sp", "ORGANISM", 125, 135], ["yellow head virus", "SPECIES", 43, 60], ["shrimp", "SPECIES", 117, 123], ["Penaeus sp", "SPECIES", 125, 135], ["IntroductionTaura syndrome virus", "SPECIES", 0, 32], ["TSV", "SPECIES", 34, 37], ["yellow head virus", "SPECIES", 43, 60], ["YHV", "SPECIES", 62, 65], ["IntroductionTaura syndrome virus (TSV", "PROBLEM", 0, 37], ["yellow head virus", "PROBLEM", 43, 60], ["penaeid shrimp", "TREATMENT", 109, 123], ["RNA viruses", "OBSERVATION", 94, 105], ["penaeid shrimp", "OBSERVATION", 109, 123]]], ["In the Western Hemisphere, TSV has caused serious economic losses, whereas, YHV is viewed as one of the most significant viral pathogens in the Eastern Hemisphere (Brock, 1997; Flegel, 1997) .", [["TSV", "CHEMICAL", 27, 30], ["TSV", "ORGANISM", 27, 30], ["YHV", "SPECIES", 76, 79], ["serious economic losses", "PROBLEM", 42, 65], ["serious", "OBSERVATION_MODIFIER", 42, 49], ["economic losses", "OBSERVATION", 50, 65], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["pathogens", "OBSERVATION", 127, 136], ["Eastern Hemisphere", "ANATOMY", 144, 162]]], ["The cumulative losses due to TSV in the Americas from 1992 to 1996 were estimated to be US$1.2-2.0 billion (Lightner et al., 1996) .", [["The cumulative losses", "PROBLEM", 0, 21], ["TSV", "PROBLEM", 29, 32], ["cumulative losses", "OBSERVATION", 4, 21]]], ["YHV has affected significantly shrimp farming in South East Asian countries including Thailand, China, Malaysia, Indonesia and India (Lightner et al., 1996) .IntroductionTaura syndrome disease, caused by the TSV, was first described in samples collected from shrimp farms located near the mouth of the Taura river in Ecuador in 1992 (Jimenez, 1992; Hasson et al., 1995) .", [["samples", "ANATOMY", 236, 243], ["mouth", "ANATOMY", 289, 294], ["YHV", "CHEMICAL", 0, 3], ["Taura syndrome disease", "DISEASE", 170, 192], ["Taura", "GENE_OR_GENE_PRODUCT", 170, 175], ["samples", "CANCER", 236, 243], ["mouth", "ORGANISM_SUBDIVISION", 289, 294], ["YHV", "SPECIES", 0, 3], ["IntroductionTaura syndrome disease", "PROBLEM", 158, 192], ["the TSV", "PROBLEM", 204, 211], ["significantly", "OBSERVATION_MODIFIER", 17, 30], ["shrimp farming", "OBSERVATION", 31, 45], ["Taura syndrome", "OBSERVATION", 170, 184], ["mouth", "ANATOMY", 289, 294]]], ["TSV virions are non-enveloped, icosahedral, 31-32 nm in diameter and contain a single stranded positive sense RNA genome of 10 kb capable of encoding three major (55, 40 and 24 kDa) and one minor (58 kDa) capsid proteins Bonami et al., 1997) .", [["TSV virions", "ORGANISM", 0, 11], ["major (55, 40 and 24 kDa", "PROTEIN", 156, 180], ["58 kDa) capsid proteins", "PROTEIN", 197, 220], ["TSV virions", "PROBLEM", 0, 11], ["icosahedral", "TEST", 31, 42], ["a single stranded positive sense RNA genome", "PROBLEM", 77, 120], ["non-enveloped", "OBSERVATION_MODIFIER", 16, 29], ["icosahedral", "OBSERVATION_MODIFIER", 31, 42], ["32 nm", "OBSERVATION_MODIFIER", 47, 52], ["single", "OBSERVATION_MODIFIER", 79, 85], ["stranded", "OBSERVATION_MODIFIER", 86, 94], ["positive", "OBSERVATION_MODIFIER", 95, 103], ["sense RNA genome", "OBSERVATION", 104, 120]]], ["We have cloned and sequenced the 3%-end of TSV genome (Robles-Sikisaka et al., 2001) .", [["3%-end", "DNA", 33, 39], ["TSV genome", "DNA", 43, 53], ["TSV genome", "OBSERVATION", 43, 53]]], ["Sequence analysis showed that, unlike mammalian picornaviruses, TSV capsid protein genes are located at the 3%-end of the genome and the TSV genome organization is similar to insect picornaviruses (Robles-Sikisaka et al., 2001) .IntroductionYHV was first reported in 1990 with the occurrence of mass mortalities in farm reared black tiger shrimp (P. monodon) in Thailand (Chantanachookin et al., 1993) .", [["mammalian picornaviruses", "ORGANISM", 38, 62], ["TSV capsid", "ORGANISM", 64, 74], ["genome", "CELLULAR_COMPONENT", 122, 128], ["insect picornaviruses", "ORGANISM", 175, 196], ["tiger shrimp", "ORGANISM", 333, 345], ["P. monodon", "ORGANISM", 347, 357], ["TSV capsid protein genes", "DNA", 64, 88], ["3%-end", "DNA", 108, 114], ["TSV genome", "DNA", 137, 147], ["black tiger shrimp", "SPECIES", 327, 345], ["P. monodon", "SPECIES", 347, 357], ["black tiger shrimp", "SPECIES", 327, 345], ["P. monodon", "SPECIES", 347, 357], ["Sequence analysis", "TEST", 0, 17], ["unlike mammalian picornaviruses", "PROBLEM", 31, 62], ["TSV capsid protein genes", "TEST", 64, 88], ["insect picornaviruses", "PROBLEM", 175, 196], ["mass mortalities", "PROBLEM", 295, 311], ["mammalian picornaviruses", "OBSERVATION", 38, 62], ["protein genes", "OBSERVATION", 75, 88], ["genome", "ANATOMY", 122, 128], ["TSV genome", "OBSERVATION", 137, 147], ["mass", "OBSERVATION", 295, 299]]], ["YHV virions have an enveloped bacilliform shape of 150-170 \u00d7 40 -50 nm in size (Wongteerasupaya et al., 1995) .", [["bacilliform", "ANATOMY", 30, 41], ["YHV virions", "ORGANISM", 0, 11], ["YHV", "SPECIES", 0, 3], ["enveloped", "OBSERVATION_MODIFIER", 20, 29], ["bacilliform", "OBSERVATION_MODIFIER", 30, 41], ["shape", "OBSERVATION_MODIFIER", 42, 47], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["The viral genome contains a single stranded, positive sense RNA and encodes four major structural proteins of 170, 135, 67 and 22 kDa.", [["viral genome", "DNA", 4, 16], ["single stranded, positive sense RNA", "RNA", 28, 63], ["major structural proteins", "PROTEIN", 81, 106], ["170, 135, 67 and 22 kDa", "PROTEIN", 110, 133], ["a single stranded, positive sense RNA", "PROBLEM", 26, 63], ["viral genome", "OBSERVATION", 4, 16], ["single", "OBSERVATION_MODIFIER", 28, 34], ["stranded", "OBSERVATION_MODIFIER", 35, 43], ["positive", "OBSERVATION_MODIFIER", 45, 53], ["sense RNA", "OBSERVATION", 54, 63]]], ["The partial nucleotide sequence (open reading frame 1b) revealed that the genome organization of YHV is very similar to the gill-associated virus (GAV), reported from Australia.", [["nucleotide", "CHEMICAL", 12, 22], ["YHV", "GENE_OR_GENE_PRODUCT", 97, 100], ["gill-associated virus", "ORGANISM", 124, 145], ["partial nucleotide sequence", "DNA", 4, 31], ["open reading frame 1b", "DNA", 33, 54], ["YHV", "DNA", 97, 100], ["YHV", "SPECIES", 97, 100], ["GAV", "SPECIES", 147, 150], ["The partial nucleotide sequence", "TEST", 0, 31], ["the genome organization of YHV", "PROBLEM", 70, 100], ["the gill-associated virus", "PROBLEM", 120, 145], ["virus", "OBSERVATION", 140, 145]]], ["It has been proposed that YHV and GAV should belong to a new taxon (proposed name Oka6irus) in the order Nidovirales that also included Coronaviruses, toroviruses and arteriviruses (Walker et al., 2001) .IntroductionThe current diagnostic methods for TSV and YHV include bioassay using indicator hosts, monitoring clinical signs, histopathology, dot blot, in situ hybridization using virus specific gene probe, immunohistochemistry and by the polymerase chain reaction (PCR) (Lightner and Redman, 1998) .", [["YHV", "GENE_OR_GENE_PRODUCT", 26, 29], ["GAV", "GENE_OR_GENE_PRODUCT", 34, 37], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 136, 149], ["YHV", "SPECIES", 26, 29], ["TSV", "SPECIES", 251, 254], ["YHV", "SPECIES", 259, 262], ["GAV", "TREATMENT", 34, 37], ["Nidovirales", "TREATMENT", 105, 116], ["Coronaviruses", "PROBLEM", 136, 149], ["toroviruses", "TREATMENT", 151, 162], ["arteriviruses", "TREATMENT", 167, 180], ["monitoring clinical signs", "TEST", 303, 328], ["histopathology", "TEST", 330, 344], ["dot blot", "TEST", 346, 354], ["immunohistochemistry", "TEST", 411, 431], ["the polymerase chain reaction", "PROBLEM", 439, 468]]], ["Although conventional PCR is most sensitive among these methods, it is unable to detect a single copy of the viral genome in the infected tissue.", [["tissue", "ANATOMY", 138, 144], ["tissue", "TISSUE", 138, 144], ["viral genome", "DNA", 109, 121], ["conventional PCR", "TEST", 9, 25], ["the viral genome in the infected tissue", "PROBLEM", 105, 144], ["viral genome", "OBSERVATION", 109, 121], ["infected tissue", "OBSERVATION", 129, 144]]], ["SYBR Green dye has a high affinity for double-stranded DNA (ds-DNA) and exhibits enhancement of fluorescence upon binding to the dsDNA.", [["SYBR Green dye", "CHEMICAL", 0, 14], ["SYBR", "GENE_OR_GENE_PRODUCT", 0, 4], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["dsDNA", "CELLULAR_COMPONENT", 129, 134], ["double-stranded DNA", "DNA", 39, 58], ["ds-DNA", "DNA", 60, 66], ["a high affinity", "PROBLEM", 19, 34], ["double-stranded DNA", "TREATMENT", 39, 58], ["enhancement of fluorescence", "PROBLEM", 81, 108], ["high affinity", "OBSERVATION_MODIFIER", 21, 34], ["enhancement", "OBSERVATION_MODIFIER", 81, 92], ["dsDNA", "ANATOMY", 129, 134]]], ["In the GeneAmp \u00ae 5700 Sequence Detection System, the fluorescence of the SYBR Green dye is monitored at the end of the each cycle and the increase in fluorescence above background is dependent on the initial template concentration (PE Biosystem GeneAmp \u00ae 5700 User Manual, 1998).", [["SYBR", "GENE_OR_GENE_PRODUCT", 73, 77], ["the fluorescence", "TEST", 49, 65], ["the SYBR Green dye", "TREATMENT", 69, 87], ["increase", "OBSERVATION_MODIFIER", 138, 146], ["dependent", "OBSERVATION_MODIFIER", 183, 192], ["PE", "OBSERVATION", 232, 234]]], ["The method does not need any post PCR analyses and the specificity of the product is monitored by analyzing the melting curve (Ririe et al., 1997) .IntroductionThe objectives of the present study were (1) to determine the sensitivity and specificity of SYBR Green RT-PCR using the GeneAmp 5700 Sequence Detection system in detecting TSV and YHV; and (2) to determine the TSV and YHV load in laboratory challenged shrimp. of Arizona, Arizona) was prepared by homogenizing PCR confirmed TSV and YHV infected tail tissue in 2% saline (1:10 w/v) and centrifuging the homogenate in a tabletop centrifuge (Beckman Microfuge Lite Model) at 12 000 rpm for 5 min.", [["tail tissue", "ANATOMY", 506, 517], ["homogenate", "ANATOMY", 563, 573], ["shrimp", "ORGANISM", 413, 419], ["tail tissue", "TISSUE", 506, 517], ["saline", "SIMPLE_CHEMICAL", 524, 530], ["shrimp", "SPECIES", 413, 419], ["TSV", "SPECIES", 333, 336], ["YHV", "SPECIES", 341, 344], ["TSV", "SPECIES", 371, 374], ["YHV", "SPECIES", 379, 382], ["TSV", "SPECIES", 485, 488], ["YHV", "SPECIES", 493, 496], ["any post PCR analyses", "TEST", 25, 46], ["the present study", "TEST", 178, 195], ["the sensitivity", "TEST", 218, 233], ["SYBR", "TEST", 253, 257], ["TSV", "TEST", 333, 336], ["homogenizing PCR", "TEST", 458, 474], ["TSV", "PROBLEM", 485, 488], ["YHV infected tail tissue", "PROBLEM", 493, 517], ["2% saline", "TREATMENT", 521, 530], ["a tabletop centrifuge (Beckman Microfuge Lite Model)", "TREATMENT", 577, 629], ["infected tail tissue", "OBSERVATION", 497, 517]]], ["The supernatants were diluted to 1:10 before injecting the animals.", [["supernatants", "ANATOMY", 4, 16], ["The supernatants", "TREATMENT", 0, 16]]], ["Healthy juvenile shrimp were injected with a virus inoculum (30 ml :10 6 copies) using a 26-gauge needle and 1 ml tuberculin syringe between the last 2-3 tail segments on the ventral surface.", [["ventral surface", "ANATOMY", 175, 190], ["shrimp", "ORGANISM", 17, 23], ["ventral surface", "MULTI-TISSUE_STRUCTURE", 175, 190], ["shrimp", "SPECIES", 17, 23], ["Healthy juvenile shrimp", "TREATMENT", 0, 23], ["a virus inoculum", "TREATMENT", 43, 59], ["a 26-gauge needle", "TREATMENT", 87, 104], ["1 ml tuberculin syringe", "TREATMENT", 109, 132], ["juvenile shrimp", "OBSERVATION", 8, 23], ["3 tail", "ANATOMY_MODIFIER", 152, 158], ["segments", "ANATOMY_MODIFIER", 159, 167], ["ventral", "ANATOMY_MODIFIER", 175, 182], ["surface", "ANATOMY_MODIFIER", 183, 190]]], ["Control group animals were injected with a tail muscle homogenate from PCR-confirmed virus negative healthy animals.", [["tail muscle homogenate", "ANATOMY", 43, 65], ["animals", "ORGANISM", 14, 21], ["tail muscle homogenate", "ORGANISM_SUBSTANCE", 43, 65], ["a tail muscle homogenate", "TEST", 41, 65], ["PCR", "TEST", 71, 74], ["virus", "PROBLEM", 85, 90]]], ["Healthy tissue homogenate was prepared same as described above.", [["tissue homogenate", "ANATOMY", 8, 25], ["tissue homogenate", "TISSUE", 8, 25], ["Healthy tissue homogenate", "PROBLEM", 0, 25], ["tissue", "ANATOMY", 8, 14], ["homogenate", "OBSERVATION", 15, 25]]], ["Animals were kept indoors within environmentally controlled tanks, reared on a commercially available feed formulation (MADMAC-MS Dry pellet, Bio-Marine, Inc. Hawthorne, CA) and routinely monitored during the course of the study.Isolation of total RNAVirus challenged moribund animals were killed at 3 -4 days post-injection (p.i.) for TSV susceptible P. 6annamei and YHV susceptible P. stylirostris.", [["Animals", "ORGANISM", 0, 7], ["RNAVirus", "GENE_OR_GENE_PRODUCT", 248, 256], ["P. 6annamei", "ORGANISM", 352, 363], ["P. stylirostris", "ORGANISM", 384, 399], ["P. 6annamei", "SPECIES", 352, 363], ["P. stylirostris", "SPECIES", 384, 399], ["P. 6annamei", "SPECIES", 352, 363], ["YHV", "SPECIES", 368, 371], ["P. stylirostris", "SPECIES", 384, 399], ["the study", "TEST", 219, 228], ["total RNAVirus", "TREATMENT", 242, 256], ["TSV susceptible P. 6annamei", "PROBLEM", 336, 363], ["YHV susceptible P. stylirostris", "PROBLEM", 368, 399], ["total", "OBSERVATION_MODIFIER", 242, 247]]], ["For TSV resistant Super Shrimp P. stylirostris, animals were sacrificed 3-5 days p.i.", [["Shrimp P. stylirostris", "ORGANISM", 24, 46], ["animals", "ORGANISM", 48, 55], ["P. stylirostris", "SPECIES", 31, 46], ["P. stylirostris", "SPECIES", 31, 46], ["TSV", "PROBLEM", 4, 7]]], ["The sampling time was based on the observation that in Super Shrimp P. stylirostris TSV titer attains a high level after 3-5 days p.i., as determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) (K.R. Klimpel, unpublished) .", [["Super Shrimp P. stylirostris TSV", "ORGANISM", 55, 87], ["reverse transcriptase", "PROTEIN", 163, 184], ["P. stylirostris", "SPECIES", 68, 83], ["P. stylirostris", "SPECIES", 68, 83], ["the observation", "TEST", 31, 46], ["TSV titer", "TEST", 84, 93], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 163, 210], ["RT-PCR", "TEST", 212, 218]]], ["Tail muscle tissue ( 50 mg) from virus challenged as well as control animals were taken for the extraction of RNA using TRI Reagent\u2122 (Molecular Research Center, Inc. Ohio).", [["Tail muscle tissue", "ANATOMY", 0, 18], ["TRI", "CHEMICAL", 120, 123], ["Tail muscle tissue", "TISSUE", 0, 18], ["Tail muscle tissue", "PROBLEM", 0, 18], ["virus", "PROBLEM", 33, 38], ["the extraction of RNA", "TREATMENT", 92, 113], ["TRI Reagent\u2122", "TREATMENT", 120, 132], ["muscle tissue", "ANATOMY", 5, 18]]], ["The RNA pellets were dissolved in DNase, RNase free distilled water and the yield of total RNA was measured by using a spectrophotometer (Shimadzu UV-1201).", [["Shimadzu UV-1201", "CHEMICAL", 138, 154], ["DNase", "GENE_OR_GENE_PRODUCT", 34, 39], ["RNase", "GENE_OR_GENE_PRODUCT", 41, 46], ["DNase", "PROTEIN", 34, 39], ["RNase", "PROTEIN", 41, 46], ["The RNA pellets", "PROBLEM", 0, 15], ["DNase", "PROBLEM", 34, 39], ["RNase free distilled water", "TREATMENT", 41, 67], ["total RNA", "TREATMENT", 85, 94], ["a spectrophotometer (Shimadzu UV", "TREATMENT", 117, 149], ["RNA pellets", "OBSERVATION", 4, 15], ["dissolved", "OBSERVATION_MODIFIER", 21, 30]]], ["The RNA quality was assessed by running the samples in a 1% formaldehyde agarose gel following standard protocol (Sambrook et al., 1989) .", [["samples", "ANATOMY", 44, 51], ["formaldehyde", "CHEMICAL", 60, 72], ["formaldehyde", "CHEMICAL", 60, 72], ["agarose", "SIMPLE_CHEMICAL", 73, 80], ["a 1% formaldehyde agarose gel", "TREATMENT", 55, 84]]], ["Total RNA was treated with DNase I using the MessageClean \u00ae kit of GenHunter Corp. (Nashville, TN) before synthesizing cDNA for SYBR Green RT-PCR.Cloning and sequencing of TSV, YHV, i-actin and elongation factor-1h genesA list of primers used for the RT-PCR amplification of TSV, YHV, b-actin, and elongation factor-1a (EF-1a) is given in Table 1 .", [["DNase I", "GENE_OR_GENE_PRODUCT", 27, 34], ["SYBR", "GENE_OR_GENE_PRODUCT", 128, 132], ["YHV", "GENE_OR_GENE_PRODUCT", 177, 180], ["i-actin", "GENE_OR_GENE_PRODUCT", 182, 189], ["TSV", "ORGANISM", 275, 278], ["YHV", "GENE_OR_GENE_PRODUCT", 280, 283], ["b-actin", "GENE_OR_GENE_PRODUCT", 285, 292], ["elongation factor-1a", "GENE_OR_GENE_PRODUCT", 298, 318], ["EF-1a", "GENE_OR_GENE_PRODUCT", 320, 325], ["DNase I", "PROTEIN", 27, 34], ["TN", "PROTEIN", 95, 97], ["cDNA", "DNA", 119, 123], ["TSV, YHV, i-actin and elongation factor-1h genesA list", "DNA", 172, 226], ["TSV", "PROTEIN", 275, 278], ["YHV", "PROTEIN", 280, 283], ["b-actin", "PROTEIN", 285, 292], ["elongation factor-1a", "PROTEIN", 298, 318], ["EF", "PROTEIN", 320, 322], ["YHV", "SPECIES", 177, 180], ["TSV", "SPECIES", 275, 278], ["YHV", "SPECIES", 280, 283], ["DNase I", "TREATMENT", 27, 34], ["synthesizing cDNA", "TREATMENT", 106, 123], ["TSV", "PROBLEM", 172, 175], ["YHV", "PROBLEM", 177, 180], ["i-actin and elongation factor", "PROBLEM", 182, 211], ["the RT", "TEST", 247, 253], ["PCR amplification", "TEST", 254, 271], ["TSV", "TEST", 275, 278], ["YHV", "TEST", 280, 283], ["b-actin", "TEST", 285, 292], ["elongation factor", "TEST", 298, 315], ["EF", "TEST", 320, 322]]], ["For TSV, YHV and b-actin RT-PCR, cDNA was synthesized using Omniscript\u2122 cDNA synthesis protocol (Qiagen, CA) and 1 mg total RNA in a 20 ml reaction volume.", [["YHV", "DNA", 9, 12], ["cDNA", "DNA", 33, 37], ["1 mg total RNA", "RNA", 113, 127], ["TSV", "SPECIES", 4, 7], ["YHV", "SPECIES", 9, 12], ["TSV", "TEST", 4, 7], ["YHV", "TEST", 9, 12], ["b-actin RT", "TREATMENT", 17, 27], ["PCR", "TEST", 28, 31], ["Omniscript\u2122 cDNA synthesis protocol", "TREATMENT", 60, 95], ["Qiagen, CA)", "TREATMENT", 97, 108]]], ["The RT-PCR mixture contained, 4 ml cDNA reaction mixture, 1\u00d7 PCR buffer (Sigma, St. Louis, MO), 1 mM dNTP, 1.25 mM of each forward and reverse primer and 0.6 U of RED Taq DNA polymerase (Sigma) in a 25 ml reaction volume.", [["NTP", "CHEMICAL", 102, 105], ["NTP", "SIMPLE_CHEMICAL", 102, 105], ["RED Taq", "GENE_OR_GENE_PRODUCT", 163, 170], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["RED Taq DNA polymerase", "PROTEIN", 163, 185], ["The RT-PCR mixture", "TREATMENT", 0, 18], ["4 ml cDNA reaction mixture", "TREATMENT", 30, 56], ["1 mM dNTP", "TREATMENT", 96, 105], ["RED Taq DNA polymerase", "TEST", 163, 185]]], ["The temperature profile for the PCR amplification was 94\u00b0C 2 min followed by 35 cycles of 94\u00b0C 1 min, 55\u00b0C 2 min, 72\u00b0C 1 min with extension at 72\u00b0C 7 min.", [["The temperature profile", "TEST", 0, 23], ["the PCR amplification", "TEST", 28, 49]]], ["The PCR amplified products were run in a 1% agarose gel at 80 V for 1 h and stained with ethidium bromide to visualize the products on a UV transilluminator.", [["ethidium bromide", "CHEMICAL", 89, 105], ["ethidium bromide", "CHEMICAL", 89, 105], ["agarose", "SIMPLE_CHEMICAL", 44, 51], ["ethidium bromide", "SIMPLE_CHEMICAL", 89, 105], ["PCR amplified products", "DNA", 4, 26], ["The PCR amplified products", "TREATMENT", 0, 26], ["a 1% agarose gel", "TREATMENT", 39, 55], ["ethidium bromide", "TREATMENT", 89, 105], ["a UV transilluminator", "TREATMENT", 135, 156]]], ["The EF-1a gene was previously isolated from a white spot syndrome virus (WSSV) challenged P. stylirostris shrimp by using the mRNA differential display technique (Dhar et al., 2001b) .Cloning and sequencing of TSV, YHV, i-actin and elongation factor-1h genesTSV, YHV and b-actin cDNAs were cloned into a TOPO cloning vector (Invitrogen, CA) and the EF-1a cDNA was cloned into a PCR-TRAP vector (GenHunter Corp., Inc.).", [["white spot syndrome", "DISEASE", 46, 65], ["EF-1a", "GENE_OR_GENE_PRODUCT", 4, 9], ["white spot syndrome virus", "ORGANISM", 46, 71], ["WSSV", "ORGANISM", 73, 77], ["P. stylirostris shrimp", "ORGANISM", 90, 112], ["TSV", "GENE_OR_GENE_PRODUCT", 210, 213], ["YHV", "GENE_OR_GENE_PRODUCT", 215, 218], ["i-actin", "GENE_OR_GENE_PRODUCT", 220, 227], ["elongation factor-1h", "GENE_OR_GENE_PRODUCT", 232, 252], ["YHV", "GENE_OR_GENE_PRODUCT", 263, 266], ["b-actin", "GENE_OR_GENE_PRODUCT", 271, 278], ["TOPO", "GENE_OR_GENE_PRODUCT", 304, 308], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 325, 335], ["CA", "GENE_OR_GENE_PRODUCT", 337, 339], ["EF-1a", "GENE_OR_GENE_PRODUCT", 349, 354], ["TRAP", "GENE_OR_GENE_PRODUCT", 382, 386], ["EF-1a gene", "DNA", 4, 14], ["TSV, YHV, i-actin and elongation factor-1h genesTSV, YHV and b-actin cDNAs", "DNA", 210, 284], ["TOPO cloning vector", "DNA", 304, 323], ["Invitrogen, CA", "DNA", 325, 339], ["EF-1a cDNA", "DNA", 349, 359], ["PCR-TRAP vector", "DNA", 378, 393], ["P. stylirostris shrimp", "SPECIES", 90, 112], ["white spot syndrome virus", "SPECIES", 46, 71], ["WSSV", "SPECIES", 73, 77], ["P. stylirostris shrimp", "SPECIES", 90, 112], ["YHV", "SPECIES", 215, 218], ["YHV", "SPECIES", 263, 266], ["The EF", "TEST", 0, 6], ["a white spot syndrome virus", "PROBLEM", 44, 71], ["TSV", "PROBLEM", 210, 213], ["YHV", "PROBLEM", 215, 218], ["i-actin", "PROBLEM", 220, 227], ["elongation factor", "PROBLEM", 232, 249], ["YHV", "PROBLEM", 263, 266], ["b-actin cDNAs", "TREATMENT", 271, 284], ["a TOPO cloning vector", "TREATMENT", 302, 323], ["the EF", "TEST", 345, 351], ["a PCR", "TEST", 376, 381]]], ["The recombinant plasmid DNA was sequenced in an automated DNA sequencer (model ABI 373A, PE Applied Biosystems).", [["plasmid", "ANATOMY", 16, 23], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["recombinant plasmid DNA", "DNA", 4, 27], ["The recombinant plasmid DNA", "TREATMENT", 0, 27], ["an automated DNA sequencer", "TEST", 45, 71], ["model ABI", "TEST", 73, 82], ["PE Applied Biosystems", "TREATMENT", 89, 110], ["plasmid DNA", "OBSERVATION", 16, 27], ["PE", "OBSERVATION", 89, 91]]], ["The Sequence analyses were carried out using the NCBI BLAST search program (http://www.ncbi.nlm.nih.gov/gorf/gorf.html) to confirm identity between the cloned and the published sequences based on which the primers were designed (Table 1 ).SYBR Green RT-PCRThe primers used for SYBR Green RT-PCR are listed in Table 2 .", [["SYBR", "GENE_OR_GENE_PRODUCT", 239, 243], ["SYBR Green", "GENE_OR_GENE_PRODUCT", 277, 287], ["SYBR Green RT-PCRThe primers", "DNA", 239, 267], ["The Sequence analyses", "TEST", 0, 21], ["the published sequences", "TEST", 163, 186], ["PCRThe primers", "TREATMENT", 253, 267]]], ["The primers were designed based on the sequence of the cloned segment of TSV, YHV, b-actin and EF-1a genes and using the Primer Express Software version 1.0 (PE Ap-plied Biosystem).", [["TSV", "GENE_OR_GENE_PRODUCT", 73, 76], ["YHV", "GENE_OR_GENE_PRODUCT", 78, 81], ["b-actin", "GENE_OR_GENE_PRODUCT", 83, 90], ["EF-1a", "GENE_OR_GENE_PRODUCT", 95, 100], ["TSV, YHV, b-actin and EF-1a genes", "DNA", 73, 106], ["YHV", "SPECIES", 78, 81], ["TSV", "TEST", 73, 76], ["YHV", "TEST", 78, 81], ["b-actin", "TEST", 83, 90], ["EF", "TEST", 95, 97], ["Software version", "TEST", 136, 152], ["PE Ap", "TEST", 158, 163], ["TSV", "ANATOMY", 73, 76]]], ["The primers were checked by running a virtual PCR and the amplifications were analyzed for expected product, mispairing and primer dimer formation using a computer program (Amplify v1.2B, Dr William Engles, University of Wisconsin, Department of Genetics).", [["The primers", "TEST", 0, 11], ["a virtual PCR", "TEST", 36, 49], ["the amplifications", "TEST", 54, 72], ["mispairing and primer dimer formation", "PROBLEM", 109, 146]]], ["The best primer set was taken for amplification.SYBR Green RT-PCRThe SYBR Green RT-PCR amplifications were undertaken in a GeneAmp 9600 Thermocycler coupled with a GeneAmp \u00ae 5700 Sequence Detection System (PE Applied Biosystems).", [["SYBR", "TEST", 48, 52], ["PCR amplifications", "TEST", 83, 101], ["PE", "OBSERVATION", 206, 208]]], ["The cDNA synthesis was carried out in a 20 ml reaction volume containing 1 mg DNase I treated total RNA, 1 \u00d7 RT-PCR buffer, 1 mM dNTPs (PE Applied Biosystems), 0.75 mM oligo dT, 4 U of RNase inhibitor (PE Applied Biosystems) and 5 U of MutiScribe\u2122 reverse transcriptase (PE Applied Biosystems).", [["dNTPs", "CHEMICAL", 129, 134], ["oligo dT", "CHEMICAL", 168, 176], ["dNTPs", "CHEMICAL", 129, 134], ["RNase", "GENE_OR_GENE_PRODUCT", 185, 190], ["DNase I", "PROTEIN", 78, 85], ["MutiScribe\u2122 reverse transcriptase", "PROTEIN", 236, 269], ["The cDNA synthesis", "TEST", 0, 18], ["a 20 ml reaction volume", "TREATMENT", 38, 61], ["total RNA", "TREATMENT", 94, 103], ["RT-PCR buffer", "TREATMENT", 109, 122], ["1 mM dNTPs (PE Applied Biosystems", "TREATMENT", 124, 157], ["0.75 mM oligo dT", "TREATMENT", 160, 176], ["4 U of RNase inhibitor", "TREATMENT", 178, 200], ["PE Applied Biosystems", "TREATMENT", 202, 223], ["MutiScribe\u2122 reverse transcriptase (PE Applied Biosystems", "TREATMENT", 236, 292], ["PE", "OBSERVATION", 136, 138], ["PE", "OBSERVATION", 202, 204], ["PE", "OBSERVATION", 271, 273]]], ["The cDNA reaction mixture was diluted 1:10 using DNase, RNase free molecular biology grade water and 1 ml was taken for each amplification reaction.", [["DNase", "GENE_OR_GENE_PRODUCT", 49, 54], ["RNase", "GENE_OR_GENE_PRODUCT", 56, 61], ["DNase", "PROTEIN", 49, 54], ["RNase", "PROTEIN", 56, 61], ["The cDNA reaction mixture", "TREATMENT", 0, 25], ["DNase", "TREATMENT", 49, 54], ["each amplification reaction", "PROBLEM", 120, 147]]], ["The amplifications were carried out in a 96 well plate in a 25 ml reaction volume containing 7.1 ml of 2\u00d7 SYBR \u00ae Green Master Mix (PE Biosystems), 0.24 mM each of forward and reverse primers and 1 ml of the 1: 10 diluted cDNA.", [["1: 10 diluted cDNA", "DNA", 207, 225], ["a 25 ml reaction volume", "TREATMENT", 58, 81], ["SYBR", "TEST", 106, 110], ["PE Biosystems", "TEST", 131, 144], ["reverse primers", "TREATMENT", 175, 190], ["PE", "OBSERVATION", 131, 133]]], ["The thermal profile for SYBR RT-PCR was 50\u00b0C 2 min, 95\u00b0C 10 min followed by 40 cycles of 95\u00b0C 10 s and 60\u00b0C 1 min.", [["SYBR RT", "TEST", 24, 31], ["PCR", "TEST", 32, 35]]], ["In each 96 well plate, a dilution series of the plasmid standard for the respective virus was run along with the unknown samples for the corresponding virus and the EF-1a control.", [["samples", "ANATOMY", 121, 128], ["samples", "CANCER", 121, 128], ["EF", "PROTEIN", 165, 167], ["a dilution series", "TREATMENT", 23, 40], ["the plasmid standard", "TREATMENT", 44, 64], ["the respective virus", "PROBLEM", 69, 89], ["the corresponding virus", "PROBLEM", 133, 156], ["the EF", "TEST", 161, 167]]], ["Each sam-ple had 2 -3 replicates and all reactions were repeated at least 3 times independently to ensure the reproducibility of the results.SYBR Green RT-PCRFor comparing the efficiency of amplification of EF-1a and b-actin genes with TSV and YHV, cDNA was synthesized in a 20 ml reaction volume as described above.", [["SYBR", "GENE_OR_GENE_PRODUCT", 141, 145], ["EF-1a", "GENE_OR_GENE_PRODUCT", 207, 212], ["b-actin", "GENE_OR_GENE_PRODUCT", 217, 224], ["SYBR Green RT-PCRFor", "DNA", 141, 161], ["EF-1a and b-actin genes", "DNA", 207, 230], ["TSV", "DNA", 236, 239], ["YHV", "DNA", 244, 247], ["cDNA", "DNA", 249, 253], ["TSV", "SPECIES", 236, 239], ["YHV", "SPECIES", 244, 247], ["EF", "TEST", 207, 209], ["TSV", "PROBLEM", 236, 239], ["a 20 ml reaction volume", "TREATMENT", 273, 296]]], ["A serial dilution was then made using sheared salmon sperm DNA (5 ng/ml) as a diluent.", [["sperm", "ANATOMY", 53, 58], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["salmon", "SPECIES", 46, 52], ["A serial dilution", "TREATMENT", 0, 17], ["sheared salmon sperm DNA", "TREATMENT", 38, 62]]], ["SYBR Green RT-PCR was performed in a 96 well plate using 1 ml of each of the cDNA dilutions for TSV and YHV detection along with EF-1a and b-actin controls following the reaction parameters as described above.TSV and YHV Plasmid standard for quantification by SYBR Green PCRThe plasmid DNAs containing 220 bp TSV insert and 821 bp YHV insert were separately linearized by HindIII (Promega, WI) digestions.", [["SYBR", "GENE_OR_GENE_PRODUCT", 0, 4], ["EF-1a", "GENE_OR_GENE_PRODUCT", 129, 134], ["HindIII", "GENE_OR_GENE_PRODUCT", 372, 379], ["EF", "PROTEIN", 129, 131], ["SYBR Green PCRThe plasmid DNAs", "DNA", 260, 290], ["220 bp TSV insert", "DNA", 302, 319], ["821 bp YHV insert", "DNA", 324, 341], ["TSV", "SPECIES", 96, 99], ["YHV", "SPECIES", 104, 107], ["TSV", "SPECIES", 209, 212], ["YHV", "SPECIES", 217, 220], ["Green RT-PCR", "TEST", 5, 17], ["the cDNA dilutions", "TREATMENT", 73, 91], ["TSV", "TEST", 96, 99], ["YHV detection", "TEST", 104, 117], ["EF", "TEST", 129, 131], ["b-actin controls", "TREATMENT", 139, 155], ["the reaction parameters", "TEST", 166, 189], ["TSV", "TEST", 209, 212], ["YHV Plasmid", "TREATMENT", 217, 228], ["quantification", "TEST", 242, 256], ["Green PCRThe plasmid DNAs", "TREATMENT", 265, 290], ["bp TSV insert", "TREATMENT", 306, 319], ["bp YHV insert", "TREATMENT", 328, 341]]], ["An aliquot of the digested plasmids were run in a 1% agarose gel to confirm the digestion before purifying the remaining digestion reactions by Qiaquick Gel Purification kit (Qiagen, CA).", [["plasmids", "ANATOMY", 27, 35], ["agarose", "SIMPLE_CHEMICAL", 53, 60], ["digested plasmids", "DNA", 18, 35], ["the digested plasmids", "TREATMENT", 14, 35], ["a 1% agarose gel", "TREATMENT", 48, 64], ["the digestion", "PROBLEM", 76, 89], ["the remaining digestion reactions", "PROBLEM", 107, 140], ["Qiaquick Gel Purification", "TREATMENT", 144, 169]]], ["DNA was quantified using a spectrophotometer (Shimadzu UV-1201) and dilutions were made using sheared salmon sperm DNA (5 ng/ml) as a diluent.Data analysesAfter a SYBR Green PCR run, data acquisition and subsequent data analyses were done using the 5700 Sequence Detection System (SDS Version 1.3).", [["sperm", "ANATOMY", 109, 114], ["Shimadzu UV-1201", "CHEMICAL", 46, 62], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["salmon", "SPECIES", 102, 108], ["a spectrophotometer (Shimadzu UV", "TREATMENT", 25, 57], ["dilutions", "TREATMENT", 68, 77], ["sheared salmon sperm DNA", "TREATMENT", 94, 118], ["Data analyses", "TEST", 142, 155], ["a SYBR Green PCR run", "TEST", 161, 181], ["data acquisition", "TEST", 183, 199], ["subsequent data analyses", "TEST", 204, 228], ["SDS Version", "TEST", 281, 292]]], ["In the 5700 Sequence Detection System, the fluorescence of SYBR Green against the internal passive reference dye, ROX (DR n ) is measured at the end of each cycle.", [["ROX", "CHEMICAL", 114, 117], ["SYBR Green", "GENE_OR_GENE_PRODUCT", 59, 69], ["ROX", "SIMPLE_CHEMICAL", 114, 117], ["SYBR Green", "PROTEIN", 59, 69]]], ["A sample is considered positive when DR n exceeds the threshold value.", [["A sample", "TEST", 0, 8], ["the threshold value", "TEST", 50, 69]]], ["The threshold value is set at the midpoint of DR n vs. cycle number plot.", [["The threshold value", "TEST", 0, 19]]], ["The threshold cycle (C T ) is defined as the cycle at which a statistically significant increase in R n is first detected.", [["R n", "GENE_OR_GENE_PRODUCT", 100, 103], ["The threshold cycle (C T )", "TREATMENT", 0, 26], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96]]], ["Target cDNA copy number and C T values are related inversely.", [["C T", "GENE_OR_GENE_PRODUCT", 28, 31], ["Target cDNA copy", "TEST", 0, 16], ["C T values", "TEST", 28, 38]]], ["A sample containing higher copies of the target cDNA will cross the threshold at an earlier cycle compared to a sample with lower copies of the same target.", [["sample", "ANATOMY", 2, 8], ["sample", "ANATOMY", 112, 118], ["target cDNA", "DNA", 41, 52], ["A sample", "TEST", 0, 8], ["the target cDNA", "TREATMENT", 37, 52], ["a sample", "TEST", 110, 118]]], ["The copy number of TSV and YHV samples were determined by normalizing the C T values of the samples with respect to EF-1a and then extrapolating the normalized C T values to the standard curve of the corresponding virus.Data analysesFor further statistical analyses, the C T values were exported into a Microsoft Excel Worksheet.", [["YHV samples", "ANATOMY", 27, 38], ["samples", "ANATOMY", 92, 99], ["YHV samples", "CANCER", 27, 38], ["EF-1a", "GENE_OR_GENE_PRODUCT", 116, 121], ["C T", "GENE_OR_GENE_PRODUCT", 160, 163], ["EF", "PROTEIN", 116, 118], ["YHV", "SPECIES", 27, 30], ["TSV", "TEST", 19, 22], ["YHV samples", "TEST", 27, 38], ["EF", "TEST", 116, 118], ["the corresponding virus", "PROBLEM", 196, 219], ["Data analyses", "TEST", 220, 233], ["further statistical analyses", "TEST", 237, 265], ["the C T values", "TEST", 267, 281], ["virus", "OBSERVATION", 214, 219]]], ["Regression analyses of the C T values of the cDNA dilution series were used to determine the amplification efficiency for TSV and YHV compared to the corresponding EF-1a and b-actin controls.Analytical sensiti6ity of SYBR Green PCR using plasmid DNA templateThe analytical sensitivity of SYBR Green PCR was determined by using a serial dilution of TSV and YHV plasmid DNA as template for amplification.", [["C T", "GENE_OR_GENE_PRODUCT", 27, 30], ["EF-1a", "GENE_OR_GENE_PRODUCT", 164, 169], ["b-actin", "GENE_OR_GENE_PRODUCT", 174, 181], ["DNA", "CELLULAR_COMPONENT", 246, 249], ["DNA", "CELLULAR_COMPONENT", 368, 371], ["EF", "PROTEIN", 164, 166], ["plasmid DNA template", "DNA", 238, 258], ["YHV plasmid DNA", "DNA", 356, 371], ["TSV", "SPECIES", 122, 125], ["YHV", "SPECIES", 130, 133], ["TSV", "SPECIES", 348, 351], ["YHV", "SPECIES", 356, 359], ["Regression analyses", "TEST", 0, 19], ["the C T values", "TEST", 23, 37], ["the cDNA dilution series", "TEST", 41, 65], ["the amplification efficiency", "PROBLEM", 89, 117], ["TSV", "PROBLEM", 122, 125], ["YHV", "TEST", 130, 133], ["the corresponding EF", "TEST", 146, 166], ["b-actin controls", "TREATMENT", 174, 190], ["Green PCR", "TEST", 222, 231], ["plasmid DNA template", "TREATMENT", 238, 258], ["The analytical sensitivity", "TEST", 258, 284], ["SYBR Green PCR", "TEST", 288, 302], ["a serial dilution of TSV", "TREATMENT", 327, 351], ["YHV plasmid DNA", "TREATMENT", 356, 371]]], ["Dilution series of plasmid standard contained 1.51-2.42\u00d7 10 6 copies for TSV and 1.33-2.12\u00d7 10 6 copies for YHV.", [["YHV", "SPECIES", 108, 111], ["plasmid", "TEST", 19, 26], ["TSV", "TEST", 73, 76], ["YHV", "TEST", 108, 111]]], ["A linear relationship between the input plasmid DNA and the C T values with regression coefficient (r 2 ) greater than 0.99 were obtained for both the viruses.", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["C T", "GENE_OR_GENE_PRODUCT", 60, 63], ["input plasmid DNA", "DNA", 34, 51], ["the input plasmid DNA", "TREATMENT", 30, 51], ["the C T values", "TEST", 56, 70], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["plasmid DNA", "OBSERVATION", 40, 51], ["viruses", "OBSERVATION", 151, 158]]], ["The mean C T values of replicate assays ranged from 19.3839 0.267 (for 2.42\u00d7 10 6 copies) to 40.09 0.0 (for 1.51 copies) for TSV and 18.6019 0.169 (for 2.12\u00d7 10 6 copies) to 38.94490.337 (for 1.33 copies) for YHV, respectively (Fig. 1, Table 3 ).", [["C T", "GENE_OR_GENE_PRODUCT", 9, 12], ["YHV", "SPECIES", 209, 212], ["The mean C T values", "TEST", 0, 19], ["replicate assays", "TEST", 23, 39], ["TSV", "TEST", 125, 128], ["YHV", "TEST", 209, 212]]], ["The coefficient of variation was less than 4.0% for both TSV and YHV samples (Table 3) .Comparison of amplification efficiency of TSV and YHV with EF-1h and i-actin controlsTo compare the amplification efficiency of TSV and YHV with the internal control genes, EF-1a and b-actin, a serial dilution of the cDNA derived from TSV and YHV infected samples were made.", [["YHV samples", "ANATOMY", 65, 76], ["samples", "ANATOMY", 344, 351], ["EF-1a", "GENE_OR_GENE_PRODUCT", 261, 266], ["b-actin", "GENE_OR_GENE_PRODUCT", 271, 278], ["TSV", "ORGANISM", 323, 326], ["samples", "CANCER", 344, 351], ["EF", "PROTEIN", 147, 149], ["YHV", "DNA", 224, 227], ["internal control genes", "DNA", 237, 259], ["EF", "DNA", 261, 263], ["1a", "DNA", 264, 266], ["b-actin", "DNA", 271, 278], ["cDNA", "DNA", 305, 309], ["YHV", "SPECIES", 65, 68], ["YHV", "SPECIES", 138, 141], ["TSV", "SPECIES", 216, 219], ["YHV", "SPECIES", 224, 227], ["TSV", "SPECIES", 323, 326], ["YHV", "SPECIES", 331, 334], ["amplification efficiency", "PROBLEM", 102, 126], ["TSV", "PROBLEM", 130, 133], ["EF", "TEST", 147, 149], ["i-actin controls", "TREATMENT", 157, 173], ["TSV", "PROBLEM", 216, 219], ["YHV", "TREATMENT", 224, 227], ["EF", "TEST", 261, 263], ["b-actin", "TREATMENT", 271, 278], ["a serial dilution", "TREATMENT", 280, 297], ["the cDNA", "TREATMENT", 301, 309], ["TSV", "TREATMENT", 323, 326], ["YHV infected samples", "TREATMENT", 331, 351]]], ["If the amplification efficiency of TSV and YHV with the corresponding internal controls, EF-1a and b-actin, is very similar then the difference in slope (Ds) of curves for the virus and the corresponding internal controls will approach to 0.", [["YHV", "CANCER", 43, 46], ["EF-1a", "GENE_OR_GENE_PRODUCT", 89, 94], ["b-actin", "GENE_OR_GENE_PRODUCT", 99, 106], ["TSV", "PROTEIN", 35, 38], ["YHV", "PROTEIN", 43, 46], ["EF", "PROTEIN", 89, 91], ["1a", "PROTEIN", 92, 94], ["b-actin", "PROTEIN", 99, 106], ["YHV", "SPECIES", 43, 46], ["TSV", "PROBLEM", 35, 38], ["EF", "TEST", 89, 91], ["b-actin", "TREATMENT", 99, 106], ["slope (Ds) of curves", "PROBLEM", 147, 167], ["the virus", "PROBLEM", 172, 181]]], ["The Ds value of TSV and EF-1a was \u2212 0.139 and TSV and b-actin was \u2212 0.833 ( Fig. 2A) .", [["EF-1a", "GENE_OR_GENE_PRODUCT", 24, 29], ["b-actin", "GENE_OR_GENE_PRODUCT", 54, 61], ["Ds", "DNA", 4, 6], ["EF", "PROTEIN", 24, 26], ["The Ds value", "TEST", 0, 12], ["TSV", "TEST", 16, 19], ["EF", "TEST", 24, 26], ["TSV", "TEST", 46, 49], ["b-actin", "TEST", 54, 61]]], ["The Ds value of YHV and EF-1a (+0.033) was closer than the Ds value of YHV and b-actin (+ 0.378) (Fig. 2B) .Comparison of amplification efficiency of TSV and YHV with EF-1h and i-actin controlsTo determine the sample to sample variation in the EF-1a and b-actin C T values, SYBR Green RT-PCR was run for TSV, EF-1a and b-actin or YHV, EF-1a and b-actin in parallel in the same 96 well plate.", [["EF-1a", "GENE_OR_GENE_PRODUCT", 24, 29], ["EF-1a", "GENE_OR_GENE_PRODUCT", 244, 249], ["b-actin C T", "GENE_OR_GENE_PRODUCT", 254, 265], ["SYBR Green", "GENE_OR_GENE_PRODUCT", 274, 284], ["EF-1a", "GENE_OR_GENE_PRODUCT", 309, 314], ["b-actin", "GENE_OR_GENE_PRODUCT", 319, 326], ["YHV", "SIMPLE_CHEMICAL", 330, 333], ["EF-1a", "GENE_OR_GENE_PRODUCT", 335, 340], ["b-actin", "GENE_OR_GENE_PRODUCT", 345, 352], ["Ds", "DNA", 4, 6], ["YHV", "PROTEIN", 16, 19], ["EF", "PROTEIN", 24, 26], ["Ds", "DNA", 59, 61], ["EF", "PROTEIN", 167, 169], ["EF", "PROTEIN", 244, 246], ["EF", "PROTEIN", 309, 311], ["b-actin", "PROTEIN", 319, 326], ["YHV", "DNA", 330, 333], ["EF", "DNA", 335, 337], ["1a", "DNA", 338, 340], ["b-actin", "DNA", 345, 352], ["YHV", "SPECIES", 158, 161], ["YHV", "SPECIES", 330, 333], ["The Ds value", "TEST", 0, 12], ["YHV", "TEST", 16, 19], ["EF", "TEST", 24, 26], ["the Ds value", "TEST", 55, 67], ["YHV", "TEST", 71, 74], ["b-actin", "TEST", 79, 86], ["amplification efficiency", "PROBLEM", 122, 146], ["TSV", "PROBLEM", 150, 153], ["EF", "TEST", 167, 169], ["i-actin controls", "TREATMENT", 177, 193], ["the EF", "TEST", 240, 246], ["b-actin C T values", "TEST", 254, 272], ["SYBR", "TEST", 274, 278], ["Green RT-PCR", "TEST", 279, 291], ["TSV", "TEST", 304, 307], ["EF", "TEST", 309, 311], ["b-actin", "PROBLEM", 319, 326], ["YHV", "TEST", 330, 333], ["EF", "TEST", 335, 337], ["b-actin", "TEST", 345, 352], ["well plate", "OBSERVATION", 380, 390]]], ["For the TSV samples, the C T values for EF-1a ranged from 21.502 to 25.023 and the C T values of b-actin ranged from 19.437 to 25.955 (Table 4 ).", [["TSV samples", "ANATOMY", 8, 19], ["C T", "GENE_OR_GENE_PRODUCT", 25, 28], ["EF-1a", "GENE_OR_GENE_PRODUCT", 40, 45], ["b-actin", "GENE_OR_GENE_PRODUCT", 97, 104], ["EF", "PROTEIN", 40, 42], ["the TSV samples", "TEST", 4, 19], ["the C T values", "TEST", 21, 35], ["EF", "TEST", 40, 42], ["the C T values", "TEST", 79, 93], ["b-actin", "TEST", 97, 104]]], ["For the YHV samples, the C T values for both EF-1a and b-actin genes were quite variable although the variability for b-actin C T values (20.418-29.405) were slightly higher than EF-1a C T values (21.395-29.807) for the corresponding samples (Table 4 ).Amplification specificity for TSV, YHV, EF-1h and i-actin genesSince the SYBR Green RT-PCR does not involve any post-PCR analysis, amplification of specific vs. non-specific products was confirmed by analyzing the dissociation curve of the target amplicons.", [["YHV samples", "ANATOMY", 8, 19], ["samples", "ANATOMY", 234, 241], ["YHV samples", "CANCER", 8, 19], ["C T", "GENE_OR_GENE_PRODUCT", 25, 28], ["EF-1a", "GENE_OR_GENE_PRODUCT", 45, 50], ["b-actin", "GENE_OR_GENE_PRODUCT", 55, 62], ["b-actin C T", "GENE_OR_GENE_PRODUCT", 118, 129], ["YHV", "GENE_OR_GENE_PRODUCT", 288, 291], ["EF-1h", "GENE_OR_GENE_PRODUCT", 293, 298], ["i-actin", "GENE_OR_GENE_PRODUCT", 303, 310], ["SYBR", "GENE_OR_GENE_PRODUCT", 326, 330], ["EF-1a and b-actin genes", "DNA", 45, 68], ["EF", "PROTEIN", 179, 181], ["TSV, YHV, EF-1h and i-actin genes", "DNA", 283, 316], ["YHV", "SPECIES", 8, 11], ["YHV", "SPECIES", 288, 291], ["the YHV samples", "TEST", 4, 19], ["the C T values", "TEST", 21, 35], ["EF", "TEST", 45, 47], ["b-actin genes", "PROBLEM", 55, 68], ["b-actin C T values", "TEST", 118, 136], ["EF", "TEST", 179, 181], ["T values", "TEST", 187, 195], ["the corresponding samples", "TEST", 216, 241], ["Amplification specificity", "TEST", 253, 278], ["TSV", "TEST", 283, 286], ["YHV", "TEST", 288, 291], ["EF", "TEST", 293, 295], ["any post-PCR analysis", "TEST", 361, 382], ["non-specific products", "PROBLEM", 414, 435], ["target amplicons", "OBSERVATION", 493, 509]]], ["A dissociation curve with a single peak at temperature expected for that amplicon indicated specific amplification.", [["A dissociation curve", "TEST", 0, 20], ["a single peak at temperature", "TREATMENT", 26, 54]]], ["The amplification profiles and the dissociation curves for TSV and YHV along with their corresponding internal controls (EF-1a and b-actin) are shown in Fig. 3 and Fig. 4 .", [["EF-1a", "GENE_OR_GENE_PRODUCT", 121, 126], ["b-actin", "GENE_OR_GENE_PRODUCT", 131, 138], ["YHV", "PROTEIN", 67, 70], ["EF", "PROTEIN", 121, 123], ["b-actin", "PROTEIN", 131, 138], ["The amplification profiles", "TEST", 0, 26], ["the dissociation curves", "TEST", 31, 54], ["TSV", "PROBLEM", 59, 62], ["YHV", "TREATMENT", 67, 70], ["EF", "TEST", 121, 123]]], ["When amplification was undertaken with cDNA from TSV infected shrimp, a significant increase in SYBR Green fluorescence was recorded with a C T value of 31.25 (Fig. 3A) .", [["TSV infected", "DISEASE", 49, 61], ["SYBR", "GENE_OR_GENE_PRODUCT", 96, 100], ["cDNA", "DNA", 39, 43], ["SYBR", "PROTEIN", 96, 100], ["cDNA", "TREATMENT", 39, 43], ["TSV infected shrimp", "PROBLEM", 49, 68], ["a significant increase in SYBR Green fluorescence", "PROBLEM", 70, 119], ["a C T value", "TEST", 138, 149], ["infected shrimp", "OBSERVATION", 53, 68], ["significant", "OBSERVATION_MODIFIER", 72, 83], ["increase", "OBSERVATION_MODIFIER", 84, 92]]], ["Amplification using cDNA from healthy shrimp, did not provide any significant increase in fluorescence indicating absence of TSV specific target (Fig. 3A) .", [["cDNA", "DNA", 20, 24], ["any significant increase in fluorescence", "PROBLEM", 62, 102]]], ["The dissociation curves showed a single peak at melting temperature (T m = 72.0\u00b0C) expected for the TSV amplicon only in the TSV infected, but not in the healthy sample (Fig. 3B) .", [["sample", "ANATOMY", 162, 168], ["TSV infected", "DISEASE", 125, 137], ["The dissociation curves", "TEST", 0, 23], ["melting temperature", "TEST", 48, 67], ["T m", "TEST", 69, 72], ["the TSV amplicon", "PROBLEM", 96, 112], ["the TSV infected", "PROBLEM", 121, 137], ["TSV", "ANATOMY", 125, 128], ["infected", "OBSERVATION", 129, 137]]], ["However, both healthy and the TSV infected sample provided successful amplification of EF-1a and b-actin genes ( Fig. 3C and E) with a single peak at expected melting temperature (T m = 79.2\u00b0C for EF-1a and T m = 78.8\u00b0C for b-actin) ( Fig. 3D and F) .Amplification specificity for TSV, YHV, EF-1h and i-actin genesFor YHV sample, only the cDNA from infected but not healthy animals provided the am- Fig. 1 .", [["sample", "ANATOMY", 43, 49], ["YHV sample", "ANATOMY", 318, 328], ["EF-1a", "GENE_OR_GENE_PRODUCT", 87, 92], ["b-actin", "GENE_OR_GENE_PRODUCT", 97, 104], ["b-actin", "GENE_OR_GENE_PRODUCT", 224, 231], ["YHV", "GENE_OR_GENE_PRODUCT", 286, 289], ["EF-1h", "GENE_OR_GENE_PRODUCT", 291, 296], ["i-actin", "GENE_OR_GENE_PRODUCT", 301, 308], ["cDNA", "CELLULAR_COMPONENT", 339, 343], ["EF-1a and b-actin genes", "DNA", 87, 110], ["E", "DNA", 125, 126], ["EF", "PROTEIN", 197, 199], ["b-actin", "PROTEIN", 224, 231], ["TSV, YHV, EF-1h and i-actin genes", "DNA", 281, 314], ["YHV sample", "DNA", 318, 328], ["cDNA", "DNA", 339, 343], ["TSV", "SPECIES", 281, 284], ["YHV", "SPECIES", 286, 289], ["EF", "TEST", 87, 89], ["melting temperature", "TEST", 159, 178], ["T m", "TEST", 180, 183], ["C", "TEST", 191, 192], ["EF", "TEST", 197, 199], ["T m", "TEST", 207, 210], ["b-actin)", "TREATMENT", 224, 232], ["Amplification specificity", "TEST", 251, 276], ["TSV", "TEST", 281, 284], ["YHV", "TEST", 286, 289], ["EF", "TEST", 291, 293], ["YHV sample", "TEST", 318, 328], ["the cDNA", "PROBLEM", 335, 343], ["infected", "OBSERVATION", 349, 357]]], ["The standard curve for TSV (A) and YHV (B) obtained by SYBR Green PCR using plasmid DNA as template.", [["DNA", "CELLULAR_COMPONENT", 84, 87], ["plasmid DNA", "DNA", 76, 87], ["YHV", "SPECIES", 35, 38], ["plasmid DNA", "TREATMENT", 76, 87]]], ["The number of copies of TSV plasmid DNA added to each reaction mixture (corresponding to the numbers on the linear curve in panel A) were as follows: (1) 2.42 \u00d710 6 , (2) 2.42 \u00d7 10 5 , (3) 2.42 \u00d7 10 4 , (4) 2.42 \u00d710 3 , (5) 2.42 \u00d7 10 2 , (6) 2.42 \u00d7 10 1 , (7) 12.1, (8) 6.05, (9) 3.03 and (10) 1.51.", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["TSV plasmid DNA", "DNA", 24, 39], ["TSV plasmid DNA", "TREATMENT", 24, 39], ["each reaction mixture", "PROBLEM", 49, 70], ["the linear curve", "TEST", 104, 120]]], ["For YHV sample, the plasmid copy numbers (corresponding to the numbers on the linear curve in panel B) were as follows: (1) 2.12 \u00d7 10 6 , (2) 2.12\u00d7 10 5 , (3) 2.12 \u00d710 4 , (4) 2.12\u00d710 3 , (5) 2.12\u00d710 2 , (6) 2.12\u00d7 10 1 , (7) 10.6, (8) 5.3, (9) 2.6 and (10) 1.33. plification of virus-specific product (Fig. 4A ).", [["YHV sample", "ANATOMY", 4, 14], ["plasmid", "ANATOMY", 20, 27], ["Fig. 4A", "PROTEIN", 302, 309], ["YHV sample", "TEST", 4, 14], ["the plasmid copy numbers", "TEST", 16, 40], ["the linear curve", "TEST", 74, 90], ["virus", "PROBLEM", 278, 283], ["virus", "OBSERVATION", 278, 283]]], ["The dissociation curves indicated that the amplicon had melting temperature (T m =79.2\u00b0C) as expected for the YHV specific product (Fig. 4B) .", [["YHV specific product", "PROTEIN", 110, 130], ["Fig. 4B", "PROTEIN", 132, 139], ["The dissociation curves", "TEST", 0, 23], ["the amplicon", "TEST", 39, 51], ["melting temperature", "TEST", 56, 75]]], ["However, both healthy and infected samples provided successful amplification of EF-1a and bactin genes ( Fig. 4C and E) with each dissociation curve showing a single peak at the expected melting temperature for EF-1a and b-actin ( Fig. 4D and F).Reproducibility of the SYBR Green assayTo assess the reproducibility of SYBR Green assays, amplifications were carried out independently on different days.", [["samples", "ANATOMY", 35, 42], ["EF-1a", "GENE_OR_GENE_PRODUCT", 80, 85], ["bactin", "GENE_OR_GENE_PRODUCT", 90, 96], ["EF-1a", "GENE_OR_GENE_PRODUCT", 211, 216], ["EF-1a and bactin genes", "DNA", 80, 102], ["E", "DNA", 117, 118], ["EF", "PROTEIN", 211, 213], ["b-actin", "PROTEIN", 221, 228], ["EF", "TEST", 80, 82], ["bactin genes", "TREATMENT", 90, 102], ["each dissociation curve", "TEST", 125, 148], ["a single peak", "PROBLEM", 157, 170], ["EF", "TEST", 211, 213], ["b-actin", "TREATMENT", 221, 228], ["the SYBR", "TEST", 265, 273], ["infected", "OBSERVATION", 26, 34]]], ["In a 96 well plate, each sample had 3-4 replicates.", [["each sample", "TEST", 20, 31]]], ["The coefficient of variation for the C T values of TSV, YHV, EF-1a and b-actin genes were less than 5.0% indicating that the assay was highly reproducible (Table 4 ).Determining the load of TSV and YHV in laboratory challenged shrimp by SYBR Green RT-PCRThe TSV and YHV viral load in the laboratorychallenged shrimp was determined by normalizing the C T values of the virus with EF-1a C T values and then extrapolating the normalized C T values of the samples to the standard curves of the corresponding virus.", [["samples", "ANATOMY", 452, 459], ["C T", "GENE_OR_GENE_PRODUCT", 37, 40], ["EF-1a", "GENE_OR_GENE_PRODUCT", 61, 66], ["b-actin", "GENE_OR_GENE_PRODUCT", 71, 78], ["YHV", "GENE_OR_GENE_PRODUCT", 198, 201], ["shrimp", "ORGANISM", 227, 233], ["SYBR Green RT-PCRThe TSV", "ORGANISM", 237, 261], ["YHV viral", "ORGANISM", 266, 275], ["shrimp", "ORGANISM", 309, 315], ["C T", "GENE_OR_GENE_PRODUCT", 434, 437], ["TSV, YHV, EF-1a and b-actin genes", "DNA", 51, 84], ["EF", "PROTEIN", 379, 381], ["shrimp", "SPECIES", 227, 233], ["YHV", "SPECIES", 56, 59], ["YHV", "SPECIES", 198, 201], ["YHV", "SPECIES", 266, 269], ["the C T values", "TEST", 33, 47], ["TSV", "TEST", 51, 54], ["YHV", "TEST", 56, 59], ["EF", "TEST", 61, 63], ["b-actin genes", "TEST", 71, 84], ["the assay", "TEST", 121, 130], ["TSV", "PROBLEM", 190, 193], ["PCRThe TSV", "TEST", 251, 261], ["YHV viral load", "PROBLEM", 266, 280], ["the laboratorychallenged shrimp", "PROBLEM", 284, 315], ["the virus", "PROBLEM", 364, 373], ["EF", "TEST", 379, 381], ["T values", "TEST", 387, 395], ["the corresponding virus", "PROBLEM", 486, 509], ["viral load", "OBSERVATION", 270, 280], ["virus", "OBSERVATION", 504, 509]]], ["The TSV load in P. 6annamei (Kona stock) varied from 54 to 6745 copies/mg of total RNA and the TSV load in Super Shrimp P. stylirostris was 5 -135 copies/mg of total RNA.", [["P. 6annamei", "ORGANISM", 16, 27], ["Kona stock", "ORGANISM", 29, 39], ["Super Shrimp P. stylirostris", "ORGANISM", 107, 135], ["total RNA", "RNA", 77, 86], ["total RNA", "RNA", 160, 169], ["P. 6annamei", "SPECIES", 16, 27], ["P. stylirostris", "SPECIES", 120, 135], ["P. 6annamei", "SPECIES", 16, 27], ["P. stylirostris", "SPECIES", 120, 135], ["The TSV load", "TEST", 0, 12], ["total RNA", "TREATMENT", 77, 86], ["the TSV load in Super Shrimp P. stylirostris", "TREATMENT", 91, 135], ["total RNA", "TREATMENT", 160, 169], ["TSV load", "OBSERVATION", 4, 12]]], ["The YHV load in the Super Shrimp P. stylirostris varied from 4.5\u00d7 10 3 to 2.89\u00d710 5 copies/mg of total RNA.", [["YHV", "GENE_OR_GENE_PRODUCT", 4, 7], ["Super Shrimp P. stylirostris", "ORGANISM", 20, 48], ["total RNA", "RNA", 97, 106], ["P. stylirostris", "SPECIES", 33, 48], ["YHV", "SPECIES", 4, 7], ["P. stylirostris", "SPECIES", 33, 48], ["The YHV load", "TEST", 0, 12], ["stylirostris", "TEST", 36, 48], ["Super Shrimp", "ANATOMY", 20, 32]]], ["This indicated that Super Shrimp P. stylirostris has greater resistance to TSV compared to P. 6annamei (Kona stock) but it is highly susceptible to YHV.DiscussionThe shrimp aquaculture industry has expanded rapidly over the last three decades.", [["TSV", "DISEASE", 75, 78], ["Super Shrimp P. stylirostris", "ORGANISM", 20, 48], ["P. 6annamei", "ORGANISM", 91, 102], ["Kona stock", "ORGANISM", 104, 114], ["P. stylirostris", "SPECIES", 33, 48], ["P. 6annamei", "SPECIES", 91, 102], ["P. stylirostris", "SPECIES", 33, 48], ["P. 6annamei", "SPECIES", 91, 102], ["YHV", "SPECIES", 148, 151], ["Super Shrimp P. stylirostris", "TREATMENT", 20, 48], ["greater resistance to TSV", "PROBLEM", 53, 78], ["P. 6annamei (Kona stock", "TREATMENT", 91, 114], ["expanded", "OBSERVATION_MODIFIER", 198, 206], ["rapidly", "OBSERVATION_MODIFIER", 207, 214]]], ["This has coincided with the emergence of new viral pathogens that were unknown previously to shrimp farming.", [["new viral pathogens", "PROBLEM", 41, 60], ["new", "OBSERVATION_MODIFIER", 41, 44], ["viral pathogens", "OBSERVATION", 45, 60]]], ["In addition, there have been considerable movements of live and frozen shrimp from one country to another increasing the risk of spread of diseases into naive populations (Lightner et al., 1996) .", [["diseases", "PROBLEM", 139, 147], ["considerable", "OBSERVATION_MODIFIER", 29, 41], ["movements", "OBSERVATION_MODIFIER", 42, 51]]], ["For example, until 1998 the geographic distribution of TSV was restricted to the Americas.", [["TSV", "SPECIES", 55, 58], ["TSV", "OBSERVATION", 55, 58]]], ["From late 1998 to early 1999, TSV epizootics were recorded in Taiwan that was attributed to the introduction of TSV contaminated postlarvae and spawners from Ecuador and elsewhere in the Latin America to Taiwan (Tu et al., 1999) .", [["TSV epizootics", "DISEASE", 30, 44], ["TSV", "SPECIES", 30, 33], ["TSV epizootics", "PROBLEM", 30, 44], ["TSV contaminated postlarvae", "TREATMENT", 112, 139]]], ["To prevent the spread of viral epizootics and to monitor the movement of live and frozen shrimp among countries and continents, there is a growing and urgent need to develop rapid and highly sensitive detection methods.", [["viral epizootics", "DISEASE", 25, 41], ["viral epizootics", "PROBLEM", 25, 41], ["viral epizootics", "OBSERVATION", 25, 41]]], ["The real-time RT-PCR described here is highly sensitive.", [["The real-time RT-PCR", "TEST", 0, 20]]], ["It is capable of detecting up to a single copy equivalent of the TSV or the YHV genome (Fig. 1) .", [["YHV", "GENE_OR_GENE_PRODUCT", 76, 79], ["YHV genome", "DNA", 76, 86], ["YHV", "SPECIES", 76, 79], ["the TSV", "PROBLEM", 61, 68], ["TSV", "ANATOMY", 65, 68]]], ["In SYBR Green RT-PCR, it takes 40 cycles (C T = 40) to detect a single copy of a viral genome (Perkin Elmer User Manual, GeneAmp \u00ae 5700 Sequence Detection System, User Manual, 1998) .", [["viral genome", "DNA", 81, 93], ["viral genome", "OBSERVATION", 81, 93]]], ["A linear relationship between the input plasmid DNA and the C T values was observed from 10 6 down to a single copy of both TSV and YHV.", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["C T", "GENE_OR_GENE_PRODUCT", 60, 63], ["input plasmid DNA", "DNA", 34, 51], ["YHV", "SPECIES", 132, 135], ["the input plasmid DNA", "TREATMENT", 30, 51], ["the C T values", "TEST", 56, 70], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["plasmid DNA", "OBSERVATION", 40, 51]]], ["Detection of viruses over such a large dynamic range is useful for measuring the viral load in animals with different levels of infection.", [["infection", "DISEASE", 128, 137], ["viruses", "PROBLEM", 13, 20], ["the viral load", "TEST", 77, 91], ["infection", "PROBLEM", 128, 137], ["viruses", "OBSERVATION", 13, 20], ["viral load", "OBSERVATION", 81, 91], ["infection", "OBSERVATION", 128, 137]]], ["Thus SYBR Green RT-PCR provides a continuous scale for measuring the viral load.", [["SYBR", "GENE_OR_GENE_PRODUCT", 5, 9], ["a continuous scale", "TREATMENT", 32, 50], ["the viral load", "TEST", 65, 79], ["viral load", "OBSERVATION", 69, 79]]], ["In addition, since SYBR Green RT-PCR is capable of detecting a single copy of viral genome, it will be useful to detect sub-clinical infections.", [["infections", "DISEASE", 133, 143], ["SYBR", "GENE_OR_GENE_PRODUCT", 19, 23], ["viral genome", "DNA", 78, 90], ["SYBR Green RT-PCR", "TEST", 19, 36], ["viral genome", "PROBLEM", 78, 90], ["sub-clinical infections", "PROBLEM", 120, 143], ["viral genome", "OBSERVATION", 78, 90], ["infections", "OBSERVATION", 133, 143]]], ["Due to exquisite sensitivity of SYBR Green PCR, it is highly susceptible to PCR carry over or other contamination.", [["SYBR", "GENE_OR_GENE_PRODUCT", 32, 36], ["SYBR Green PCR", "PROBLEM", 32, 46], ["PCR", "PROBLEM", 76, 79], ["other contamination", "PROBLEM", 94, 113]]], ["Therefore, laboratory hygiene practices should be followed very strictly to pre-vent any potential contamination that may give false positive result.", [["laboratory hygiene practices", "TREATMENT", 11, 39], ["false positive result", "PROBLEM", 127, 148]]], ["In addition, any negative result as well as samples with C T values close to 40 should be tested at least twice for confirmation.DiscussionThe SYBR Green RT-PCR was not only highly sensitive but also very specific for detecting TSV, YHV and the internal control genes, EF-1a and b-actin.", [["samples", "ANATOMY", 44, 51], ["C T", "GENE_OR_GENE_PRODUCT", 57, 60], ["SYBR", "GENE_OR_GENE_PRODUCT", 143, 147], ["YHV", "CANCER", 233, 236], ["EF-1a", "GENE_OR_GENE_PRODUCT", 269, 274], ["b-actin", "GENE_OR_GENE_PRODUCT", 279, 286], ["TSV, YHV and the internal control genes", "DNA", 228, 267], ["EF", "DNA", 269, 271], ["1a", "DNA", 272, 274], ["b-actin", "DNA", 279, 286], ["TSV", "SPECIES", 228, 231], ["YHV", "SPECIES", 233, 236], ["C T values", "TEST", 57, 67], ["The SYBR Green RT-PCR", "TEST", 139, 160], ["TSV", "PROBLEM", 228, 231], ["YHV", "PROBLEM", 233, 236], ["the internal control genes", "PROBLEM", 241, 267], ["EF", "TEST", 269, 271], ["b-actin", "TREATMENT", 279, 286]]], ["The specificity of SYBR Green RT-PCR was determined by monitoring the amplification profile and the dissociation curve of the target amplicons.", [["SYBR", "GENE_OR_GENE_PRODUCT", 19, 23], ["target amplicons", "DNA", 126, 142], ["SYBR Green RT-PCR", "TEST", 19, 36], ["the amplification profile", "TEST", 66, 91], ["the dissociation curve", "TEST", 96, 118]]], ["In SYBR Green RT-PCR, a sample is considered positive when the amplification plot crosses the threshold value.", [["SYBR Green RT-PCR", "DNA", 3, 20], ["a sample", "TEST", 22, 30], ["the amplification plot", "TEST", 59, 81]]], ["For example, in Fig. 3A the amplification plot of TSV infected sample exceeds the threshold value at cycle number 31.45 whereas the amplification plot of the healthy sample did not exceed the threshold line.", [["sample", "ANATOMY", 63, 69], ["TSV", "ORGANISM", 50, 53], ["A the amplification plot", "TEST", 22, 46], ["TSV infected sample", "PROBLEM", 50, 69], ["the amplification plot", "TEST", 128, 150], ["the threshold line", "TREATMENT", 188, 206], ["Fig", "OBSERVATION_MODIFIER", 16, 19], ["infected", "OBSERVATION", 54, 62], ["threshold line", "OBSERVATION", 192, 206]]], ["To ensure that the amplification plot obtained for TSV infected sample was indeed due to the amplification of TSV specific product, the dissociation curve of the product was analyzed (Fig. 3B ).", [["sample", "ANATOMY", 64, 70], ["TSV infected", "DISEASE", 51, 63], ["TSV specific product", "PROTEIN", 110, 130], ["TSV", "SPECIES", 51, 54], ["TSV", "SPECIES", 110, 113], ["the amplification plot", "TEST", 15, 37], ["TSV infected sample", "PROBLEM", 51, 70], ["the dissociation curve", "TEST", 132, 154]]], ["Since the dissociation curve of a product depends on its GC content, length and sequence composition; amplification of a specific versus non-specific product could be differentiated by examining the dissociation curve.", [["the dissociation curve", "TEST", 6, 28], ["length and sequence composition", "TEST", 69, 100], ["a specific versus non-specific product", "PROBLEM", 119, 157], ["the dissociation curve", "TEST", 195, 217]]], ["The TSV amplicon provided a dissociation curve with a single peak at 72.0\u00b0C which is expected for the TSV specific amplicon.", [["C", "GENE_OR_GENE_PRODUCT", 74, 75], ["TSV amplicon", "DNA", 4, 16], ["TSV specific amplicon", "DNA", 102, 123], ["The TSV amplicon", "TEST", 0, 16], ["a dissociation curve", "TEST", 26, 46], ["the TSV specific amplicon", "TREATMENT", 98, 123]]], ["To determine the quality and any variation in the amount of input RNA as well as the efficiency of the reverse transcriptase reaction in both healthy and TSV infected samples, EF-1a and b-actin genes were amplified in parallel to the target virus.", [["samples", "ANATOMY", 167, 174], ["EF-1a", "GENE_OR_GENE_PRODUCT", 176, 181], ["b-actin", "GENE_OR_GENE_PRODUCT", 186, 193], ["input RNA", "RNA", 60, 69], ["reverse transcriptase", "PROTEIN", 103, 124], ["EF-1a and b-actin genes", "DNA", 176, 199], ["TSV", "SPECIES", 154, 157], ["input RNA", "PROBLEM", 60, 69], ["the reverse transcriptase reaction", "PROBLEM", 99, 133], ["TSV infected samples", "TEST", 154, 174], ["EF", "TEST", 176, 178], ["b-actin genes", "PROBLEM", 186, 199], ["input RNA", "OBSERVATION", 60, 69]]], ["Both healthy and TSV infected samples provided successful amplification of EF-1a and b-actin genes with the dissociation curve showing a single peak at the expected temperature (T m for EF-1a was 79.2\u00b0C and T m for b-actin was 78.8\u00b0C, Fig. 3C -F).", [["samples", "ANATOMY", 30, 37], ["EF-1a", "GENE_OR_GENE_PRODUCT", 75, 80], ["b-actin", "GENE_OR_GENE_PRODUCT", 85, 92], ["T m", "GENE_OR_GENE_PRODUCT", 207, 210], ["EF-1a and b-actin genes", "DNA", 75, 98], ["EF", "PROTEIN", 186, 188], ["b-actin", "PROTEIN", 215, 222], ["TSV", "SPECIES", 17, 20], ["EF", "TEST", 75, 77], ["the dissociation curve", "TEST", 104, 126], ["EF", "TEST", 186, 188], ["b-actin", "TEST", 215, 222]]], ["Similar observations were recorded for YHV amplicon and the EF-1a and b-actin controls for the corresponding samples ( Fig. 4A-F) .DiscussionIn addition to sensitivity and specificity, SYBR Green RT-PCR is very rapid and robust in nature.", [["samples", "ANATOMY", 109, 116], ["EF-1a", "GENE_OR_GENE_PRODUCT", 60, 65], ["b-actin", "GENE_OR_GENE_PRODUCT", 70, 77], ["YHV amplicon", "DNA", 39, 51], ["EF", "PROTEIN", 60, 62], ["YHV amplicon", "TREATMENT", 39, 51], ["the EF", "TEST", 56, 62], ["b-actin controls", "TREATMENT", 70, 86], ["the corresponding samples", "TEST", 91, 116], ["sensitivity", "TEST", 156, 167], ["specificity", "TEST", 172, 183], ["SYBR Green RT-PCR", "TEST", 185, 202]]], ["It takes about 2 h to run a 96 well plate from the time the plate is put into the instrument.", [["a 96 well plate", "TREATMENT", 26, 41]]], ["After amplification, the data analysis takes a few minutes.", [["the data analysis", "TEST", 21, 38]]], ["In a 96 well plate, 22 samples can be run at a time with two replicates for each virus sample, internal control, positive control and negative control.", [["samples", "ANATOMY", 23, 30], ["sample", "ANATOMY", 87, 93], ["each virus sample", "TREATMENT", 76, 93], ["internal control", "TREATMENT", 95, 111]]], ["Thus, SYBR Green RT-PCR can be used for high throughput assays for YHV and TSV detection.", [["SYBR", "GENE_OR_GENE_PRODUCT", 6, 10], ["YHV", "SPECIES", 67, 70], ["TSV", "SPECIES", 75, 78], ["PCR", "TEST", 20, 23], ["YHV", "TEST", 67, 70], ["TSV detection", "TEST", 75, 88]]], ["In recent years, real-time RT-PCR based on TaqMan chemistry, has been used for the detection of RNA viruses infecting plants (Roberts et al., 2000) , animals (Moody et al., 2000; Komurian-Pradel et al., 2001; Oleksiewicz et al., 2001) and to quantitate cellular transcripts in yeast and mammals (Kang et al., 2000; Leutenegger et al., 1999; Schmittgen et al., 2000) .", [["cellular", "ANATOMY", 253, 261], ["cellular", "CELL", 253, 261], ["cellular transcripts", "PROTEIN", 253, 273], ["yeast", "SPECIES", 277, 282], ["yeast", "SPECIES", 277, 282], ["TaqMan chemistry", "TEST", 43, 59], ["RNA viruses infecting plants", "PROBLEM", 96, 124], ["cellular transcripts", "OBSERVATION", 253, 273]]], ["Schmittgen et al. (2000) compared the endpoint RT-PCR to TaqMan and SYBR Green real-time RT-PCR to evaluate the time course of mRNA Fig. 4 .", [["mRNA Fig", "RNA", 127, 135], ["the endpoint RT", "TEST", 34, 49], ["PCR", "TEST", 50, 53], ["TaqMan", "TEST", 57, 63], ["SYBR", "TEST", 68, 72], ["RT-PCR", "TEST", 89, 95], ["mRNA Fig", "TREATMENT", 127, 135]]], ["The amplification plots and the dissociation curves of YHV, EF-1a and b-actin genes.", [["YHV", "GENE_OR_GENE_PRODUCT", 55, 58], ["EF-1a", "GENE_OR_GENE_PRODUCT", 60, 65], ["b-actin", "GENE_OR_GENE_PRODUCT", 70, 77], ["YHV, EF-1a and b-actin genes", "DNA", 55, 83], ["The amplification plots", "TEST", 0, 23], ["the dissociation curves", "TEST", 28, 51], ["YHV", "TEST", 55, 58], ["EF", "TEST", 60, 62]]], ["The melting temperature (T m ) of each amplicon is shown alongside its dissociation curve. formation and decay of human chimeric b globin gene.", [["human", "ORGANISM", 114, 119], ["chimeric b globin", "GENE_OR_GENE_PRODUCT", 120, 137], ["human chimeric b globin gene", "DNA", 114, 142], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["The melting temperature", "TEST", 0, 23], ["(T m ) of each amplicon", "TREATMENT", 24, 47], ["human chimeric b globin gene", "TREATMENT", 114, 142]]], ["Both real-time RT-PCR methods produced a 4-to 5-log dynamic range of amplification compared to 1-log dynamic range for endpoint RT-PCR.", [["PCR methods", "TEST", 18, 29], ["endpoint RT-PCR", "TEST", 119, 134]]], ["They reported that although both real-time RT-PCR methods provided comparable dynamic range and sensitivity, SYBR Green detection was more precise and produced a more linear decay plot than the TaqMan detection system.", [["PCR methods", "TEST", 46, 57], ["sensitivity", "TEST", 96, 107], ["SYBR Green detection", "TEST", 109, 129]]], ["In contrast to SYBR Green detection, multiple fluorogenic probes can be used in a TaqMan assay to detect more than one target in a reaction.", [["SYBR", "GENE_OR_GENE_PRODUCT", 15, 19], ["multiple fluorogenic probes", "TREATMENT", 37, 64], ["a TaqMan assay", "TEST", 80, 94], ["a reaction", "PROBLEM", 129, 139]]], ["However, TaqMan assay is more costly than SYBR Green assay.DiscussionRecently, we isolated EF-1a by mRNA differential technique while comparing the RNA fingerprints of healthy and WSSV, a double stranded DNA containing virus, infected shrimp (Dhar et al., 2001b) .", [["EF-1a", "GENE_OR_GENE_PRODUCT", 91, 96], ["WSSV", "ORGANISM", 180, 184], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["EF", "PROTEIN", 91, 93], ["WSSV", "SPECIES", 180, 184], ["TaqMan assay", "TEST", 9, 21], ["EF", "TEST", 91, 93], ["mRNA differential technique", "TEST", 100, 127], ["WSSV", "PROBLEM", 180, 184], ["a double stranded DNA containing virus", "PROBLEM", 186, 224]]], ["The EF-1a was expressed constitutively in both healthy and WSSV infected shrimp.", [["WSSV infected shrimp", "DISEASE", 59, 79], ["EF-1a", "GENE_OR_GENE_PRODUCT", 4, 9], ["WSSV", "ORGANISM", 59, 63], ["shrimp", "ORGANISM", 73, 79], ["EF", "PROTEIN", 4, 6], ["shrimp", "SPECIES", 73, 79], ["WSSV", "SPECIES", 59, 63], ["The EF", "TEST", 0, 6], ["infected shrimp", "OBSERVATION", 64, 79]]], ["We compared the amplification efficiency and sensitivity of EF-1a and b-actin to that of TSV and YHV to determine which of these two genes could serve as a better internal reference.", [["EF-1a", "GENE_OR_GENE_PRODUCT", 60, 65], ["b-actin", "GENE_OR_GENE_PRODUCT", 70, 77], ["EF", "PROTEIN", 60, 62], ["b-actin", "PROTEIN", 70, 77], ["TSV", "SPECIES", 89, 92], ["YHV", "SPECIES", 97, 100], ["the amplification efficiency", "PROBLEM", 12, 40], ["EF", "TEST", 60, 62], ["b-actin", "TREATMENT", 70, 77], ["TSV", "PROBLEM", 89, 92]]], ["Ideally, the amplification efficiency as well as the sensitivity of an internal control should be comparable to the RNA under study and the internal control should be expressed at an equivalent level irrespective of tissue used, stages of development and the experimental treatments (Bustin, 2000) .", [["tissue", "ANATOMY", 216, 222], ["tissue", "TISSUE", 216, 222], ["the amplification efficiency", "PROBLEM", 9, 37], ["an internal control", "TREATMENT", 68, 87], ["the RNA under study", "TEST", 112, 131], ["the internal control", "TREATMENT", 136, 156], ["the experimental treatments", "TREATMENT", 255, 282]]], ["The sensitivity (Y intercepts) and amplification efficiency (slope) of EF-1a was greater than b-actin when compared to both TSV and YHV amplification.", [["EF-1a", "GENE_OR_GENE_PRODUCT", 71, 76], ["b-actin", "GENE_OR_GENE_PRODUCT", 94, 101], ["EF", "PROTEIN", 71, 73], ["b-actin", "PROTEIN", 94, 101], ["YHV", "SPECIES", 132, 135], ["amplification efficiency", "TEST", 35, 59], ["EF", "TEST", 71, 73], ["YHV amplification", "TREATMENT", 132, 149]]], ["For example, the sensitivity (Y intercept 39.765) and amplification efficiency (slope \u22123.582) of TSV was more similar to EF-1a (Y intercepts 40.121, slope \u2212 3.443) than b-actin (Y intercepts 34.984 and slope \u22122.749) ( Fig. 2A) .", [["EF", "PROTEIN", 121, 123], ["amplification efficiency", "PROBLEM", 54, 78], ["slope", "TEST", 80, 85], ["TSV", "TEST", 97, 100], ["EF", "TEST", 121, 123], ["slope", "TEST", 149, 154], ["Y intercepts", "TEST", 178, 190], ["slope", "TEST", 202, 207]]], ["Similarly, the slope and the intercepts of YHV curve were more similar to the EF-1a than b-actin (Fig. 2B ).", [["EF-1a", "GENE_OR_GENE_PRODUCT", 78, 83], ["EF", "PROTEIN", 78, 80], ["b-actin", "PROTEIN", 89, 96], ["YHV curve", "TEST", 43, 52], ["the EF", "TEST", 74, 80], ["slope", "OBSERVATION_MODIFIER", 15, 20]]], ["There is considerable evidence that the bactin transcription varies widely in response to experimental treatment in human breast epithelial cells, porcine tissues and canine myocardium (reviewed in Bustin, 2000) .", [["breast epithelial cells", "ANATOMY", 122, 145], ["tissues", "ANATOMY", 155, 162], ["canine myocardium", "ANATOMY", 167, 184], ["bactin", "GENE_OR_GENE_PRODUCT", 40, 46], ["human", "ORGANISM", 116, 121], ["breast epithelial cells", "CELL", 122, 145], ["porcine tissues", "TISSUE", 147, 162], ["canine myocardium", "TISSUE", 167, 184], ["bactin", "PROTEIN", 40, 46], ["human breast epithelial cells", "CELL_TYPE", 116, 145], ["human", "SPECIES", 116, 121], ["porcine", "SPECIES", 147, 154], ["human", "SPECIES", 116, 121], ["canine", "SPECIES", 167, 173], ["the bactin transcription", "TREATMENT", 36, 60], ["experimental treatment in human breast epithelial cells", "TREATMENT", 90, 145], ["porcine tissues and canine myocardium", "PROBLEM", 147, 184], ["breast", "ANATOMY", 122, 128], ["epithelial cells", "OBSERVATION", 129, 145], ["porcine tissues", "OBSERVATION", 147, 162], ["canine myocardium", "ANATOMY", 167, 184]]], ["In the current study, Both EF-1a and b-actin showed variation in their level of expression in TSV and YHV in-fected samples.", [["samples", "ANATOMY", 116, 123], ["EF-1a", "GENE_OR_GENE_PRODUCT", 27, 32], ["b-actin", "GENE_OR_GENE_PRODUCT", 37, 44], ["EF", "PROTEIN", 27, 29], ["b-actin", "PROTEIN", 37, 44], ["YHV", "SPECIES", 102, 105], ["the current study", "TEST", 3, 20], ["Both EF", "TEST", 22, 29], ["b-actin", "TEST", 37, 44], ["TSV", "TEST", 94, 97], ["YHV", "TEST", 102, 105], ["variation", "OBSERVATION_MODIFIER", 52, 61]]], ["However, based on the sensitivity and the amplification efficiency, as well as the level of variation, EF-1a appeared to be a better internal reference for SYBR Green RT-PCR detection of TSV and YHV.DiscussionOne of the obstacles in the development of virus resistant lines in shrimp is the lack of method(s) for quantification of viruses.", [["EF-1a", "GENE_OR_GENE_PRODUCT", 103, 108], ["lines", "CELL", 268, 273], ["shrimp", "ORGANISM", 277, 283], ["EF", "PROTEIN", 103, 105], ["virus resistant lines", "CELL_LINE", 252, 273], ["TSV", "SPECIES", 187, 190], ["YHV", "SPECIES", 195, 198], ["the sensitivity", "TEST", 18, 33], ["the amplification efficiency", "PROBLEM", 38, 66], ["EF", "TEST", 103, 105], ["TSV", "PROBLEM", 187, 190], ["YHV", "PROBLEM", 195, 198], ["virus resistant lines", "TREATMENT", 252, 273], ["viruses", "PROBLEM", 331, 338], ["virus resistant lines", "OBSERVATION", 252, 273], ["viruses", "OBSERVATION", 331, 338]]], ["Lack of established crustacean cell lines further emphasizes the need to develop methods for virus quantitation.", [["cell lines", "ANATOMY", 31, 41], ["crustacean cell lines", "CELL", 20, 41], ["crustacean cell lines", "CELL_LINE", 20, 41], ["crustacean cell lines", "TREATMENT", 20, 41], ["virus quantitation", "TEST", 93, 111], ["crustacean cell lines", "OBSERVATION", 20, 41]]], ["Recently, we have developed a real-time PCR assay based on SYBR Green chemistry for the detection and quantification of two penaeid DNA viruses, infectious hypodermal and haematopoietic necrosis virus (IHHNV) and WSSV (Dhar et al., 2001a) .", [["hypodermal", "ANATOMY", 156, 166], ["infectious hypodermal and haematopoietic necrosis", "DISEASE", 145, 194], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["hypodermal", "TISSUE", 156, 166], ["haematopoietic necrosis virus", "ORGANISM", 171, 200], ["WSSV", "ORGANISM", 213, 217], ["infectious hypodermal and haematopoietic necrosis virus", "SPECIES", 145, 200], ["IHHNV", "SPECIES", 202, 207], ["WSSV", "SPECIES", 213, 217], ["PCR assay", "TEST", 40, 49], ["the detection", "TEST", 84, 97], ["two penaeid DNA viruses", "PROBLEM", 120, 143], ["infectious hypodermal", "PROBLEM", 145, 166], ["haematopoietic necrosis virus", "PROBLEM", 171, 200], ["penaeid DNA viruses", "OBSERVATION", 124, 143], ["infectious", "OBSERVATION_MODIFIER", 145, 155], ["haematopoietic", "ANATOMY", 171, 185], ["necrosis", "OBSERVATION", 186, 194]]], ["We used the SYBR Green PCR method, along with random amplified polymorphic DNA (RAPD) technique, to identify genetic markers in P. stylirostris shrimp populations that differ in their IHHNV load (Hizer et al., 2002) .", [["DNA", "CELLULAR_COMPONENT", 75, 78], ["P. stylirostris shrimp", "ORGANISM", 128, 150], ["random amplified polymorphic DNA", "DNA", 46, 78], ["P. stylirostris shrimp", "SPECIES", 128, 150], ["P. stylirostris", "SPECIES", 128, 143], ["the SYBR Green PCR method", "TREATMENT", 8, 33], ["random amplified polymorphic DNA (RAPD) technique", "TREATMENT", 46, 95]]], ["Thus, SYBR Green RT-PCR, along with other molecular techniques, will be useful for developing TSV and YHV resistant lines in shrimp.DiscussionIn summary, the SYBR Green RT-PCR method described above is a major development in the detection and quantification of TSV and YHV in shrimp.", [["lines", "ANATOMY", 116, 121], ["YHV", "CHEMICAL", 102, 105], ["SYBR", "GENE_OR_GENE_PRODUCT", 6, 10], ["TSV", "ORGANISM", 94, 97], ["YHV resistant lines", "CELL", 102, 121], ["shrimp", "ORGANISM", 125, 131], ["SYBR", "GENE_OR_GENE_PRODUCT", 158, 162], ["TSV", "ORGANISM", 261, 264], ["YHV", "GENE_OR_GENE_PRODUCT", 269, 272], ["TSV and YHV resistant lines", "CELL_LINE", 94, 121], ["shrimp", "SPECIES", 276, 282], ["TSV", "SPECIES", 94, 97], ["YHV", "SPECIES", 102, 105], ["TSV", "SPECIES", 261, 264], ["YHV", "SPECIES", 269, 272], ["SYBR Green RT-PCR", "TEST", 6, 23], ["TSV", "PROBLEM", 94, 97], ["YHV resistant lines in shrimp", "PROBLEM", 102, 131], ["the SYBR", "TEST", 154, 162], ["the detection", "TEST", 225, 238], ["TSV", "PROBLEM", 261, 264], ["resistant lines", "OBSERVATION", 106, 121]]], ["The method is very rapid, highly sensitive and is applicable to routine high throughput assay making it a suitable tool for diagnostic, epidemiological and genetic studies in shrimp aquaculture.", [["shrimp", "ORGANISM", 175, 181], ["The method", "TEST", 0, 10], ["genetic studies", "TEST", 156, 171]]]]}